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  1 
SUMMARY 
 
ADP-ribosyltransferases (ARTs) are important enzymes involved in diverse biological 
functions of the cell. ARTD1 and ARTD2 are two chromatin-associated proteins that share a 
similar catalytic domain, which is responsible for the modification of these proteins and other 
target proteins. Despite the high degree of amino-acid conservation between ARTD1 and 
ARTD2 and the limited number of studies of ARTD2, there are initial indications that 
ARTD2 might regulate distinct cellular processes, although molecular details and 
mechanistic insights remain elusive. The aim of the thesis was to provide additional insights 
that ARTD1 and ARTD2 regulate different cellular processes or use different mechanisms to 
regulate common processes. Therefore, we studied the role of ARTD1 and ARTD2 in 
response to genotoxic stress as well as in cell cycle regulation, in particular during G0 to G1 
progression. 
H2O2 or MNNG both induce genotoxic stress, which is known to activate ARTD1 and to a 
lesser extent ARTD2. Interestingly, the combined treatment of H2O2 or MNNG with low 
doses of Actinomycin D induced strong ARTD2-dependent poly-ADP-ribose formation. 
Actinomycin D treatment lead to the accumulation of short rRNA transcripts in vivo, which 
strongly activated ARTD2 in vitro, while comparable DNA fragments were not able to do so. 
Interestingly, ARTD1 was activated more by DNA and to a lesser extent by RNA.  
A second project focusing on cell cycle re-entry revealed distinct functions for both proteins, 
ARTD1 and ARTD2. Knockdown of ARTD1 by siRNA treatment of T24 cells (urinary 
bladder carcinoma cells) repressed the expression of Cyclin E and thereby lead to decelerated 
cell cycle entry and progression. In contrast, down-regulation of ARTD2 specifically affected 
p27 expression as well as its protein level and rendered T24 unable to re-enter the cell cycle. 
Analysis of the histone modifications and compositions at the two promoters (Cyclin E and 
p27) suggested that ARTD1 and ARTD2 repress transcription by different means. 
Together, these findings identified RNA as new activator for ARTD2-dependent ADP-
ribosylation and provide further strong evidence, that ARTD1 and ARTD2 regulate cell cycle 
regulation and the cellular genotoxic stress response as well as possibly other biological 
processes in the nucleus by different mechanisms.  
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ZUSAMMENFASSUNG 
 
ADP-ribosyl-transferasen (ARTs) sind wichtige Enzyme, die in diversen biologischen Prozessen eine 
Rolle spielen. ARTD1 und ARTD2 sind chromatin-assozierte Proteine, die eine sehr ähnliche 
Domänenstruktur aufweisen und deren katalytische Domänen homolog sind. Diese Domänen sind für 
die Automodifizierung und die Modifizierung anderer Zielproteine verantwortlich. Abgesehen von 
dem hohen Grad der Homologie beider Enzyme, und abgesehen davon, dass die meisten 
biochemischen Studien nur mit ARTD1 durchgeführt wurden, gibt es erste Hinweise, dass ARTD2 
unterschiedliche zelluläre Prozesse reguliert, auch wenn molekulare Details und mechanistische 
Erkenntnisse oft noch nicht genau geklärt sind.  
Das Ziel dieser Doktorarbeit war es, zusätzliche Erkenntnisse zu gewinnen, wie ARTD1 und ARTD2 
verschiedene zelluläre Prozesse beeinflussen oder wie diese Enzyme die gleichen Prozesse mittels 
verschiedener Mechanismen regulieren. Daher haben wir die Rolle von ARTD1 und ARTD2 in der 
Antwort auf oxidativen Stress eruiert und den Zellzyklus untersucht, besonders während des 
Übertritts von der G0 zur G1 Phase.  
H2O2 und MNNG sind Substanzen, die genotoxischen Stress auslösen können. Es ist bekannt, dass 
dieser Stress ARTD1 und in geringerem Masse auch ARTD2 aktiviert. Interessanterweise führt die 
kombinierte Behandlung von H2O2 oder MNNG mit Actinomycin D in geringer Konzentration zur 
starken Aktivierung von ARTD2. Behandlung mit Actinomycin D führte durch die Inhibierung von 
RNA polymerase I in vivo zur Anreicherung von kurzen rRNA Transkripten, welche ARTD2 auch in 
vitro stark aktivieren konnte, während DNA Fragmente selber keine Induktion hervorgerufen haben. 
Interessanterweise, wurde ARTD1 stärker durch DNA aktiviert als durch RNA.  
Das zweite Projekt befasste sich mit dem Zellzyklus-Wiedereintritt und hat gezeigt, dass ARTD1 und 
ARTD2 dabei unterschiedliche Funktionen haben. Die Herunterregulierung von ARTD1 mittels 
siRNA in T24 Zellen (Blasenkarzinom-Zellen) hemmte die Expression von Cyclin E und führte damit 
zu einem verlangsamten Zellzykluseintritt und –verlauf. Im Gegensatz dazu beeinflusste die 
Herunterregulierung von ARTD2 die p27 Expression sowie den p27 Porteingehalt positiv, wodurch 
T24 Zellen nicht in der Lage waren in den Zellzyklus einzutreten. Analysen der Histonmodifizierung 
und der Zusammensetzung beider Promotoren (Cyclin E und p27) legten nahe, dass ARTD1 und 
ARTD2 die Transkription auf verschiedene Weise reprimierten. 
Zusammenfassend zeigen diese Ergebnisse, dass RNA ein neuer Aktivator von ARTD2-abhängiger 
ADP-Ribosylierung ist und beweisen, dass ARTD1 und ARTD2 den Zellzyklus und die zelluläre 
Stressantwort, sowie andere biologische Prozesse im Nukleus durch verschiedene Mechanismen 
regulieren. 
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ABBREVIATIONS 
 
aa   Amino acid 
ADP   Adenosine diphosphate 
ART   ADP-ribosyltransferase 
ARTD   ADP-ribosyltransferase diphtheria toxin-like 
ActD   Actinomycin D 
ATP    Adenosine triphosphate 
BER    Base excision repair 
bp    Base pair 
CAIX   Carbonic anhydrase IX 
CAK   Cdk-activating kinase 
Chk1   Serine/threonine-protein checkpoint kinase 1 
Cdk    Cyclin-dependent kinase 
ChIP    Chromatin immunoprecipitation 
DAPI   4',6-diamidino-2-phenylindole 
DDR    DNA damage response 
DNA    Deoxyribonucleic acid 
DNMT  DNA methyltransferase 
DSB    Double-strand break 
FCS   Fetal calf serum 
!H2AX  gamma-histone 2A variant X (phosphorylated) 
HDAC   Histone deacteylase 
HIF    Hypoxia-inducible factor 
H2O2   Hydrogen peroxide 
IL6   Interleukin 6 
LPS   Lipopolysaccharide 
MEF   Mouse embryonic fibroblasts 
miRNA  microRNA 
MNNG  Methylnitronitrosoguanidine 
NAD   Nicotinamide adenine dinucleotide 
NAM   Nicotinamide 
NF-"B   Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
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NRH   Dihydronicotinamide ribosyl 
PAR   Poly-ADP-ribose 
PARG   Poly-(ADP-ribose)-glycohydrolase 
PARP    Poly-(ADP-ribose)-polymerase 
PARylation   Poly-ADP-ribosylation 
PBS   Phosphate buffered saline 
Pol I   RNA- Polymerase I 
pRb   Retinoblastoma protein 
PTM   Post-translational modification 
rDNA   ribosomal DNA 
RNA   Ribonucleic acid 
rRNA   Ribosomal RNA 
SSB   Single-strand break 
snoRNP  small nucleolar ribonucleoprotein 
TNF#   Tumor necrosis factor # 
XRCC1  X-ray repair cross-complementing protein 1 
Introduction  
  
 7 
1. INTRODUCTION 
1.1  The nucleus 
The nucleus is the central organelle of eukaryotic cells containing the genetic material – the 
DNA. It is the compartment where transcription, RNA processing and DNA replication take 
place, which all ensure the correct function of the cell. Throughout these processes, the DNA 
plays different roles: on one hand, the DNA needs to be well protected from damage or 
modification to ensure the correct inheritance of the genetic information. On the other hand, 
expression of this information as RNA or proteins allows the cell to react and respond 
immediately to internal (cellular) or external (environmental) changes. The accessibility of 
this information is ensured by an extensive protein network, which is comprised of a DNA-
nucleoprotein-complex, the chromatin.  
 
1.1.1 Chromatin 
 
Chromatin structure 
Chromatin is the complex structure of DNA and nucleoproteins, which guarantees the 
compaction of the DNA in the nucleus. Uncompact human DNA would reach a length of 
approximately 2 meters. Due to the compaction of the DNA by histone binding and the 
resulting condensation, the DNA can be packaged into cells with a diameter of 1 $m -100 $m 
(1). The smallest structural unit of the chromatin is called the nucleosome. A nucleosome is 
formed by the core histones – two stable H3-H4 histone dimers forming a tetramer, which is 
flanked by two H2A-H2B dimers (2). 147 bp of double stranded DNA are wound around this 
octamer forming a “beads on a string” fiber of 11 nm in diameter. Further compaction is 
induced by the addition of the linker histone H1, which binds the entry and exit sites of the 
linker DNA to the nucleosome and influences nucleosome positioning (3). The complex of 
core nucleosomes and linker histone together with DNA is known as chromatosome, a fiber 
of 30 nm in diameter (4).  Further condensation by association with the chromosome scaffold 
leads to 300 nm and 700 nm diameter structures and eventually to the condensed metaphase 
chromosomes of the eukaryotic cells. 
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DNA methylation and posttranslational modifications of histones 
Since the DNA is tightly compacted in eukaryotic cells, multifaceted mechanisms have 
evolved to regulate an easy accessibility. The chromatin is not a homogenous rigid structure; 
it is rather highly heterogeneous and contains different degrees of compaction, also referred 
as flavors. Major changes in this “open-close” conformation are induced by chemical 
modifications on the histones and the DNA. The DNA can for example be directly modified 
by DNA methyltransferases (DNMT) on cytosines (then named 5-methyl-cytosine) 
embedded in CpG dinucleotides. Theses CpG dinucleotides tend to cluster in regions that are 
called islands and the inheritance of this modification is termed epigenetics, which nowadays 
includes also the inheritance of posttranslational modifications (PTM) of histones (5, 6). The 
short amino-terminal domains of the histones (less than 40 amino acids) as well as the short 
protease-accessible carboxy-terminal domains (2, 7) are subject to different PTMs, which 
include methylation, acetylation, phosphorylation, SUMOylation, ubiquitination and ADP-
ribosylation (8, 9). Many different proteins such as histone acetyltransferses (HAT), histone 
deacetylases (HDAC), histone methyltransferases (HMT), histone demethylases (HDM), and 
also ADP-ribosyltransferases  (ART) are involved in the modification of histones (10, 11).  
Different activities are assigned to distinct chromatin compaction degrees, which also 
correlate with different PTMs. There are regions of uncondensed chromatin occupied by 
lower amount of nucleosomes and which contains high levels of acetylation and also specific 
tri-methylated lysine sites (e.g., H3K4, H3K36 and H3K79). These regions indicate actively 
transcribed euchromatin (12). On the other hand, the highly compact and rather silent 
heterochromatin is characterized by low acetylation and enhanced methylation of lysines K9, 
K27, K20 on histone H3 (13). The chromatin compaction that can change quite rapidly is also 
referred to as chromatin plasticity.   
Posttranslational modifications of histones and DNA methylation profiles are important 
marks that can be detected by chromatin immunoprecipitation (ChIP) to analyze the dynamic 
structure of the DNA. Inheritance of these modification profiles (epigenetics) is very 
important. Epigenetic deregulation occurs at various disease stages. Virtually all human 
cancers show epigenetic abnormalities, which often affects tumor suppressor genes leading to 
deregulation of regulatory pathways (14). Profiles of PTMs and DNA methylation are 
therefore also used as prognostic markers and even as therapeutic targets. However, only a 
few biomarkers are currently in clinical use and even less commercial tests are actually 
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available, since the identification of a single biomarker as well as the required specificity and 
sensitivity of a test is difficult to achieve (15). 
 
Histone variants  
Although histones are highly conserved proteins, their genes are repeated tens of times per 
genome and variably arranged in clusters (16). Not all histone genes encode a conserved 
histone type, allowing a certain diversity or variation among the histone proteins and their 
functions. For every canonical histone, different variants with distinct amino acid sequences 
are known. The histones H3 and H2A exhibit the most variations with specialized functions 
(1). For example, the human genome contains 10 genes encoding H2A1 variants. Six of these 
have identical sequences and four genes vary in 3 to 4 positions. Together with the H2A2 
variants, these genes encode the bulk of mammalian H2A. In addition, there are five other 
H2A genes that encode amino acid sequences, which differ tremendously from the bulk H2A 
peptide and those variants might have different but important roles in cellular processes (1). 
Core histone biosynthesis is largely restricted to the S phase, when DNA replication takes 
place (17). In contrast, histone variants are constantly expressed throughout the cell cycle as 
described for the H3.3 variant, which substantially differs in amino acid sequence from the 
major H3.1 (18). The variant H3.3 can replace H3.1 independently of DNA synthesis and 
marks active promoter sites (19). Thus, variants also appear to serve as markers for a distinct 
chromatin status. H2A.Z and H2A.X, discovered in the 1980s, are two other prominent 
examples (20). H2A can be substituted by H2A.Z at transcriptionally active start sites (21). 
H2A.X, when phosphorylated on serine 139 (called !-H2A.X), appears at chromatin sites in 
close proximity of double strand breaks (DSB) and is thus used as a marker for DNA damage 
(22). It is interesting to note that only about 20 % of H2A.X in the distinct region of damage 
is phosphorylated during this process (1). 
 
1.1.2 The nucleolus  
 
Found in every eukaryotic cell, the nucleoli are specific, membrane-less, nuclear organelles 
and sites of rDNA transcription, rRNA maturation and ribosome production (23, 24). Mélèse 
et al. showed that the efficiency of ribosome biogenesis is dependent on the size and 
organization of the nucleoli (25). In cycling cells, the nucleoli are formed at the end of 
mitosis, functionally active throughout the interphase, and disassembled in the proceeding 
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prophase of the cell division (26). In terminal stages of differentiation (e.g., in lymphocytes 
or erythrocytes), the nucleoli are rather small or not formed, whereas in rapidly dividing cells 
(e.g., in cancer cells), the nucleoli represent dominant and highly productive structures (27). 
The nucleoli assemble around the nucleolar organizer regions (NOR) (26). These are located 
on the short arm of 5 acrocentric chromosomes, where multiple rDNA copies cluster in head-
to-tail tandem repeats. The nucleolus is either built around a single NOR or around several 
active NORs that converge in a single nucleolus (28). The rDNA encodes the ribosomal RNA 
and each active rRNA gene is transcribed by the DNA-dependent RNA polymerase I (Pol I) 
to synthesize a 45S pre-rRNA. This 45S pre-rRNA is further processed to generate three 
ribosomal RNAs (18S, 5.8S, 28S), which are post-transcriptionally modified by small 
nucleolar ribonucleoproteins (snoRNP). These mature RNAs together with the 5S RNA, 
transcribed by Polymerase III (24, 29, 30), form together with the expressed ribosomal 
proteins the ribosomal subunits in the cytoplasm. 
Even though the nucleolus is a transient compartment, it is highly structured and organized in 
different sub-regions (Figure 1). RNA polymerase I is highly enriched in the fibrillar center 
(FC) and at the edge of the dense fibrillar component (DFC), where rRNA transcription takes 
place. In the DFC, pre-ribosomal RNA is spliced and modified by snoRNPs. The final 
maturation and assembly with ribosomal proteins takes place in the granular component (26). 
Subsequently, the 40S and 60S ribosomal sub-units are transported to the cytoplasm, where 
they assemble into an active complex. Besides contributing to ribosome biogenesis, nucleoli 
serve additional functions. Nucleolar proteome analyses identified over 700 proteins in the 
nucleolus of human cells, of which only 30 % are designated to ribosome subunit production 
(31-33). The other proteins of the nucleolus were reported in part to play a role in cell cycle 
regulation (34, 35) and stress response (36, 37) and have been linked to various multiple 
genetic disorders such as the Werner syndrome or to the Diamond-Blackfan anaemia, which 
is characterized by aberrant ribosome biogenesis (26, 38). 
Introduction  
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Figure 1: Compartmentalization and function of the nucleolus. The nucleolus is 
compartmentalized into different sub-regions shown here with their different functions – picture from 
(26) 
 
RNA polymerase I  
The DNA-dependent RNA polymerase I (Pol I) is exclusively found in the nucleolus. For the 
initiation of rRNA transcription, Pol I has to be part of a protein-multi-complex that includes 
factors like UBF, SL1, CK2, SIRT7, NM1, TTF-1 and TIF-IA (39). Pol I promoter 
specificity is mediated by TIF-IB/SL1, a complex containing the TAT-binding protein and 
five TATA binding protein-associated factors (TAF). UBF serves as a recruiter of Pol I and 
mediates the binding of Pol I to the DNA strand throughout the transcription process (40). 
Pol I was also found to interact with several DNA repair and replication factors, for example 
Topoisomerases I and II#, Ku70/80 and PCNA (39). 
 
rRNA genes 
Somatic cells of higher eukaryotes contain several hundreds of rRNA genes with the same 
structure (Figure 2). A human diploid cell contains about 400 rRNA genes that are all 
organized in head-to-tail tandem repeats on five different chromosomes (24). However, also 
in highly active metabolic cells, only a subset of these genes (approximately 50 %) is 
transcribed (41). The remaining rRNA genes are silenced in a tissue- and cell type-specific 
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manner (42). These genes underlie the same epigenetic characteristics as any other gene of 
the chromosome and are regulated by post-translational modifications of histones and DNA 
methylation (as described in Chapter 1.1.2). RNA polymerase I can bind to the rRNA 
promoter (site of transcription initiation), but also binds to the highly homologous spacer 
promoter (43). The region of the repetitive enhancer elements is also called intergenic spacers 
(IGS). Transcripts from the spacer promoter are co-directed with the pre-mRNA and 
probably enhance transcription from the main rDNA promoter by directing Pol I (44, 45). 
The IGS is also relevant for the silencing of the rRNA genes since it gives rise to the dubbed 
promoter RNA (pRNA), important for the recruitment of the silencing complex (nucleolar 
remodeling complex, NoRC) (41, 46, 47). 
 
 
Figure 2: Structure of a rDNA gene. The diagram shows the structure of one copy of rDNA, which 
encodes for the 45S pre-mRNA. Black boxes indicate terminator elements, ETS indicates external 
transcribed sequence. The transcript of the ETS generates a non-functional RNA. 
 
rRNA gene expression is influenced by diverse stress stimuli 
The production of ribosome-subunits is heavily influenced by diverse stress stimuli and 
metabolic changes (36). The cell reacts to nutrient starvation, oxidative stress or inhibition of 
protein synthesis with a decrease of rRNA expression, whereas growth factors and 
proliferation stimulating agents increase the rRNA expression. A key regulator in this process 
is UBF, which enhances or represses rRNA production of active rDNA genes depending on 
its phosphorylation status (48-50). Furthermore, the down regulation of rRNA expression 
following different stress stimuli correlates with the binding ability of the transcription factor 
TIF-IA. It was shown that the phosphorylation of TIF-IA by JNK upon stress prevents the 
interaction between the TIF-IA and Pol I and hence inhibits rRNA expression (37).  
 
 
             18S 5.8 28S 
ETS      
Site of 
transcription 
initiation 
Repetitive enhancer 
elements 
Spacer 
promoter 
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Inhibition of rDNA transcription by Actinomycin D 
Actinomycin D (ActD) or Dactinomycin is a cyclic polypeptide-containing antibiotic with 
DNA intercalating functions that is isolated from Streptomyces bacteria (51, 52). ActD 
intercalates in CG-rich regions of the DNA, thus stabilizing covalent topoisomerase I-DNA 
complexes and preventing RNA polymerase progression and RNA synthesis (53). The 
intercalation takes place downstream of rDNA transcription start sites, thus inhibiting 
transcription during elongation with the consequence that the RNA polymerase falls off the 
strand and synthesizes only a short RNA transcript (54). ActD treatment thus leads to an 
accumulation of short RNA transcripts over time (55). Nucleolar rRNA synthesis is 
particularly sensitive to ActD at a concentration of 50 ng/ml, while RNA polymerases II and 
III are only inhibited at higher concentrations (Pol II > 0.5 $g/ml, Pol III > 5$g/ml) (56, 57). 
In comparison, #-Amanitin is a potent Pol II and Pol III inhibitor that does not target RNA 
polymerase I (58). Upon ActD treatment, the nucleolar structure is reorganized. The different 
sub-components of the nucleolus segregate and nucleolar caps are formed around the 
nucleolar remnant (59). Nucleolar caps contain mainly RNA binding proteins, for instance 
the splicing factor PSF and pre-rRNA transcripts (60). ActD is a long known and established 
chemotherapeutic compound that is used to treat gestational trophoblastic cancer, testis 
cancer, Wilm’s tumor, rhabdomyosarcoma and Ewing’s sarcoma (58).  
 
1.2  ARTD family 
The ARTD (ADP-ribosyltransferases diphtheria toxin-like) family comprises a group of 18 
proteins that share a common catalytic ART core domain. These enzymes have been formerly 
named PARPs (poly-ADP-ribose-polymerase), but were renamed based on structural and 
enzymatic evidences (61). The ARTD enzymes use NAD+ as a substrate to modify target 
proteins by mono- or poly-ADP-ribosylation. The first discovery of a nuclear enzymatic 
activity able to synthesize an adenine-containing polymer was made in 1963 by the group of 
Mandel (62). The enzyme mainly responsible for the formation of this polymer and until now 
the most studied family member is ARTD1 (formerly PARP1) (63, 64). Over the last decades 
several additional family members have been identified and described. Some of these are also 
able to synthesize polymers of ADP-ribose (ARTD2, ARTD5, ARTD6), but contribute only 
little to polymer formation in the cell. Other family members exhibit only mono-ADP-
ribosyltransferase activity (e.g., ARTD8 and ARTD10) or seem to be inactive, although 
containing the common catalytic domain (ARTD9 and ARTD13) (61).  
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Overall, the ARTD family members are involved in a variety of cellular functions such as 
genomic stability, transcriptional regulation, energy metabolism and cell death (65-67). 
However the mechanisms underlying these functions remain often unsolved and are the 
subject of a broad field of research. 
 
1.2.1 Structure of ARTD1 and ARTD2  
 
Mammalian ARTD1 is a 113.2 kDa protein consisting of different domains with distinct 
functions: an N-terminal DNA-binding domain comprised of three zinc-binding domains (Zn 
I, II and III) and a nuclear localization sequence (NLS), a central automodification domain 
containing a BRCA1 C-terminal (BRCT) phosphopeptide-binding motif, which was 
suggested to promote protein-protein interactions, a C-terminal catalytic domain containing 
the functionally uncharacterized tryptophan-, glycine-, and arginine-(WGR)-rich domain, a 
PARP regulatory domain which might be involved in polymer branching and the catalytic 
ART domain (61) (Figure 3). Recently, the group of Satoh showed that the WGR domain of 
ARTD1 was necessary for the enzymatic activation by RNA (68). 
In comparison to ARTD1, ARTD2 was only discovered in 1990s as a result of the detection 
of residual poly-ADP-ribose forming activity in mouse embryonic fibroblasts (MEFs) lacking 
ARTD1 (knockout) (69). Mammalian ARTD2 is a 66.2 kDA protein that shares the C-
terminal domain of ARTD1. The catalytic domains of both enzymes show 69% similarity 
(69). ARTD2 lacks the N-terminal DNA-binding domain with the three zinc fingers and the 
central automodification domain, but has a SAF/Acinus/PIAS-DNA-binding domain, which 
comprises the nuclear localization sequence (Figure 3) (70). Haenni et al. could show that 
ARTD2 is able to auto-modify itself within the SAP domain (71, 72).  
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Figure 3: Structural overview of ARTD1 and ARTD2. ZF= zinc finger, BRCT= BRCA1 C-terminal 
(BRCT) phosphopeptide-binding motif, AMD= automodification domain, WGR= tryptophan-, 
glycine-, and arginine-(WGR)-rich domain, PRD=PARP regulatory domain, ART=catalytical domain, 
SAP= SAF/Acinus/PIAS-DNA-binding domain, NLS= Nuclear Localization Sequence. 
 
1.2.2 ADP-ribosylation 
 
Mono-ADP-ribosylation was originally identified as an activity of bacterial toxins such as 
Corynebacterium diphtheria toxin, which ADP-ribosylates the uncommon amino acid 
diphthamide (73). In contrast, poly-ADP-ribosylation (PARylation) is only found in higher 
eukaryotes, but not in yeast (74). The list of acceptor proteins is constantly growing and until 
now over 150 proteins have already been identified to be poly-ADP-ribose (PAR) acceptors. 
These proteins include ARTDs that are auto-modified as well as different DNA-binding 
proteins such as histones and topoisomerases that are trans-modified (65, 66). Furthermore, 
covalently modified PAR acceptors and non-covalently PAR binding protein modules have to 
be distinguished (75). 
The detailed mechanistic process of ADP-ribose formation is depicted in Figure 4. In brief, 
the enzymes use nicotinamide adenine dinucleotide (NAD+) as a substrate to transfer an 
ADP-ribose unit during initiation to an acceptor site of a target protein, generating 
nicontinamide (NAM) as a byproduct. The acceptor sites for mono-ADP-ribose are side 
chains of specific amino acid residues and so far the following acceptor amino acids in 
eukaryotic cells were reported to covalently bind ADP-ribose: lysine (K), arginine (R), 
glutamate (E), aspartate (D), cysteine (C), diphthamide (Dph), phospho-serine (pS) and 
asparagine (N) (61). The attached mono-ADP-ribose is further extended to oligomers and 
polymers of a length of 200 units in vivo and 400 units in vitro (76). Classical PAR 
antibodies can recognize only polymers over 10 ADP-ribose-units, which is a limiting factor 
for detecting PAR formation in vivo (77). The turnover of PAR formed upon cellular stress is 
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rather quick (in vivo half-life > 40s to 6min). Within the first 40s, 85% of polymers are 
degraded. The residual fraction is more slowly catabolized (78-80). 
 
 
Figure 4: Poly- ADP-ribose metabolism. Different steps of initiation, elongation, branching and 
degradation of PAR formation are shown (modified from Hassa et. al (65)). 
 
The rapid turnover of the polymers depends mainly on the activity of cellular ADP-ribose-
protein hydrolases such as poly-(ADP-ribose)-glycohydrolase (PARG) or ADP-ribosyl 
hydrolase 3 (ARH3). These enzymes are able to hydrolyze the protein–ADP-ribose bonds 
between different ADP-ribose units (81-84). PARG is the major PAR-degrading enzyme. The 
knockout of PARG in mice leads to lethality in early embryogenesis, which hints at the 
importance of the enzyme and the regulation of PAR formation (85). PARG is an enzyme 
with exo-and endoglycosidase activity and generates large amounts of free ADP-ribose, but 
cannot cleave off the last ADP-ribose-moiety from the target protein (86, 87). Very recently, 
our group reported that some macrodomain-containing proteins are able to hydrolyze the 
mono-ADP-ribose modification catalyzed by ARTD10, providing strong evidence that ADP-
ribosylation is a reversible PTM (88). Free ADP-ribose may for example function as a signal 
transducer in apoptosis signaling, DNA repair or cell cycle progression (89). Furthermore, 
poly-ADP-riboses can be non-covalently bound by PAR-binding proteins, which coordinate 
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several intracellular pathways (for detailed review see (75)). The major fraction of rapidly 
produced polymers plays a role in transient and dynamic cellular processes such as chromatin 
regulation and transcriptional response upon stress induction (66). PAR formation is not only 
stimulated by genotoxic stress, but also by mitogen induction (90). The contribution of 
ARTD2 to the total PAR synthesis upon genotoxic stress was shown to be approximately 
15 %, which might be due to a lower abundance of ARTD2 or to lower enzymatic activity 
(91, 92). The highly negatively charged poly-ADP-ribose polymers lead to changes in 
physical and biochemical properties of the target proteins, which can result in the disruption 
of protein-DNA or protein-protein binding, as seen for ARTD1 and Topoisomerase I (93-95). 
Furthermore, the polymers can even inhibit the enzymatic activity of some DNA dependent 
enzymes such as Topoisomerase I and the ATPase Cockayne Syndrome group B (96).  The 
activity of the enzyme is strictly dependent on the NAD+ levels in cells (66, 97). The half-life 
of NAD+ in proliferating cells is around 1-2h (98-100), but when ADP-ribose polymers are 
formed under strong stimulating conditions such as genotoxic stress, the cellular pool of 
NAD+ is rapidly depleted and diminishes to 10-20% of the normal NAD+ levels (101, 102). 
The NAD+/ATP depletion after ARTD1 hyperactivation can lead to poly-ADP-ribosylation 
dependent translocation of apoptosis inducing factor (AIF) to the nucleus and consecutive 
cellular deregulation or programmed cell death (103). 
 
1.2.3 Cellular processes regulated by ARTD1 and ARTD2 
 
ARTD1 and ARTD2 are involved in several biological processes such as genome stability, 
chromatin regulation, genotoxic stress response, cell cycle regulation, cell death, 
inflammation and transcriptional regulation (65-67). Mice lacking ARTD1 are healthy and 
fertile, but hypersensitive to ionizing radiation and alkylating agents (104-106). ARTD2 
knockout (-/-) mice are also viable and hypersensitive to ionizing irradiation. Initial 
description of the ARTD2 -/- phenotype provided evidence of an involvement of ARTD2 in 
different developmental processes, such as T-cell development or spermatogenesis (107). 
Double knockout mice (ARTD1-/- and ARTD2 -/-) are not viable and die at the onset of 
gastrulation, indicating that ARTD1 and ARTD2 play a crucial role during embryonic 
development and that the enzymes might be functionally redundant (108). However, ARTD2 
is not as well studied as ARTD1 and besides some overlapping functions with ARTD1, a 
clear comprehension of its cellular function is still missing.  
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Genotoxic stress signaling 
Originally, ARTD1 activity was described to play a role in the DNA damage response, 
particularly the base excision repair (BER) since it is strongly stimulated by genotoxic stress 
such as reactive oxygen species or alkylating agents (e.g., MNNG) (109, 110). ARTD1 was 
shown to be recruited to single-strand breaks (SSB) in vivo and thereby attracts X-ray repair 
cross-complementing I (XRCC1), a crucial scaffold protein that recruits other factors to SSBs 
and initiates base excision repair (BER) (111). Similarly, overexpressed ARTD2 was found 
to interact with XRCC1 and with other proteins of the DNA repair pathway, including DNA 
polymerase ! and DNA ligase III (112). However, recent findings show that ARTD1 has 
only a minor function in BER and only participates in BER under conditions when the 
amount of unrepaired SSB exceeds the repair capacity of the cell (110, 113-115). 
Furthermore, it was suggested that ARTD1 is not only binding SSB, but also double strand 
breaks (DSB) as well as other DNA structures such as replication fork structures in vitro and 
might thus play a role in DNA damage repair at stalled replication forks (116-118). The 
diverse and sometimes contradictory observations reveal that the functions of ARTD1 and 
ARTD2 during DNA damage and repair processes are not yet completely understood. 
Ongoing research points more and more at functions of ARTD1 in non DNA damage 
response processes (119). Along this line, ARTD1 activity can be induced independent of 
DNA damage, most likely by phosphorylation via different kinases such as extracellular-
signal regulated kinase 2 (ERK2) (120). Thus, posttranslational modification of ARTD1 and 
probably ARTD2 likely plays a significant role in the PAR-signaling process.  
 
Chromatin regulation 
ARTD1 is also known as an architectural nucleosome-binding factor and as a chromatin-
modifying enzyme. Unmodified ARTD1 can bind to nucleosomes and lead to compaction, 
but upon automodification the structure is relaxed (121, 122). Histones can be poly-ADP-
ribosylated as described earlier (see chapter 1.1.2) and thus, ARTD1 is involved in the 
regulation of higher-order chromatin structure. However, only a small fraction (less than 1%) 
of the histones were found to be modified in vivo (123, 124). Histone H1 is the main ADP-
ribose acceptor in native chromatin, whereas in H1-depleted chromatin (open status), H2B is 
the preferential target of ARTD1 (125). Similar functions were also proposed for ARTD2 
(126). However, ARTD2 is not able to modify histones in vitro (127, 128). As described 
above, genotoxic stress induces ADP-ribosylation, which consecutively leads to the 
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recruitment of different factors. Another model proposed that poly-ADP-ribosylation of 
histones might cause their dissociation from the DNA, thus giving distinct repair factors 
access to damaged DNA (129, 130). ADP-ribosylation of histones likely also takes place 
throughout other cellular processes such as transcription and remodeling, but the variation in 
polymer length may not be detectable by antibodies (as described earlier). Together, these 
models define ARTD1 rather as a chromatin remodeler, than a direct DNA damage repair 
enzyme (10, 11). In contrast, it was very recently shown that ARTD1 plays a major role 
during heterochromatin formation and interacts with pRNA – the non-coding RNA 
transcribed from a part of the intergenic spacers (131). 
ARTD1 and ARTD2 have also other chromosome-related functions, since they both interact 
with the kinetochore proteins centromere protein A (CENPA), centromere protein B 
(CENPB) and with the mitotic spindle checkpoint protein BUB3 in a cell-cycle dependent 
manner (132, 133). ARTD2 -/- male mice exhibit problems with accurate chromosome 
segregation, since the maintenance of centromeric heterochromatin structure and/or mitotic 
spindle integrity is disturbed (108). Moreover, ARTD2 has been implicated in the regulation 
of facultative heterochromatin integrity during X chromosome inactivation (Xi) (108).  
 
Transcriptional regulation 
ARTD1 influences transcriptional activation either as co-factor of the transcription 
complexes or via histone modifications and histone replacement. Hassa et al. could show for 
the first time that ARTD1 is a promoter-specific co-activator of nuclear factor kappaB (NF-
"B) – a regulator of inflammation and the release of cytokines and inflammatory mediators 
(134-137). Moreover, ARTD1 was shown to physically interact with p300/CBP and with 
both subunits of NF-"B (p65 and p50) and to synergistically co-activate NF-"B-dependent 
target gene expression (134, 136). Ju et al. confirmed those observations with their report that 
ARTD1 forms a co-activator/co-repressor exchange complex with factors such as nucleolin, 
nucleophosmin and topoisomerase IIb (66, 138-140). Moreover, by modulating the chromatin 
environment, ARTD1 also influences the transcription of diverse genes (141, 142). ARTD1 
was found to be enriched at promoter sites of actively transcribed genes, whereas histone H1 
is absent from these sites (67, 141). It appears that ARTD1 can exclude H1 from certain 
promoters, suggesting an interplay between both proteins (67, 143). Moreover, ARTD1 
activity is required for a nucleosome specific histone H1-high-mobility group B (HMGB1) 
exchange event and thus influences local chromatin structure (144). ARTDI was also 
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reported to maintain levels of H3K4me3 by inhibiting the recruitment of a lysine-specific 
demethylase KDM5B to sustain open chromatin (142). ADP-riboslyation of transcription 
factors has also been reported to have regulatory functions, as it regulates for example the 
CLOCK transcription factor, which is crucial for the maintenance of circadian rhythms of 
organisms (145). 
Independent of ARTD1’s function, ARTD2 was found to be involved in the modulation of 
several transcription factors, such as TTF-1and SIRT1 (146). Thereby, ARTD2 has a dual 
role, since it is a transcriptional repressor of SIRT1 and has activator functions together with 
TTF-1 for the expression of surfactant protein B (147, 148). ARTD2 was additionally 
reported to directly interact with topoisomerase I and II! and thus influences transcription 
indirectly by regulating the DNA structure (149, 150). As a modulator of the chromatin, 
ARTD2 was shown to regulate transcriptional intermediary factor (TIF)-1! and 
heterochromatin protein (HP)-1# (151). Furthermore, a recent publication inferred that 
ARTD2 acts as a co-repressor in an activity independent function by recruiting deacetlyases 
(HDACs) to active genes such as c-myc (152). Finally, Meder et al. analyzed the role of 
ARTD1 and ARTD2 in the nucleolus, showing that both enzymes colocalize with 
B23/nucleophosmin. No functional evidence of ARTD1 and ARTD2 on RNA polymerase I 
transcription was however described in that study (153). Another study showed that 
ribosomal biogenesis was influenced by ARTD1 at the post-transcriptional level and by pre-
rRNA processing in D. melanogaster (154). 
 
1.2.4 PARP inhibitors 
 
The first PARP inhibitors were developed based on the benzamide structure to mimic NAD+ 
- the substrate of the ARTDs. One of the first effective PARP inhibitors was 3-
Aminobenzamide (3-AB), which functions as a competitive inhibitor (Figure 5). This rather 
simple structure is prone to bind not only to ARTDs but also to other NAD+-consuming 
enzymes. Furthermore, its solubility and efficiency is poor (155, 156). Due to the homology 
of the catalytic active domain of the different ARTDs (especially ARTD1 and ARTD2), 
PARP inhibitors are not isoform specific, but rather inhibit several family members (156, 
157). The basic compound 3-AB was improved and second and third generation PARP 
inhibitors have emerged. An inhibitor of the second generation is N-(5,6-Dihydro-6-oxo-2-
phenanthridi-nyl)-2-acetamide hydro-chloride, also known as PJ-34 (Figure 5), which is a 
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potent PARP inhibitor (EC50=20nM), but lacks specificity as described above (157, 158). 
Furthermore, it was recently shown that PJ-34 binds to Pim kinases, which are proteins that 
are unrelated to ARTD (159). However, PJ-34 is still widely used in different fields of 
research (160) (see later). 
 
 
 
Figure 5: Structure of nicotinamide adenine dinucleotide and two PARP inhibitors. 
 3-Aminobenzamide – a first-generation PARP inhibitor and PJ-34 – a second-generation PARP 
inhibitor. 
 
The third generation of PARP inhibitors comprises competitive inhibitors binding tightly to 
the active site of ARTDs. Olaparib and Veliparib seem to specifically inhibit ARTD1 and 
ARTD2 with high efficiency (Olaparib IC50 for ARTD1= 5nM, for ARTD2= 1nM; Veliparib 
IC50 for ARTD1=5.2 nM for ARTD2= 2.9nM; Figure 6), but also bind ARTD3, which 
however was not confirmed to be active in vivo (157). PARP inhibitors recently reached great 
attention due to their beneficial effect as therapies for patients with breast or ovarian cancer 
with genetic defects in the BRCA1/2 gene (161-164), which later was shown not to be a 
requirement for sensitivity to PARP inhibitors (155). There are currently ongoing clinical 
trials with PARP inhibitors also in combination with radiation or chemotherapeutics, 
including the treatment of other cancer types such as advanced solid tumors and lymphoma 
(Figure 6) (155, 161, 165). However, none of the PARP inhibitors has so far been approved 
for clinical use. 
Nicotinamide adenine dinucleotide 
3- Aminobenzamide 
PJ-34 
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Interestingly, these inhibitors might have a broader application spectrum, for instance in 
inflammatory or ischemia-reperfusion-associated diseases (161). Preliminary experiments for 
this kind of application have however only been tested in animal models. Especially PJ-34 
was shown to be an effective inhibitor in angiogenesis (166, 167) and to improve endothelial 
and cardiac dysfunction associated with aging in mice (168, 169). This wide range of 
applications raises the question to which extent the effect is indeed due to inhibition of 
ARTD1 and 2. Thus, their specific mode of action remains to be further investigated. 
 
 
Figure 6: Overview of third generation of PARP inhibitors in clinical trials (165) 
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1.3  The cell cycle 
The term “cell cycle” refers to the process of cell division and the duplication of DNA, which 
is one of the most fundamental processes in biology (170). To ensure a proper cell division, a 
tremendous network of proteins and checkpoints tightly controls this process.  
The cell cycle is divided into two parts, the interphase and mitosis, and takes on average 24 h 
for a normal cycling human cell (171). The interphase is further divided into the G1, S and G2 
phases. During G1, which is in most cases the longest cell cycle phase, the cell is growing and 
preparing itself for DNA synthesis. In S phase, DNA duplication takes place and by the end 
of the S phase, the cell contains the double amount of chromatids. The replicated copy of 
each chromatid is still connected to the original copy. During G2 phase the proteins required 
for mitosis are synthesized. Moreover, the cell ensures that the DNA was replicated correctly 
before entering into mitosis. Mitosis is the stage of cell division, which is further divided into 
Pro-, Meta-, Ana- and Telophase (172). The sister chromatids are separated and two daughter 
cells arise. If extracellular conditions are disadvantageous, cells delay their progression 
through G1 phase and may even enter a quiescent stage known as G0 phase, in which they can 
remain for days, weeks or years before resuming proliferation (172). The aspects described 
above relate mainly to mammalian cells, since the cell cycle of yeast and plant cells functions 
slightly differently, although there are many homologous cell cycle factors (173). 
 
1.3.1 Control of the cell cycle 
 
The key-class of proteins responsible for a correct cell division are the Cyclins and the 
Cyclin-dependent kinases (Cdks) (174). The Cyclins received their names due to the cyclic 
fluctuation of their protein levels throughout the cell cycle (Figure 7). The Cyclins (the 
regulatory subunits) form a complex with Cdks (the catalytic subunit) and thus form active 
enzyme-complexes. The Cdks themselves are expressed constantly during the cell cycle and 
have only very little activity in the Cyclin-unbound state. The kinases are phosphorylated by 
Cdk activating kinases (CAK) after interacting with Cyclins, an event which turns them into 
active serine-threonine kinases that phosphorylate different target proteins in a cell cycle 
phase specific manner (174). The activity of the Cyclin-Cdk-complex is regulated by 
different events such as the induction and degradation of the Cyclin subunit, the 
phosphorylation of the Cdk subunit by CAK, the inhibition of the active complex by Cdk 
inhibitors and the spatial distribution of these factors in different cellular compartments (175). 
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At least 29 genes were found to encode related Cyclin proteins that share a conserved amino 
acid sequence termed the “Cyclin box”. This domain is responsible for protein-protein 
interactions with different enzymes, including the Cdks (176). The best-known Cyclins are 
those directly regulating the cell cycle: Cyclin A, B, D and E. For other Cyclins (e.g., Cyclin 
F, G, I, J) it is not even known if they interact with Cdks (176).  
 
 
 
Figure 7: Scheme of the cell cycle. The different cell cycle phases are indicated and a cell division is 
schematically depicted. The cyclin-Cdk complexes of the different cell cycle phases are indicated and 
the possible Cyclin-cdk- inhibitors are shown (CIP/KIP and INK4 family). The restriction point in 
mid-G1 phase is labeled in blue and cell cycle checkpoints are shown in red. 
 
Cyclin A forms a complex with Cdk2 during the S-phase and exists in two isoforms. While 
Cyclin A1 is only expressed during embryogenesis, Cyclin A2 is active throughout cell 
progression of somatic cells (177). Cyclin B interacts with Cdk1 and regulates the entry into 
mitosis. There are three Cyclin B isoforms, which differ in their subcellular localization. 
However, Cyclin B1 is the most studied one (178). Cyclin D appears in three isoforms, which 
are expressed as long as growth factors are present in the extracellular matrix and forms an 
active complex with Cdk4 or 6 throughout the G1 phase (179). The three different Cyclin D 
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isoforms are very similar, but are expressed in a tissue-specific or developmental-stage 
dependent manner (180). Cyclin E forms a complex with Cdk2 to enable G1-S phase 
transition. The Cyclin E1 isoform is the major isoform, whereas Cyclin E2 is usually 
expressed at low levels, but more strongly expressed in various cancer cells (181).  
 
1.3.2 Progression from G0 phase to S phase 
 
In regard to the results of the thesis, a detailed explanation of G0 phase, G0-G1 phase 
transition and G1-S-phase transition is presented here. Detailed explanations of the later cell 
cycle phases are descried elsewhere (172, 177, 182-184).  
 
G0 phase 
Cells enter the G0 phase because of growth inhibition or when they are terminally 
differentiated. During this process, transcription is reduced by the dREAM complex, which is 
responsible for the repression of many cell-cycle-regulating genes (over 800 genes) (185). 
The dREAM complex is composed of E2F-4, p130, DP and MuvB (185). When E2F-4 is 
removed from this complex, uncontrolled cellular proliferation is induced (186). In addition, 
E2F-4 can interact with HDAC and other chromatin-remodeling factors, which are important 
for repression of the G1 phase genes (187). Furthermore, p27 – a Cyclin-Cdk-Inhibitor – is 
strongly induced in resting, quiescent cells. p27 is an important factor for establishing the G0 
phase, because its depletion prevents the exit from the cell cycle and entering into the G0 
phase (188). In certain circumstances, cells can rest in the G0 phase until they die, but in most 
cases it is a transient state (172). For instance, liver cells neither grow nor divide, but keep 
the capacity to start cell division and to regenerate the tissue upon damage (172). Under 
favorable conditions, such as growth factor induction, cells are able to re-enter the cell cycle. 
In contrast, differentially terminated cells are insensitive to mitogens and rest permanently in 
the G0 phase (189). Very often, the resting/re-entry of the cells is defective in tumor cells, 
which makes it an interesting subject to study, although the G0 phase is still not very well 
understood (190).  
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G0-G1 phase transition 
Because of the reduced transcriptional activity, it is assumed that transcription factors are 
repressed in G0 phase and re-activated after mitogen induction. Several studies implicate that 
the E2F transcription factor family is involved in regulating cell cycle re-entry. For example, 
cells lacking E2F-1 show a delayed cell cycle re-entry (191). Furthermore, it has been 
recently shown that Cdk3, which is structurally similar to Cdk1 and Cdk2, binds Cyclin C 
during G0-G1transition and stimulates the phosphorylation of pRb during this transition in 
some human tumor cells (192). The inactivation of pRb seems to be sufficient for cell cycle 
re-entry (189). During the process of re-entry, p27 is exported from the nucleus to the 
cytoplasm and targeted for degradation. This process is mediated by Cyclin D2 (193). 
Furthermore, microRNAs should be considered as important cell cycle regulators, especially 
for the re-entry from G0 phase. Levels of several miRNAs are decreasing during the transition 
from G0 to G1 phase. For example, miR-503, an extended member of the miR-16 family, was 
shown to be highly expressed in G0 phase, but immediately decreases when cells enter 
G1hase. Although its function is not yet clear, the increased expression points to its 
importance during cell cycle entry (194). 
 
G1-S phase progression 
pRb is one of the key players of the early cell cycle phases and part of a protein family of 
three members (pRb= p110, p130, p107) (195). pRb functions as a classical tumor suppressor 
gene and is absent or mutated in one third of all tumors (196, 197). A specific mutation of the 
Rb gene leads to a rare pediatric eye tumor, retinoblastoma, which gave the protein its name 
(198). Especially in human bladder carcinoma, pRb was found to be hyper-phosphorylated in 
asynchronous cells, which hints at a disruption of p16 function or an overexpression of 
Cyclin D1 (199). pRb protein is normally hypo-phosphorylated in G0 phase and thus able to 
repress transcription by binding E2F-1. The most prominent candidates bound by pRB are 
the E2F proteins, but also histone deacetylases and chromatin remodeling complexes (200). 
The large pocket region of pRb binds to E2F, the small pocket binds proteins with an 
LXCXE motif (e.g., HDAC or Cyclin D1) (195). The D-type Cyclins are induced in early G1 
phase after mitogen induction and interact with Cdk4 and/or Cdk6. The active complex 
phosphorylates the members of the retinoblastoma protein family, which all contain multiple 
phosphorylation sites (e.g., pRb has 16), of which only some are recognized by the Cyclin D-
Cdk4/6 complex.  
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E2F proteins are a family of transcription factors of which three are activators (E2F-1 to 3) 
and five are repressors (E2F-4 to 8) (201). E2F target genes are Cyclin E, A, D1, Cdc2, 
Cdc25A, DNA polymerase #, Cdc6 and minichromosome maintenance (MCM) proteins 
(202). E2F is also involved in apoptosis and thus responsible for transcription of apoptosis 
protease-activating factor 1, p73 and ARF (203). The active E2F transcription factor is a 
heterodimeric complex of E2F protein and a member of the DP family (204, 205). For 
transcriptional activity, the E2F-1 complex interacts with the histone acetyltransferase (HAT) 
p300/CBP co-activator proteins (Figure 8). p300 is bridging the E2F-1 complex to the basal 
transcriptional machinery and thus facilitates the assembly of multiprotein cofactor complex 
(206). The intrinsic HAT activity can loosen the chromatin by acetylating histones. 
Furthermore, the acetyltransferase is able to directly acetylate E2F-1, which increases its 
DNA binding activity and protein stability (207).  
 
!
 
Figure 8: Regulation of E2F-1 activity (from Stevens et al. (203)). 
pRb= Retionblastoma protein, HDAC= histone deacetylase, PCG= polycomb group proteins, 
SWI/SNF= SWItch/Sucrose Non Fermentable nucleosome remodeling complex, MTase= 
methyltransferase, p= phosphorylation. 
 
The main driver of G1-S phase progression is Cyclin E in complex with Cdk2. Cyclin E is a 
downstream target of E2F-1/DP1. Upon phosphorylation by Cyclin D-Cdk4/6, the pRb 
protein-binding pocket undergoes a conformational change and the bound protein (such as 
E2F-1) is released (208). Free E2F-1 binds to the promoter of the Cyclin E gene and thus 
Cyclin E expression is increased in late G1 phase. Via a positive feedback loop, newly 
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formed Cyclin E/Cdk2 complexes further phosphorylate pRb to fully inactivate the protein 
and release all bound E2F (195). Moreover, Cyclin E-Cdk2 kinase activity is essential for the 
initiation of DNA replication by facilitating the loading of MCM chromosome maintenance 
proteins onto origins of replication (209). During early S phase the active Cyclin A-Cdk2-
complex interacts with E2F-1, which leads to the loss of DP-1 and thus inactivates E2F-1 
transcription factor during S phase progression (203). 
 
1.3.3 Cyclin-dependent kinase inhibitors 
 
Important regulators of the Cyclin-Cdk-complex are Cdk inhibitors, which bind transiently to 
the complex and inhibit its activity (210, 211). The Cdk inhibitors are divided into two main 
families, whose members share structural and functional homologies – the INK4 family and 
the CIP/KIP family (210, 211). The INK4 family comprises four members: p16INK4a, p15INK4b, 
p18INK4c and p19INK4d, which are all specific for Cdks 4 and 6 and hence play a role during 
early G1 phase (175). The key representative of the family is p16, which is one of the most 
commonly inactivated tumor suppressors in cancer (212). p16 is also used as a senescence 
marker, since it is not up regulated in quiescent or differentiated cells, but only in senescent 
cells (213, 214).  Particularly interesting is, that the p16 gene CDKN2A can be transcribed 
from two distinct promoters, which leads to two structurally and functionally different 
proteins – p16INK4a and p14ARF (215). Both of these proteins are tumor suppressors. ARF 
is induced upon mitogen stimulation and involved in the DNA damage response of 
MDM2/p53 signaling, but also acts as an inhibitor of ribosome biogenesis in the nucleolus 
(216, 217). The second Cdk inhibitor family is named CIP/KIP family and comprises three 
proteins: p21CIP1, p27KIP1 and p57KIP2. These inhibitors share a broad concentration-dependent 
specificity towards most of the Cyclin-Cdk-complexes through binding to Cyclins and Cdks 
by a conserved N-terminal domain (210). At low concentration, they mainly inhibit the 
Cyclin D-Cdk-complex, while at higher concentration also other Cyclin-Cdk-complexes are 
targeted. Interestingly, the CIP/KIP inhibitors may also function as adaptors to promote 
Cyclin-Cdk-complex assembly and programming them for certain functions (218). CIP/KIP 
Cdk inhibitors are regulators of apoptosis in various ways depending on the cellular context 
(210). Although they share broad specificity, each of the three family members also has 
specific biological functions. p21 is an important transcriptional target of p53 during DNA-
damage induced cell cycle arrest (210). p27 is usually elevated in mitogen-starved cells and 
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other quiescent states and it is rapidly down regulated when cells resume the cell cycle in the 
G1 phase (219, 220). p57 is the least studied family member, but it was shown to play a role 
during embryonic development (219, 221, 222).  
 
1.3.4 Cell cycle checkpoints 
 
High accuracy and fidelity are required throughout each phase of the cell cycle to ensure a 
correct cell division. Therefore, the cell cycle is controlled by several cell cycle checkpoints 
and the restriction point. The restriction point in the mid-G1 phase is the is the moment when 
the cell commits to cell division if the environmental conditions (presence of growth factors) 
are favorable (196). The key regulatory event during this stage is the phosphorylation of pRb, 
which abrogates the binding to E2F-1 and subsequently leads to activation of E2F-1 and the 
expression of its target genes. As described in the previous section, Cdk-inhibitors (e.g., p16, 
p21 and p27) are important regulators of the Cyclin-Cdk- complexes, which in turn control 
the interaction of pRb with E2F-1 and thus are themselves also of great importance for this 
restriction point (223). 
The checkpoints (Figure 7) are mostly activated upon DNA damage and induce growth arrest 
to gain time for the repair of the damaged DNA in order to prevent mutated DNA from being 
replicated. Hence, regulators of these checkpoints are very often mutated in cancer cells, 
leading to impaired cell division and uncontrolled cell growth. Beside the restriction point in 
G1, a G1 checkpoint exists, which is activated upon DNA damage and leads to a sustained 
sometimes even permanent arrest of cells in late G1. This checkpoint is driven by the 
ATM/ATR-Chk2/Chk1-p53/MDM2-p21-pathway (224-226). Upon DNA damage, 
ATM/ATR phosphorylates p53 and its ubiquitin ligase MDM2, which usually targets p53 for 
degradation. Upon DNA damage, MDM2 is not only phosphorylated and thus inactivated by 
ATM/ATR, but also by Chk1/Chk2, which leads to p53 stabilization (227). p53 is the main 
transcription factor for the p21CIP1 gene – a Cdk inhibitor of the G1 phase, which itself arrests 
the cell cycle by blocking pRb phosphorylation and subsequently allowing complex 
formation with E2F-1 (224, 226). Another pathway that is activated during DNA damage is 
regulated by CDC25a, which usually is an important phosphatase to positively regulate the 
Cyclin E-Cdk2 complex. The phosphorylation of CDC25a is increased upon DNA damage 
and leads to enhanced degradation of CDC25a. Consequently, the Cyclin E-Cdk2 complex is 
not dephosphorylated and thus activated, and cells do not progress into S phase. This 
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pathway is activated much faster upon DNA damage than the rather slow p53 pathway (228, 
229). 
The intra-S-phase checkpoint can be activated in response to double strand breaks, which 
lead to a reduced DNA synthesis rate (229). On the other hand, DNA damage or depletion of 
deoxyribonucleotides can cause stalling of the replication fork to prevent replication of the 
damaged DNA and to allow the cell to recover after DNA repair (229). This checkpoint is 
additionally controlled in two ways by the ATM/ATR signaling machinery (229). On one 
hand and as described before, the phosphatase CDC25a influences Cdk2 activity. 
Destabilization of CDC25a upon DNA damage leads to a failure to activate Cdk2, thus 
prevents CDC45 loading and consecutively impairs recruitment of the DNA polymerase. 
Alternatively, NBS1, a member of the Mre11-Rad50-NBS1 (MRN) complex, is 
phosphorylated by ATM, which in turn phosphorylates H2A.X (yH2A.X) (22, 230) and 
recruits other factors of the DNA repair machinery to DNA double strand breaks (231).  
The G2/M checkpoint before mitosis prevents the segregation of defective chromosomes, 
which might be induced by DNA damage at earlier stages of the cell cycle (232). An 
important player at the G2 checkpoint is the mitosis-promoting activity of the Cyclin B-Cdk1 
kinase. ATM/ATR, Chk1/Chk2 and p38-kinase perturb Cyclin B-Cdk1 activity after stress by 
degrading the activation-promoting CDC25 family of phosphatases (182). Under normal 
conditions, CDC25 phosphorylates maturation promoting factor (MPF), which subsequently 
phosphorylates Cdk1.  
The last checkpoint is the mitotic or spindle assembly checkpoint, which is active during 
metaphase and blocks the transition to anaphase by inhibition of the CDC20 activator 
anaphase-promoting complex (APC). This checkpoint is induced by wrongly attached 
kinetochores (233). 
 
1.3.5 Role of microRNA expression in cell cycle regulation 
 
An additional level of cell cycle regulation is exerted by microRNAs (miRNAs). miRNAs 
are a class of non-coding RNAs with a length of 18-25 nucleotides that bind to and partially 
silence complementary sequences in target mRNAs by inducing mRNA degradation or via 
translational repression (234). miRNAs are often found in clusters throughout the genome 
that are transcribed simultaneously. Recent evidences suggest that miRNAs may also control 
the levels of diverse cell cycle factors since they show dynamic expression patterns in a 
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tissue- or stage-specific manner (235). In fact, the deregulation of miRNAs was shown to 
alter protein levels of critical cell cycle-related genes and is thus implicated in various cancer 
types (236, 237). In silico analyses suggest that more than 30% of the human genome may be 
regulated by miRNAs (238, 239). Most of the cell-cycle-targeting miRNAs modulate the re-
entry into the cell cycle or the G1-S phase progression (240). The anti-proliferative potential 
of the miR-15a-16-1 cluster provided the first insight into miRNAs and cell cycle regulation 
(240). This cluster encodes two mature miRNAs, miR-15a and mir-16 (240), which target 
Cdk1, Cdk2, Cdk6 as well as Cyclin D1, D3 and E (241-243), but several other miRNAs 
regulate the expression of these same cell cycle factors. For example, the level of Cyclin D is 
also affected by let-7, miR-17, -19a, -20a and -34 (240). It was shown that miR-15 and -16 
are specifically and directly target Cyclin E transcription and that these miRNA are strongly 
up regulated by E2F-1. Thus, E2F-regulated miRNAs participate in a feedback loop to 
restrict and control E2F-1 activity (244). miRNA may also play a major role in cell cycle re-
entry from the quiescent G0 phase, since there is evidence that cell-cell contact in quiescent 
cells globally activates miRNA biogenesis due to increased processing and more efficient 
incorporation of miRNAs into RNA-induced silencing complex (RISC) (245). As a 
consequence, fewer mRNAs are translated. The whole complexity of cell cycle regulation by 
miRNAs is not yet fully understood, but should be considered to better understand the 
regulatory processes. 
 
1.3.6 Role of the ARTD proteins in the cell cycle – a focus on G1                   
progression 
 
The ARTD protein family is involved in a variety of biological functions (chapter 1.2). 
Among these are also cell-cycle related processes such as heterochromatin formation during 
late S-phase (131) or the localization of ARTD1 to the centrosome and the chromosomes 
during cell division (246). Furthermore, overexpressed ARTD3 is localized at centrosomes 
and interferes with G1 to S phase progression (247) and ARTD5 (tankyrase 1) is involved in 
the separation of sister telomeres during mitosis (248). Recently, it was shown that progestin 
gene regulation involves the activation of ARTD1 via Cdk2-dependent phosphorylation, 
leading to H1 displacement (141, 249). This is essential for the effect of progestin on cell 
cycle progression in breast cancer. 
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There is also evidence indicating that ARTD1 might play a role during the early cell cycle 
phases. ARTD1 interacts with the C-terminal binding protein (CtBP) to form a co-repressor 
complex for p21 transcription. ARTD1 enzymatic activity was also reported to be necessary 
for p21 expression after genotoxic stress (250). Simbulan-Rosenthal et al. reported that 
ARTD1 interacts with E2F-1 in vitro and in vivo and up regulates E2F-1expression during 
early S phase (251, 252).  PAR formation was also detected during G0-G1 transition after 
mitogen induction, suggesting that ADP-ribosylation is involved in growth factor signaling 
and the induction of immediate-early genes (90). However, this study faced the problem that 
PAR can be induced already during synchronization with chemical agents or by serum 
starvation and subsequent growth factor addition (Vetmed Dissertation of Sandra Bäckert, 
2009), raising concerns about the physiological relevance of such findings. 
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2 AIM OF THE THESIS 
The intracellular ADP-ribosyltransferase family (ARTD family) consists of 18 members. 
Some of these enzymes were described to synthesize polymers of ADP-ribose (PAR), while 
others are only able to catalyze mono-AD-ribosylation or may even be enzymatically inactive. 
ARTD1 and ARTD2 are both chromatin-associated enzymes and therefore localized in the 
nucleus. Both proteins were described to synthesize polymers of ADP-ribose (PAR) upon 
exposure of cells to genotoxic stress. Single ARTD1 or ARTD2 knockout mice are viable, 
but the double knockout is lethal, indicating that at least one allele of either ARTD1 or 
ARTD2 is required for development. In most cellular processes that are regulated by ADP-
ribosylation, ARTD1 is the main contributor to PAR formation. However, there are 
indications that ARTD2 regulates distinct processes independent of ARTD1, but molecular 
details and mechanistic insight are still scarce. Previous biochemical analyses of our 
laboratory provide evidence that the catalytic domains of ARTD1 and ARTD2 are not 
interchangeable, suggesting that these enzymes have different roles. Furthermore, the two 
enzymes have very distinct N-termini, which also hints at different activation mechanisms. 
Based on these observations, we hypothesized that ARTD1 and ARTD2 regulate different 
cellular processes or use different mechanisms to regulate common processes. 
This hypothesis was experimentally verified by studying the function of ARTD1 and ARTD2 
in cell cycle regulation, in particular during G0 to G1 progression, and for PAR formation in 
response to oxidative stress. 
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3 RESULTS 
3.1 Overview of published and submitted manuscripts 
3.1.1 ARTD2 activity is stimulated by RNA 
 
Authors:  Karolin Léger, Natasa Savic, Raffaela Santoro,  
Michael O. Hottiger  
 
  Journal:  Manuscript submitted 
 
  Contribution:  Planning, performing and evaluating the experiments.  
              Preparation of the figures and revision of the manuscript.  
 
 
3.1.2 ARTD1 and ARTD2 differentially regulate cell-cycle re-entry and progression in 
T24 bladder carcinoma cells  
  Authors:  Karolin Léger, Michael O. Hottiger 
  Journal:  Manuscript submitted 
  Contribution:  Planning, performing and evaluating the experiments.  
               Preparation of the figures and revision of the manuscript.  
 
3.1.3 PKC signaling prevents irradiation-induced apoptosis of primary human     
fibroblasts 
 
Authors:  A. Bluwstein, N. Kumar, K. Léger, J. Traenkle, J. van 
Oostrum, H.   Rehrauer, M. Baudis and M.O. Hottiger  
  Journal:  Cell Death Dis., 2013 Feb 14 
Contribution:  Performing and evaluation of qPCR analyses (Supplementary 
                       Figure 1e, 3c, 3d), performing of flow cytometry analyses  
                              (Supplementary Figure 2a, 2d, 3a, 13e)  
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Abstract 
ADP-ribosyltransferases (ARTs) are important enzymes that regulate the genotoxic 
stress response and the maintenance of genome integrity.  ARTD1 (PARP1) and 
ARTD2 (PARP2) are homologous proteins that modify themselves and target proteins 
by the addition of mono- and poly-ADP-ribose moieties.  Although both enzymes were 
described to be involved in the genotoxic stress response, only ARTD1 is strongly 
activated by double stranded DNA in vitro, opening the question whether other 
molecules than DNA can regulate ARTD2 activity.  Here, we characterize cellular poly-
ADP-ribose (PAR) formation upon hydrogen peroxide (H2O2) or N-methyl-N’-methyl-
nitro-N-nitrosoguanidine (MNNG) stress in combination with application of the RNA 
polymerase I inhibitor Actinomycin D (ActD).  Combined treatment with ActD and 
H2O2 or MNNG substantially increased the number of PAR forming cells and enhanced 
the overall PAR content.  This enhancement was mediated by ARTD2 but not by 
ARTD1 in vivo.  Further elucidation revealed that ActD treatment lead to the 
accumulation of short RNA polymerase I-dependent rRNA transcripts. In vitro 
experiments confirmed that ARTD2, in contrast to ARTD1, is strongly activated by 
RNA but not by double-stranded DNA.  Our findings identify a new activator for 
ARTD2-dependent ADP-ribosylation, which has important implications for the future 
analysis of the biological role of ARTD2 in the nucleus. 
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Introduction 
Cells have evolved a complex and diverse arsenal of mechanisms to overcome genotoxic 
stress and to guarantee genome integrity (1).  Depending on the type of stress, different 
response mechanisms are activated in order to prevent the inheritance or repair of damaged 
DNA (2,3).  In addition to factors that directly bind and replace incorrect bases and repair 
DNA strand breaks, a variety of proteins are indirectly involved in the genotoxic stress 
response by regulating the levels and activities of other proteins or by modulating chromatin 
structure.  ADP-ribosyltransferases (ARTs) are prominent members of this group of enzymes. 
ARTs use nicotinamide adenine dinucleotide (NAD+) as a substrate for the synthesis of 
mono- and poly-ADP-ribose modifications on target proteins (4).  The ART protein family is 
divided into diphtheria toxin-like ARTs (ARTDs) and cholera toxin-like ARTs (ARTCs) (5).  
In human, the ARTD family currently comprises 18 nuclear and cytoplasmic mono- and 
poly-ADP-ribosyltransferases, while ARTCs are mainly extracellular enzymes that only 
transfer one ADP-ribose unit to their target proteins (5).   
 Proteins of the ARTD family have been implicated in a plethora of cellular functions 
(6,7).  Research during the last years has documented numerous functions of ARTD1 and of 
ADP-ribosylation in general that are not directly linked to DNA repair or the DNA damage 
response (8,9).  The function of ARTD1 in DNA repair is substantiated by the strong 
activation of ARTD1 activity by DNA in vitro, as well as by the strong induction of poly-
ADP-ribosylation upon treatment of cells with DNA damaging agents.  Nevertheless, a direct 
involvement of DNA damage in the activation of ARTD1 in vivo is still largely based on 
correlations.  PAR formation is dependent on the severity of the genotoxic stress and can 
even lead to cell death due to NAD+ and ATP depletion (10).  The functional involvement of 
ADP-ribosylation in the DNA damage response has provided the incentive to generate PARP 
inhibitors as anti-tumour drugs, which are being developed and tested as novel therapies (11-
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14).  The closest homolog of ARTD1 is ARTD2, which is also able to mono- and poly-ADP-
ribosylate itself and target proteins.  Although ARTD1 was discovered several decades ago, 
ARTD2 was only discovered in the 1990s as a result of the detection of residual PAR 
forming activity in ARTD1 knockout mouse embryonic fibroblasts (MEFs) (15).  Like 
ARTD1, ARTD2 has also been implicated in various cellular functions, which include 
genome and chromosome stability, heterochromatin integrity, cell death, differentiation and 
inflammation (16).  Mammalian ARTD2 is a 66.2 kDA protein with a C-terminal catalytic 
domain that is 69% similar to the homologous domain in ARTD1 (15) (17).  Despite this 
common domain, ARTD2 is much less active than ARTD1, suggesting that it may be 
activated by different and yet unknown stimuli, which would interact with the other domains 
found in these proteins.  While the DNA binding domain of ARTD1 contains two Zn-fingers 
and a Zn-binding domain, the DNA binding element of ARTD2 is represented by the 
SAF/Acinus/PIAS-DNA-binding (SAP) domain.  In addition, ARTD2 seems to modify 
different proteins, suggesting that both enzymes might indeed regulate distinct biological 
functions (18,19).  Thus, the identification of such new ARTD2 activators will likely also 
reveal novel biological phenomena that are regulated specifically by ARTD2.   
 The nucleoli are sites of ribosomal RNA (rRNA) genes transcription, rRNA 
maturation and ribosome production and assemble around the nucleolar organizer regions 
(NOR) (20,21).  A human diploid cell contains about 400 rRNA genes that are all organized 
in head-to-tail tandem repeats on five different chromosomes (21).  However, also in highly 
active metabolic cells, only a subset of these genes (approximately 50 %) is actively 
transcribed (22,23).  The remaining rRNA genes are silenced in a tissue- and cell type-
specific manner (24).  Active rRNA genes are transcribed by RNA polymerase I (Pol I) to 
synthesize a 45S pre-rRNA.  For the initiation of rRNA transcription, Pol I has to be part of a 
protein-multi-complex that includes factors like UBF, SL1, and TIF-IA (25).  The production 
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of ribosome-subunits is heavily influenced by diverse stress stimuli and metabolic changes 
(26).  The cell reacts to nutrient starvation, oxidative stress or inhibition of protein synthesis 
with a decrease of rRNA transcription, whereas growth factors and proliferation stimulating 
agents increase the rRNA transcription.  rRNA synthesis is particularly sensitive to ActD at a 
low concentration of 50 ng/ml, while RNA polymerases II (Pol II) and III (Pol III) are only 
inhibited at higher concentrations (Pol II > 1 $g/ml, Pol III > 5 $g/ml) (27,28).  ActD 
intercalates with CG-rich regions of the DNA and thus stabilizes covalent topoisomerase I-
DNA complexes that prevent RNA polymerase progression and consequently inhibit RNA 
synthesis (29).  The intercalation takes mainly place downstream of rDNA transcription start 
sites, thus inhibiting transcription during elongation and leading to an immense accumulation 
of short RNA transcripts over time (30,31).  In Drosophila, ARTD1 was reported to regulate 
ribosomal biogenesis on the post-transcriptional and pre-rRNA processing level (32).  
Furthermore, ARTD1 and ARTD2 have been both shown to co-localize with 
B23/nucleophosmin and nucleolin, nucleolar proteins involved in several processes including 
rRNA transcription and elongation, ribosome assembly, and rRNA processing (33,34).  No 
direct effect of ARTD1 and ARTD2 on Pol I transcription was, however, described in these 
studies.  More recently, ARTD1 has been linked to heterochromatin formation and 
specifically to silencing of rRNA genes in the nucleolus (35,36). 
Here, we characterize the nucleolar function of ARTD2 upon different stresses.  H2O2 or 
MNNG treatment induced PAR formation in the nucleolus of different cell lines.  Co-
treatment with low doses of ActD enhanced PAR formation.  Surprisingly, this co-treatment 
activated mainly ARTD2 but not ARTD1 in vivo.  ActD treatment is known to enhance the 
formation of short rRNA products.  In vitro experiments confirmed that ARTD2 is strongly 
activated by this RNA as well as other single stranded RNA but not by double-stranded DNA 
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through its SAP domain. Our findings thus reveal a new activator of ARTD2, which opens 
new possible implications for the future analysis of the biological role of ARTD2. 
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Methods 
Cell culture 
T24 cells were cultivated in McCoy’s 5A medium (Gibco, Invitrogen, CA, California, USA) 
at 37°C.  NIH/3T3, HeLa cells as well as MEFs were cultivated in Dulbecco's Modified 
Eagle's Medium (DMEM) (PAA, Pasching, Austria).  231-MD-MBA cells were cultivated in 
Roswell Park Memorial Institute medium (RPMI) (Gibco, Invitrogen, CA, California).  All 
media were supplemented with 1% (v/v) Penicillin/Streptavidin and 10% (v/v) fetal calf 
serum (Gibco, Invitrogen, CA, California, USA). 
 
siRNA transfection 
Negative control allstars (siMock), human siPARP1 #6, human siPARP2 #6, human siPARG 
#2, mouse siPARP1 #7, mouse siPARP2 # 8 were ordered from Qiagen (Hilden, Germany).  
Cells were seeded 1 day before transfection (5x105 cells per 6cm plate) and transfection was 
carried out with 40 nmol siRNA per plate and RNAi MAX lipofectamine (Invitrogen, 
Carlsbad, CA, USA).   
 
Antibodies 
Following antibodies were used: From Santa Cruz Biotechnology, Inc (Dallas, TX, USA): 
PARP1/ARTD1 (H-250, rabbit), Pol I (rabbit).  From Active motif (Carlsbad, CA, USA): 
PARP2 (rabbit).  From Sigma Aldrich (St. Louis, MO, USA): tubulin (mouse). From Cell 
Signaling (Danvers, MA, USA): fibrillarin.  From Jackson ImmunoResearch Laboratories 
(Suffolk, UK): secondary FITC-conjugated AffiniPure Goat Anti-mouse, secondary Cy3TM -
conjugated AffiniPure Goat Anti-mouse. Homemade: PAR 10H (mouse). 
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RNA extraction with TRIzol® reagent and qPCR analysis 
TRIzol® RNA Isolation Reagent (500 $l, Life Technologies, CA, California, USA) was 
applied directly to the plates and the supplier’s protocol was followed.  DNase treatment was 
performed using the TURBO DNA-freeTM Kit (Life Technologies, Carlsbad, CA, USA).  
RNA was quantified with a NanoDrop (ThermoFisherScintific, Waltham, MS, USA) and 
reverse transcribed according to the supplier’s protocol (High Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems, Foster City, CA, United States).   
Quantitative-real-time polymerase chain reactions (qPCR) were performed with SYBR® 
green SensiMix SYBR Hi-ROX Kit (Bioline Reagents Ltd, London, UK) and a Rotor-Gene 
Q 2plex HRM System (Qiagen, Hilden, Germany). 
   
Cell lysis, SDS-PAGE and Western blot analysis 
Whole cell lysis was performed either with trypsinized cells or directly on plates by using a 
Tris-lysis buffer (50 mM Tris pH 8, 500 mM NaCl, 1% Triton X-100, 1 $g/ml pepstatin, 1 
$g/ml bestatin, 1 $g/ml leupeptin, 2 mM PMSF; 10 min, 4°C).  Bradford assay (Bio-Rad 
laboratories, Hercules, CA, USA) was performed and, if not otherwise indicated, 30 $g of 
protein extract was loaded and separated on an 10% or 12% SDS-polyacrylamide gel (120V).  
The gel was blotted on a PDVF membrane and analyzed by using protein specific antibodies.   
 
Immunofluorescence microscopy  
Cells were seeded on cover slips (10x5 cells per well in a 24-well-plate) and grown overnight.  
After H2O2 (1 mM in FCS-free medium, 10 min), MNNG (500 $M in FCS-free medium, 30 
min) or medium-only treatment, cells were fixed (methanol: acetic acid 3:1, 5 min on ice), 
washed twice with PBS, and incubated with 10H PAR antibody (1:350) in PBS (containing 
5% milk and 0.05% Tween, 1 h at room temperature or overnight at 4°C).  Cover slips were 
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incubated with secondary Cy3-Antibody (1 h at room temperature in the dark).  After 
washing with PBS, cover slips were mounted with Vectashield containing DAPI (Vector 
Laboratories, Burlingame, CA, USA) and sealed with nail polish.  For quantification, at least 
100 cells per condition were analyzed. 
Conventional microscopy was carried out using a Leica DMI 6000B light microscope (Leica 
microsystems GmbH, Wetzlar, Germany).  Confocal laser scanning microscopy was carried 
out with a Leica SP 5 resonant APD system (Leica microsystems GmbH, Wetzlar, Germany). 
 
In vitro RNA transcription  
Linearized vectors containing rRNA sequences (from -16 to +130 and pRNA -232 to -1) and 
control sequences (hKCNA from +1 to +237) were used to in vitro transcribe RNA using T7 
polymerase. After DNase I treatment, transcripts were double purified using TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.  
 
In vitro ARDT1 or ARTD2 activity assay 
10 pmol baculo-virus purified MYC-hARTD1(wt)-HIS or purified human ARTD2(fl)-HIS 
were incubated with NAD+ in the reaction buffer (250 mM Tris-HCl pH 8, 20 mM MgCl2, 
1.25 mM DTT, 5 $g/ml P/B/L – proteinase inhibitors, 30°C, 10 min).  5 pmol of EcoRI 
linker or different concentrations as indicated of short RNA transcripts were added to the 
reaction.  For ADP-ribosylation reactions, radioactive NAD+ (32P, final concentration 100 
nM) and non-radioactive NAD+ (final concentration 1.6 $M) was added unless stated 
otherwise.  Reactions were terminated by adding Laemmli buffer and subsequent boiling of 
the samples (5 min, 95°C).  SDS-PAGE was performed; gels were stained with coomassie, 
de-stained, and subjected to film exposure.   
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In vitro PARG assay 
ARTD1 auto-ADP-ribosylation was carried out as described before and the reaction mix was 
purified over illustra MicroSpin G-50 Columns (GE Healthcare GmbH Europe, Freiburg, 
Germany).  Equal amounts of reaction mix were added to pre-chilled tubes containing 
baculo-purified hPARG-(fl) (2 pmol).  Reactions were carried out in the presence or absence 
of the indicated PARG inhibitors. 
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Results 
H2O2 treatment induces nucleolar PAR formation. 
To investigate the localization and molecular mechanism of PAR formation, T24 cells were 
treated with H2O2 (1 mM for 10 min).  PAR formation was analysed by immunofluorescence 
(IF) using anti-PAR antibodies and data were obtained by conventional or confocal 
fluorescence microscopy.  The PAR signal was localized to regions of the nucleus that were 
weakly stained by DAPI, indicating that nucleoli are sites of PAR formation (Figure 1A).  
The PAR signal in T24 cells treated with H2O2 co-localized with ARTD1, which suggests 
that ARTD1 is at least partly responsible for PAR synthesis in response to oxidative stress in 
T24 cells (Figure 1B).  The partial co-localization with Pol I and the nucleolar Fibrillarin 
protein confirmed that PAR formation occurs predominantly in the nucleolus of H2O2-treated 
NIH/3T3 cells (Figure 1C,D).  A similar nucleolar PAR signal was observed in H2O2 treated 
NIH/3T3 cells, HeLa cells and mouse embryonic fibroblasts (MEFs), suggesting that the 
nucleoli are the main location for the cellular PAR formation during oxidative stress (Figure 
S1A). 
 
ActD treatment enhances nucleolar PAR formation upon H2O2 and MNNG   
stimulation. 
Although PAR formation has been mostly studied in the context of DNA damage, which can 
be induced by H2O2 and MNNG, a link between PAR synthesis and Pol I-dependent 
transcription has not been documented. To investigate the link between Pol I-dependent 
transcription and stress-induced PAR formation, we optionally pre-treated cells with a low 
dose of the transcription inhibitor ActD for 20 hours and then exposed them to H2O2 or 
MNNG (28).  Unexpectedly, treatment with ActD and H2O2 or MNNG increased the number 
of PAR-positive cells and the intensity of the PAR signal in comparison to cells that were not 
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pre-treated with ActD (Figure 2A,B).  The analysis of 45S pre-rRNA levels confirmed that 
ActD was effective in impairing pre-rRNA synthesis (>90%), while H2O2 or MNNG reduced 
pre-rRNA levels only by 25-40% (Figure S1B). ActD enhanced PAR formation also in 
NIH/3T3, HeLa and MDA-MB-231 cells co-treated with H2O2 or MNNG (Figure S1C,D and 
S2A), indicating that the observed ActD effect is generally conserved.  Quantification of the 
number of responsive cells and the intensity of PAR formation per cell revealed that only a 
pre-treatment of at least 4 hours was able to enhance PAR formation, while short pre-
treatment of only 30 min had no effect.  Furthermore, PAR formation seemed to be enhanced 
stronger in MNNG treated cells as compared to H2O2 treated cells (Figure 2C and D). Since 
PAR formation could be inhibited by Olaparib, an inhibitor of ARTD1 and ARTD2 (Figure 
S2B and S1B, (37)), these data suggested the involvement of either ARTD1 or ARTD2 and 
provided evidence for a synergistic effect between oxidative stress and the interference of 
45S pre-rRNA synthesis for PAR accumulation in the nucleolus.   
 
ARTD2, but not ARTD1 is responsible for the ActD-dependent enhancement of PAR 
formation after H2O2 or MNNG treatment. 
To investigate whether ActD exerts its synergistic effect through ARTD1 or ARTD2, T24 
cells were depleted of ARTD1 or ARTD2 by siRNA (Figure S2C) and subsequently treated 
with H2O2.  Knockdown of ARTD1, but not of ARTD2, almost completely abolished PAR 
formation in T24 cells treated with H2O2, confirming that ARTD1 strongly contributes to 
H2O2-induced PAR formation (Figure 3A,C).  Co-treatment of siARTD1 cells with H2O2 and 
ActD revealed that ActD did not affect the numbers of PAR positive T24 cells after 30 min, 
but started to enhance PAR formation after 4 hours of ActD treatment (50 ng/ml) and even 
stronger (up to PAR positive cells to 90%) after 20 hours (Figure 3B).  These results 
indicated that the synergistic effect between oxidative stress and the inhibition of 45S pre-
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rRNA synthesis on PAR accumulation in the nucleolus was not mediated by ARTD1.  In 
contrast, no increase in PAR formation was observed in ARTD2 depleted T24 cells that were 
treated with H2O2 and ActD (Figure 3D), indicating that the stimulatory ActD effect on PAR 
formation was mainly regulated by ARTD2.  The presence of ARTD2, but not of ARTD1, 
seemed similarly responsible for the increased PAR formation observed after co-treatment of 
ActD and MNNG in T24 cells (Figure 3E-H). H2O2 or MNNG treatment in combination with 
ActD in NIH/3T3 cells and subsequent quantification of the PAR formation by IF or 
visualisation by Western blot furthermore confirmed that ARTD2 is also responsible for the 
stimulatory ActD effect in mouse cells (Figure S3A-G for H2O2 or S4A-C for MNNG).  
Together, these results indicated that ARTD2 is involved in PAR formation in response to 
H2O2- or MNNG-treatment in combination with ActD in T24 and NIH/3T3 cells.   
 
ARTD2 activity is stimulated by rRNA in vitro.   
The described synergistic effect between ActD and H2O2 or MNNG on PAR formation could 
either be due to an inhibition of PAR degradation or a stimulation of PAR synthesis.  The 
former was studied by determining whether ActD affects the activity of the poly-ADP-ribose-
glycohydrolase (PARG), the primary enzyme responsible for degrading protein-bound poly-
ADP-ribose (Figure 4A).  In vitro 32P-labeled PARylated ARTD1 was incubated with PARG 
in the absence or presence of ActD and PARylated ARTD1 levels were monitored by 
autoradiography. Treatment with ActD did not prevent degradation of PAR moieties of 
ARTD1, indicating that ActD does not affect PARG activity.   
The results described above indicated that H2O2 induces PAR formation in the nucleoli 
(Figure 1). Inhibition of 45S pre-rRNA synthesis by ActD prevents Pol I elongation at the 
rDNA coding region, leading to an accumulation of short RNA transcripts after 20h (Figure 
4B) (30,31). We described above that only prolonged treatment with ActD (4 and 20 h) 
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enhanced formation of PAR in cells treated with H2O2 and MNNG (Figure 2C,D). Since PAR 
formation correlated with the inhibition of 45S pre-rRNA synthesis (Figure S5A), we 
hypothesized that the known enhancement of short rRNA transcripts induced by ActD 
treatment might potentially stimulate ARTD2 activity. To test this hypothesis, we 
investigated in vitro the ability of ARTD2’s automodification in the presence of transcribed 
rRNA (corresponding to rDNA sequences from -16 to +130bp). The basal automodification 
of ARTD2 was strongly stimulated by the addition of this rRNA transcript, while equal 
amounts of double-stranded DNA induced only a moderate activation effect (Figure 4C).  
This effect did not seem to be mediated by specific rRNA sequences, as other non nucleolar 
RNA transcripts were able to stimulate ARTD2 activity to similar levels (Figure S5D).  The 
RNA mediated stimulatory effect was also observed under low NAD+ levels that only lead to 
mono-ADP-ribosylation of ARTD2 (Figure S5B).  In contrast to ARTD2, ARTD1 was 
strongly activated by double-stranded DNA and, as previously described (36), only to a lower 
extent by RNA (Figure 4D). ARTD1 mono-ADP-ribosylation levels were not affected by 
RNA (Figure S5C).   
Since the ActD effect was only observed in the presence of a genotoxic stress, we tested 
whether the activation of ARTD2 by RNA depends on DNA.  Addition of DNA did not 
enhance the stimulatory effect of RNA on ARTD2, confirming that RNA is stimulating 
ARTD2 independent of DNA (Figure 4E).  To define which domain of ARTD2 is responsible 
for the RNA mediated activation, we compared the RNA effect on the activities of human 
ARTD2FL (full length) and ARTD2%SAP (aa 95-583), a mutant that is deleted of the SAP 
domain and that displays similar basal activity as ARTD2FL.  While ARTD2FL was stimulated 
by RNA, the deletion of the SAP domain impaired the RNA mediated activation (Figure 4F).  
The additional deletion of the WGR domain (aa 231-583, ARTD2 %S%W) or removal of the 
WGR domain alone (deletion of aa 116-193, ARTD2 %WGR) showed, beside the loss of the 
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stimulation by RNA, a strong reduction of the general ARTD2 activity (Figure 4F).  Together, 
these results suggested that RNA, but not DNA, is a potent activator of ARTD2 enzymatic 
activity through the SAP domain and that the WGR domain is an important structural 
element for the overall activity of the enzyme. 
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Discussion  
ADP-ribosylation has been implicated in several nucleolar processes such as ribosome 
biogenesis, formation of rDNA heterochromatin and stress sensing (32,34,36,38-40).  Here, 
we show that H2O2 or MNNG induced PAR formation in the nucleoli of both mouse and 
human cells.  Combination of these treatments with low doses of ActD revealed a synergistic 
effect on PAR formation that is mediated by ARTD2 and not by ARTD1.  It was well known 
before that ActD treatment leads to the accumulation of short rRNA transcripts, which might 
be responsible for the enhancement of PAR formation.  Indeed, purified short rRNA 
transcripts were able to strongly stimulate ARTD2 activity via the SAP/WGR domain, while 
double-stranded DNA did not have this effect.  Our findings thus reveal a new activator for 
ARTD2-dependent ADP-ribosylation, which has important implications for the future 
analysis of the biological role of ARTD2 in the nucleus. 
 ADP-ribosylation and in particular the homologous enzymes ARTD1 and ARTD2 
have been traditionally implicated in the response to DNA damage.  An important 
cornerstone for this model is the strong activation of ARTD1 by DNA in vitro and the 
detection of PAR upon treatment of cells with genotoxic compounds.  In these DNA damage-
dependent processes, ARTD2 displays much less activity than ARTD1, questioning whether 
other molecules than DNA are able to regulate ARTD2 function.  Our results strongly 
suggest that instead to bind to sites of DNA damage, ARTD2 associates with RNA, providing 
an alternative cue to identify and respond to DNA damage.  In support of this, recent data 
implicated site-specific Dicer and Drosha RNA moieties in the control of DNA damage (41).  
Furthermore, the activation of ARTD2 by RNA may also be part of an intricate network of 
RNA surveillance and repair mechanisms to preserve RNA quality (42-44).  The 
identification of the strong ARTD2 activation by RNA is a new and unexpected result that 
may indicate an additional mean for monitoring not only genome integrity but also other 
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processes that are specific for ARTD2.  Indeed, genetic disruption of ARTD2, but not of 
ARTD1, affects various differentiation processes in mice, including spermatogenesis (45), 
adipogenesis (46), and the survival of thymocytes (47). 
 Interestingly, the stimulation of ARTD2 in vivo was dependent on the co-stimulation 
with ActD and H2O2 or MNNG, indicating that additional stress signals are required for the 
activation of ARTD2 by RNA.  These signals might include the damage of RNA.  Indeed, 
oxidative damage in RNA is usually higher than in DNA (48).  Future studies of the nucleolar 
ADP-ribose acceptors and the effect of ADP-ribosylation on the response to RNA damage 
are needed to reveal and define these functions in detail.  Alternatively, the treatment of cells 
with genotoxic compounds might induce signalling cascades that lead to the post-
translational modification of ARTD2, which is required for the stimulation with RNA.  
Interestingly, the ActD effect was observed in human and mouse cells, suggesting that the 
stimulation of ARTD2 is a conserved effect. 
 PAR formation was predominantly observed in the nucleoli, which might be due to 
the elevated occupancy of ARTD1 and ARTD2 in the nucleoli and/or to a high sensitivity of 
the nucleolus for the effects of genotoxic stress.  Growing evidence indicates that the 
nucleolus plays a key role in monitoring and responding to cellular stress.  After exposure to 
extra- or intracellular stress, signal pathways induce rapid down-regulation of 45S pre-rRNA 
synthesis that is followed by perturbation of nucleolar structure, cell cycle arrest and 
stabilization of p53 (49).  The formation of high levels of PAR in nucleoli under genotoxic 
stress conditions might be part of this nucleolus-dependent signalling.  Whether and how 
PAR formation is due to a high accessibility of nucleolar DNA and RNA to chemical agents 
remains further to be investigated.   
 Previous studies determined that RNA is a key regulator of ARTD1 in the nucleolus 
(36).  Nucleolar localization of ARTD1 is dependent on RNA and ARTD1 binds in vivo and 
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in vitro to the nucleolar non-coding pRNA, an intergenic transcript implicated in the 
establishment of rDNA heterochromatin (50).  pRNA associates with the zinc-finger DNA 
binding domain of ARTD1 and stimulates ARTD1 activity, although to a lesser degree than 
double-stranded DNA ((36) and Figure 4D).   
 In this work, we provide strong evidence that RNA is a key regulator of ARTD2’s 
enzymatic activity.  Although the lack of good antibodies prevented us from determining how 
RNA affects nucleolar occupancy of ARTD2, we could demonstrate that RNA regulates 
ARTD2 activity.  In contrast to ARTD1, RNA strongly activated ARTD2, while double 
stranded DNA displayed no stimulatory effect, suggesting that the structure and the nature of 
nucleic acid is an important determinant for the regulation of ARTD2 function.  Consistent 
with this, recent analyses with several DNA structures mimicking intermediates of different 
DNA metabolizing processes revealed that ARTD2 activation efficiency did not correlate 
with K(d) values for DNA (51).  ARTD2 displayed the highest affinity for flap-containing 
DNA, but was more efficiently activated by 5'-overhang DNA, suggesting that single-
stranded nucleic acid might be in general a stimulator of ARTD2.  As for ARTD1, the 
stimulation did not seem sequence specific, since other tested RNAs were also able to 
strongly stimulate ARTD2 (36).  We identified the SAP domain to be mainly responsible for 
the stimulation by RNA. The SAP (after SAF-A/B, Acinus and PIAS) motif is a putative 
DNA/RNA binding domain found in diverse nuclear and cytoplasmic proteins (52,53).  
Based on the presented findings, it is thus possible that other proteins with a SAP motif 
similarly bind RNA and are thereby regulated.  Interestingly, deleting only the WGR domain 
abolished the RNA stimulation but also the overall activity of ARTD2, indicating that the 
structural arrangement of the SAP and the CAT motif is functionally relevant.   
 Together, the strong activation of ARTD2 by RNA, as opposed to the activation of 
ARTD1 by double-stranded DNA, is likely the underlying cause for the distinct and 
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complementary functions of these two homologous ARTDs.  The fact that RNA stimulates 
PAR formation by ARTD2 has not only mechanistic implications, but also sheds new light on 
the function of ARTD2 and poly-ADP-ribosylation during the genotoxic stress response.   
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Figure Legends 
Figure 1.  H2O2 treatment induces mainly nucleolar PAR formation.  Confocal               
IF microscopy of PAR (red) was performed after H2O2 treatment (1 mM, 10 min).  A) Z-
Stack-resolution of T24 cells, bar= 10 µM.  B) Double-staining of T24 cells: PAR (red), 
ARTD1 (green), bar= 10$M.  C) Double-staining of T24 cells: PAR (red), RNA Pol 1 
(green), bar= 10$M.  D) Double staining of NIH/3T3 cells after H2O2 treatment (1 mM, 10 
min): PAR (red) and fibrillarin (green), bar= 10 $M, lower panel: 2.5x zoom. 
  
Figure 2. ActD treatment enhances nucleolar PAR formation upon H2O2 and       
MNNG stimulation.  A) IF microscopy of T24 cells was examined after H2O2 (1 mM, 
10 min) and/or ActD treatment (50 ng/ml, 20 h) and stained for PAR formation (red), DAPI 
(blue).  B) IF microscopy of T24 cells after MNNG (500 $M, 30 min) and/or ActD treatment 
(50 ng/ml, 20 h) was examined.  C) Quantitative analysis of PAR positive T24 cells was 
performed after treatment with 50 ng/ml ActD for different incubation times (30 min, 4 h, 20 
h) in combination with H2O2 treatment (1 mM, 10 min).  Cells were analyzed for exhibiting 
no PAR formation (white), low PAR formation (grey bar, example: grey arrow in A and high 
PAR formation (black bar, example: white arrow in A).  D) Quantitative analysis of the 
fraction of PAR positive T24 cells shown in B and analyzed as described in C).   
 
Figure 3. ARTD2, but not ARTD1 is responsible for the ActD-dependent     
enhancement of PAR formation after H2O2 and MNNG treatment.  Quantitative analysis 
of PAR positive T24 cells of A) siMock and siARTD1-treated cells after H2O2 treatment B) 
siARTD1-treated cells after treatment with 50 ng/ml ActD for different incubation times 
(30 min, 4 h, 20 h) in combination with H2O2 treatment (1 mM, 10 min).  C) siMock and 
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siARTD2-treated cells after H2O2 treatment.  D) siARTD2-treated cells after treatment with 
50 ng/ml ActD for different incubation times (30 min, 4 h, 20 h) in combination with H2O2 
treatment (1 mM, 10 min).  E) F) G) H) same as in A) B) C) D) only MNNG treated (500 $M, 
30 min). 
 
Figure 4. ARTD2 activity is stimulated by rRNA in vitro.  A) In vitro radioactive      
PARG assay carried out with in vitro modified ARTD1.  PARG was added to each reaction 
in presence or absence of ActD (1 $g/ml). The reaction was performed for 15 min at 4°C.  B) 
45S rRNA levels and 45S rRNA fragment levels (+25/+146 bp of the pre-mature 45S 
transcript) were measured after ActD treatment (20h, 50 ng/ml).  C) In vitro radioactive 
ARTD2 activity assay was performed with 1.6 $M NAD+ (32P) and in vitro transcribed rRNA 
fragment (146 bp) or DNA linker.  CB= coomassie blot.  D) In vitro ARTD1 radioactive 
activity assay was performed under the same conditions as in C) with 16 $M NAD+ (32P). E) 
In vitro radioactive ARTD2 activity assay was performed with 1.6 $M NAD+ (32P) and in 
vitro transcribed rRNA fragment (146 bp) of different amounts (0.5 pmol, 5 pmol, 10 pmol) 
and in presence or absence of 0.5 pmol DNA linker. Reaction was carried out at 30°C, 10min.  
F) In vitro radioactive ARTD2 activity assay with ARTD2 mutants was performed with 1.6 
$M NAD+ (32P) in presence or absence of 5 pmol rRNA fragment (146 bp).  FL/wt= full 
length human ARTD2, ARDT2 %SAP mutant 95-583aa, ARTD2 %S%W mutant 231-583aa, 
ARTD2 %WGR mutant without WGR domain (deleted aa 116-193). 
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Supplementary Figure 1. H2O2 treatment induces nucleolar PAR formation.                 
A) Confocal IF microscopy of PAR (red) after H2O2 treatment (1 mM, 10 min) was analyzed 
in MEF cells, HeLa cells and NIH/3T3 cells, bar= 10 $M.  B) 45S tanscription in T24 cells 
was measured by qPCR after ActD treatment (50 ng/ml, 20 h); Olaparib treatment (10 $M, 3 
h); H2O2 treatment (1 mM, 10 min) or MNNG treatment (500 $M, 30 min).  C) IF 
microscopy of different cell lines after H2O2 (1 mM, 10 min) and/or ActD treatment (50 
ng/ml, 20 h) was performed. Cells were stained with DAPI (blue) and for PAR (red).  D) IF 
microscopy of different cell lines after MNNG (500 $M, 30 min) and/or ActD treatment (50 
ng/ml, 20 h) was performed.  Cells were stained with DAPI (blue) and for PAR (red). 
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Supplementary Figure 2.  ActD treatment enhances nucleolar PAR formation.  A) 
Confocal IF microscopy of NIH/3T3 cells was performed after H2O2 (1 mM, 10 min) and/or 
ActD treatment (50 ng/ml, 20 h) to detect PAR (red).  B) Quantitative PAR analysis of 
NIH/3T3 cells in presence or absence of ActD (50 ng/ml, 20 h), H2O2 (1 mM, 10 min) 
treatment and Olaparib treatment (10 $M, 1 h).  C) Western blot analysis of T24 cells treated 
with siMock, siARTD1 or siARTD2. 
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Supplementary Figure 3. ActD treatment increases nuclear PAR formation              
upon H2O2 in siARTD1 and siARTD2 treated NIH/3T3 cells.  A) Knockdown     
efficiency of siARTD1 treatment was measured by qPCR in NIH/3T3 cells.  B) Quantitative 
analysis of IF microcopy of PAR positive NIH/3T3 cells in siARTD1 background was 
measured after H2O2 treatment (1 mM, 10 min).  C) Same as in B) but additionally ActD 
treated (50 ng/ml, 20 h).  D) Knockdown efficiency of siARTD2 treatment was measured by 
qPCR in NIH/3T3 cells.  E) Quantitative analysis of immunofluorescence microcopy of PAR 
positive NIH/3T3 cells in siARTD2 background was measured after H2O2 treatment (1 mM, 
10 min).  F) Same as in E) but additionally Act D treated (50 ng/ml, 20 h).  G) Western blot 
analysis of stably transfected NIH/3T3 cells with shMock or shARTD1 was performed, 
treated with ActD (50 ng/ml, 20 h), H2O2 (1 mM,10 min) and Olaparib (10 $M, 3 h). 
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Supplementary Figure 4. ARTD2 is responsible for ActD induced nuclear                 
PAR formation upon MNNG stimulation in NIH/3T3 cells.  A) Quantification of           
the fraction of PAR positive, siARTD2 or siARTD1 transfected NIH/3T3 cells was measured 
by analyzing IF microscopy pictures obtained after MNNG treatment (500 $M, 30 min).  B) 
as in A) but additionally ActD treated (50 ng/ml, 20 h).  C) Western blot analysis of stably 
transfected NIH/3T3 cells with shMock or shARTD1 was performed, treated with ActD (50 
ng/ml, 20 h), MNNG (500 $M, 30 min) and Olaparib (10 $M, 3 h).   
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Supplementary Figure 5.  In vitro ARTD2 activation by RNA. A) 45S rRNA    
transcription was measured of T24 cells treated with ActD (50 ng/ml) for 30 min, 4h or 20h 
in combination with H2O2 treatment for the last 10min (1mM). B) In vitro radioactive 
ARTD2 activity assay was performed with 100 nM NAD+ (32P) and an in vitro transcribed 
rRNA fragment (146 bp, 2pmol) or ecolinker DNA (5pmol).  CB= coomassie blot.  C) In 
vitro radioactive ARTD1 activity assay was performed as in A.  D) In vitro radioactive 
ARTD2 activity assay was performed with 1.6 $M NAD+ (32P) and in vitro transcribed rRNA 
fragment (146 bp), KCNA RNA (237 bp), pRNA (232 bp). 
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Abstract 
Under favorable conditions, arrested cells are able to re-enter the G1 phase and to 
progress through the cell cycle. Among the molecular factors that are involved in cell 
cycle re-entry are for example transcription factors of the E2F family, cyclin-dependent 
kinases, cyclins or microRNAs. ARTD1 (PARP1) and ARTD2 (PARP2) have recently 
been described to co-regulate the expression of proteins involved in different cellular 
processes. Here we investigated the functional contribution of ARTD1 and ARTD2 for 
cell cycle re-entry and cell-cycle progression. For this analysis, ARTD1 and ARTD2 
were down-regulated in T24 urinary bladder carcinoma cells using an siRNA approach 
and cell cycle re-entry and progression of synchronous cells was studied. We describe 
that siARTD1 treatment of T24 cells caused specific down-regulation of Cyclin E but 
not of other E2F-1 target genes and thereby lead to a decelerated cell cycle re-entry and 
progression. In absence of ARTD1, the Cyclin E promoter was enriched for H1 and 
reduced for H4 acetylation and H2A.Z, indicating at a rather compact chromatin. In 
contrast, down-regulation of ARTD2 by siRNA treatment specifically affected p27, but 
not p21 expression and rendered T24 unable to re-enter the cell cycle. Lack of ARTD2 
lead to an increase of the activating marks H3K4me3 as well as H4 acetylation and a 
decrease of the repressory mark H3K27me3. Together, our results provide evidence for 
novel, non-redundant functions in cell cycle re-entry and progression for both, ARTD1 
and ARTD2. 
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Introduction 
The G0 phase is a transcriptionally silent stage of the cell cycle that cells enter upon growth 
inhibition1. If the conditions change and become favorable for cell growth again, cells are 
able to re-enter the G1 phase and progress through the cell cycle. Among the molecular 
factors that are involved in cell cycle re-entry are for example transcription factors of the E2F 
family (e.g., E2F1, E2F4), cyclin-dependent kinases (e.g., Cdk2, Cdk3, Cdk4, Cdk6)2, cyclins, 
the retinoblastoma protein (pRb)3, or microRNAs4. pRb is one of the key players of the early 
cell cycle phases whose inactivation (phosphorylation) seems sufficient for cell cycle re-
entry5. It binds transcription factors (e.g., E2F) of downstream targets involved in cell 
proliferation and thus functions as a classical tumor suppressor gene. pRb is absent or 
mutated in one third of all tumors6, 7. For example, pRb is hyperphosphorylated in 
asynchronous human bladder carcinoma cells and should thus favor cell cycle progression8. 
The most prominent factors regulated by pRb are E2F proteins, histone deacetylases and 
chromatin remodeling complexes9. E2F proteins are a family of transcription factors of which 
three are activators (E2F-1 to 3) and five are repressors (E2F-4 to 8). E2F targets include 
Cyclin E, A, D1, Cdc2, Cdc25A, DNA polymerase, Cdc6 and minichromosome maintenance 
(MCM) proteins10. Cyclin E, in complex with Cdk2, is the main driver of G1-S phase 
progression. A further level of cell cycle regulation is carried out by cell cycle inhibitors such 
as the CIP/KIP family proteins p21 and p27. These two homologous proteins bind to cyclin - 
Cdk complexes and inhibit their activity, but have also been implicated in cyclin-independent 
functions in the nucleus as well as in the cytoplasm11, 12. 
 ADP-ribosylation is a post-translational protein modification (PTM) that consists of 
ADP-ribose units that are transferred to specific residues on target proteins. The protein 
family of the ADP-ribosyltransferases comprises 18 members, which are divided into cholera 
toxin and diphtheria toxin like ADP-ribosyltransferases (ARTCs and ARTDs, respectively). 
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The ARTD subgroup comprises only intracellular proteins that transfer the ADP-ribose 
moiety from NAD+ and thereby catalyze mono- or poly-ADP-ribosylation of acceptor 
proteins. The best-studied members are ARTD1 (formerly PARP1) and its close homologue 
ARTD2 (PARP2). Both, ARTD1 and ARTD2 are nuclear proteins that poly-ADP-ribosylate 
target proteins or themselves. Experimental evidence so far indicates that ARTD1 is the most 
active cellular ADP-ribosyltransferase and that ARTD2 only contributes 5-10 % of PAR 
synthesis13. However, ARTD1 and ARTD2 must also exhibit distinct functions, since the 
deletion of both genes causes synthetic lethality 14. This is also emphasized by the fact that in 
particular the DNA binding domains of ARTD1 and ARTD2 differ15, which may hint at 
distinct activation mechanisms and cellular functions. Furthermore, the carboxy-terminal 
catalytic domains of ARTD1 and ARTD2 are not able to compensate for each other16. 
 ADP-ribosylation is involved in a variety of biological processes, many of which are 
chromatin dependent and linked to important functions during the cell cycle. For example, 
ARTD1 localizes to and modifies centromeric proteins17-19, was described to regulate the 
mitotic chromosomal protein kinase Aurora B by PARylation20 and modifies chromatin-
associated proteins21. Importantly, depletion of ARTD1 or inhibition of ADP-ribosylation has 
also lead to a cell cycle arrest in prophase or prolongation of the G2-M phase transition, 
suggesting that it is required for chromosomal functions during mitosis22-26. Recently, it was 
also shown that progestin gene regulation involves the activation of ARDT1 via Cdk2-
dependent phosphorylation and consecutive modification and displacement of histone H1 27. 
This is essential for the effect of progestins on cell cycle progression in breast cancer. There 
are also various reports that implicate functions of ARTD1 in early cell cycle phases. For 
example, ARTD1 and the C-terminal binding protein (CtBP) form a co-repressor complex for 
p21 repression and ARTD1 activity is necessary for p21 activation after genotoxic stress28. 
Simbulan-Rosenthal et al. showed that ARTD1 up regulates the promoter activity of E2F-1 
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during the early S phase and that ARDT1 interacts with E2F-1 in vitro and in vivo in 
immortalized fibroblasts that were synchronized by serum deprivation or aphidicolin 
treatment29, 30. Another study detected PAR formation during G0-G1 transition after mitogen 
induction and thus implicated ARTD1 in growth factor signaling and the induction of 
immediate-early genes31. Deletion of ARTD2 rendered mouse embryonic fibroblasts 
sensitive to DNA base damage and consecutively prevented resumption of cell cycle 
progression14. ADP-ribosylation in general is involved in spindle formation, the assembly of 
spindle poles32, 33, heterochromatin formation34, and the maintenance of an ATR and Chk1-
dependent S-phase checkpoint35.  
 Any study on ADP-ribosylation and the cell cycle faces the problem that 
synchronization with chemical agents or by serum starvation and subsequent growth factor 
addition already activates ADP-ribosylation36. In the study described here, we used T24 
urinary bladder carcinoma cells, which represent a well-characterized exemplary bladder 
cancer cell line37, 38. Importantly, T24 cells synchronously re-enter the cell cycle after 
splitting without any additional stimuli and are therefore an ideal model to study cell cycle 
regulation. However, the molecular mechanism responsible for this characteristic cell cycle 
regulation is not known.  
 Here, ARTD1 and ARTD2 were down-regulated in T24 cells using an siRNA 
approach and cell cycle re-entry and progression were studied. Our results indicated distinct 
functions in cell cycle progression for ARTD1 and ARTD2. siARTD1 treatment of T24 cells 
caused down-regulation of Cyclin E expression and thereby lead to decelerated cell cycle 
entry and progression. Interestingly, the expression of other E2F-1 target genes was not 
affected or even enhanced. In contrast, down-regulation of ARTD2 by siRNA treatment 
specifically enhanced p27 expression, but not p21, and rendered T24 unable to re-enter the 
cell cycle. Furthermore, ChIP experiments revealed that lack of ARTD1 lead to an increase 
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of H1 recruitment and a reduction of H4 acetylation as well as H2A.Z content at the Cyclin E 
promoter, while the absence of ARTD2 lead to a reduction of the H3K27me3 and an increase 
of the H3K4me3 mark at the p27 promoter. These molecular analyses of cell cycle regulatory 
factors and promoter marks in siARTD1 and siARTD2 treated T24 cells thus confirm novel, 
non-redundant functions in cell cycle regulation of these two ARTD family members. 
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Results 
Down regulation of ARTD1 in T24 cells leads to decelerated cell cycle re-                  
entry and cell cycle progression, while knocking down ARTD2 maintains                   
cells in G0. 
In order to elucidate the role of ARTD1 and ARTD2 and their enzymatic activity on cell 
cycle re-entry and progression, the urinary bladder carcinoma cell line T24 was studied. T24 
cells have the characteristic of arresting in the G0 phase of the cell cycle upon reaching 
confluence and synchronously re-enter the cell cycle after splitting, without additional 
stimuli39, 40. These cells are thus an ideal model, because synchronization does not require 
chemical agents or stimuli that may activate these enzymes. T24 cells are characterized by 
strong, cell-cycle dependent retinoblastoma (Rb) phosphorylation8, which is indicated by the 
comparison with U2OS cells (Fig. 1A). The cell cycle effects that can be studied in T24 cells 
are thus down-stream of Rb phosphorylation. To assess the role of ARTD1 and ARTD2, both 
proteins were down-regulated by siRNA treatment of T24 cells in G0 (Fig. 1B). To 
specifically assess cell cycle re-entry and progression downstream of Rb, siRNA treated cell 
were synchronously released into the cell cycle by splitting the cells (Fig. S1A). The 
expression of ARTD1 was confirmed to remain knocked down during the whole analysis (Fig. 
S1B). 
Flow-cytometry analysis of siMock and siARTD1 T24 cells indicated a delayed cell cycle re-
entry and progression for siARTD1 cells that became apparent 16 h after splitting, which 
suggests a decelerated S-phase transition (Fig. 1C, D). This finding was confirmed by 
reduced bromodeoxyuridine (BrdU) incorporation in siARTD1 cells (Fig. S1C) and stably 
knocking down ARTD1 in T24, which similarly caused a delay in S-phase (Fig. S1D). In 
contrast, siARTD2 treatment caused an almost complete inability to re-enter the cell cycle 
(Fig. 1C, D), indicating that both ARTD1 and ARTD2 regulated cell-cycle re-entry and 
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progression, although through a different molecular mechanism. Treatment of T24 cells in G0 
with the PARP inhibitors Olaparib or Veliparib and subsequent release into the cell cycle also 
caused an increase in the cell population in S-phase and a reduction in the G2/M-phase cells 
indicated that ADP-ribosylation by ARTD1 and ARTD2 is not required for the above 
described cell cycle phenotypes, but that it is required for normal cell cycle progression of 
T24 cells through S phase  (most likely ARTD1 enzymatic activity, Fig. S1E). Based on 
these results it was concluded that ARTD1 and ARTD2 play important, non-redundant 
functions in cell cycle progression of T24 urinary bladder carcinoma cells. 
 
ARTD1 down regulation causes down-regulation of Cyclin E expression. 
Since ARTD1 was implicated in DNA repair, siARTD1 treatment of T24 may induce DNA 
damage and subsequently lead to cell cycle arrest. Western blot analysis of siMock and 
siARTD1 treated cells at different time points after release indicated that down-regulation of 
ARTD1 had no effect on protein 53 (p53), p21, p27 and p57 levels or on replication protein 
A (RPA) and Chk-1 phosphorylation (Fig. 2A and S2A-E), suggesting that the observed 
deceleration was not the results of an activated DNA damage response.  
In order to characterize and mechanistically understand the function of ARTD1 for cell cycle 
progression of T24 cells, the expression levels of the important cell cycle regulator E2F-1 
were further assessed in siMock and siARTD1 treated cells throughout the cell cycle. E2F-1 
transcript levels were only slightly elevated in siARTD1 treated cells in comparison to 
control cells and only at distinct time-points (0-4 h; 24 h), furthermore this change was not 
observed at the protein level (Fig. 2B, C), indicating that E2F-1 was not altered under the 
tested conditions. Moreover, ARTD1 depletion neither affected cyclin-dependent kinase 2 
(Cdk2) transcription, while the protein levels were slightly increased, which could however 
not account for the observed deceleration (Fig. S2F). Interestingly, when analyzing different 
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cyclins in siARTD1 treated T24 cells, mRNA and protein levels of the E2F-1 target Cyclin E 
were, at all measured time-points, lower and particularly in S-phase significantly reduced 
(Fig. 2D, E). In contrast, the Cyclin A, B and D transcript and protein levels were not or 
rather slightly increased upon knockdown of ARTD1 (Fig. S3A, B). The reduced Cyclin E 
expression could not be attributed by a lack of E2F-1 (Fig. 1A and 2B) or the inability of 
E2F-1 to activate genes, since the E2F target gene c-myc as well as miR-15 and miR-16 were 
up-regulated upon siARTD1 treatment (Fig. S3C-E). Repeating the Cyclin E expression 
analysis during the cell cycle in the presence of the PARP inhibitor Olaparib confirmed that 
the enzymatic activity of ARTD1 is dispensable for the effect on Cyclin E expression 
(Fig. 2F). Again, Cyclin E reduction was similarly observed in stable shARTD1 knock-down 
cells (Fig. S3F), indicating that the deceleration can be induced also upon permanent knock-
down of ARTD1. Based on these results it was concluded that ARTD1 down-regulation in 
T24 cells mainly affected cell cycle re-entry and progression by reducing Cyclin E expression.  
 
Knocking down ARTD1 reduces H4 acetylation and H2A.Z, but increases H1           
levels at the Cyclin E promoter. 
In order to investigate how ARTD1 down-regulation affects Cyclin E expression, repressory 
and activatory marks at the Cyclin E promoter were analyzed. In agreement with the previous 
findings, ARTD1 recruitment to the Cyclin E promoter, analyzed by chromatin immune-
precipitation, was significantly increased upon entry of siMock-treated T24 cells into G1-
phase (Fig. 3A). In siARTD1 cells, no recruitment was detectable, confirming the specificity 
of the assay and suggesting that ARTD1 might render the Cyclin E promoter permissive and 
therefore transcriptionally active. siARTD1 treatment did not affect histone H3 during cell 
cycle re-entry (compare G0 to G1), since neither H3 levels at the Cyclin E promoter nor H3 
lysine 4 trimethylation (H3K4me3), which is a mark for actively transcribed genes, were 
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influenced (Fig. 3B, C). However, histone H4 acetylation (H4ac), another mark of active 
transcription, was strongly reduced in siARTD1 T24 cells as compared to siMock treated 
cells (Fig. 3D). Additionally, another mark that is associated with promoters of actively 
transcribed genes, the presence of the histone H2A variant H2A.Z41, did change significantly 
in response to ARTD1 down-regulation. H2A.Z was highly enriched at the Cyclin E promoter 
and significantly declined upon the depletion of ARTD1 by siRNA treatment (Fig. 3E). In 
contrast, the linker histone variant H1.2 strongly increased at the Cyclin E promoter upon 
siARTD1 treatment in both the G0 and the G1 phase (Fig. 3F). In summary, knocking down 
ARTD1 changed the histone marks at the Cyclin E promoter in such a manner that the 
compaction of this chromatin region seems to be enhanced (loss of H4 acetylation, increase 
of H1 recruitment), subsequently also negatively affecting the transcription of Cyclin E (loss 
of H2A.Z). 
  
ARTD2 regulates p27 transcription at the chromatin level. 
Our initial findings (Fig. 1C) hinted at distinct, non-redundant functions of ARTD1 and 
ARTD2 for cell cycle progression of T24 cells. Additional analysis of the ARTD2 levels 
confirmed that ARTD2 was as well down regulated, during the whole time period (Fig. S4A). 
Western blot analysis of ARTD1, revealed that ARTD1 was cleaved under these conditions, 
indicating that knock-down of ARTD2 is inducing apoptosis (Fig. 4SB). Interestingly, this 
seemed not to be mediated by p53, since neither p53 nor p21 levels were altered (Fig. 4A, 
S4B). Surprisingly, p27 were very strongly up regulated under the tested conditions, 
providing an explanation for the strong cell cycle arrest and the observed induction of 
apoptosis (Fig. 4A,S4B).  
In order to elucidate the molecular mechanism by which ARTD2 affects p27 expression, the 
transcription levels of p27 and of p21 as a control were analyzed by qRT-PCR. While p21 
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expression levels were not affected, p27 levels were strongly enhanced, indicating that 
ARTD2 is regulating p27 expression mainly at the transcriptional level. This result was 
confirmed by a promoter analysis, which detected significantly increased activatory 
H3K4me3 levels and decreased repressory H3K27me3 marks at the p27 promoter in 
siARTD2 treated T24 cells, while total H3 occupancy or acetylation of H4 was minimally 
affected (Fig. 4B, 4D). Comparable analysis at the p21 promoter revealed that knocking 
down ARTD2 did not affect this chromatin region and indicated that the observed changes 
are p27 specific (Fig. 4C, 4D). Moreover, the observed chromatin changes were limited to the 
p27 promoter region, since these chromatin changes were not observed in a region of the p27 
nor the p21 gene body (Fig. S4C). Together, these results suggest that ARTD2 affects the cell 
cycle in synchronized T24 cells via modulating the expression of the cyclin-dependent kinase 
inhibitor p27, which represents a distinct and different mechanism in comparison to ARTD1. 
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Discussion  
ARTD1 and ARTD2 are the most homologous members of the ARTD protein family 
and often thought to fulfill similar functions. However, ARTD1 has been studied much more 
extensively and is in general a more active enzyme. This is one of the reasons why it has 
proven difficult to identify specific functions of ARTD2. T24 bladder carcinoma cells re-
enter the cell cycle and divide synchronously after splitting and are therefore an ideal model 
to study cell cycle regulation without the addition of toxins or stimulatory factors. Using a 
siRNA approach to down-regulate ARTD1 and ARTD2 in T24 cells and an analysis of cell 
cycle re-entry and progression of synchronous cells revealed non-redundant functions for 
both, ARTD1 and ARTD2. The work described here suggests down-regulated Cyclin E as the 
cause for decelerated cell cycle entry and progression in siARTD1 treated cells, while 
ARTD2 was shown to specifically affect p27 expression levels. The molecular analyses of 
marks at the promoter sites of Cyclin E and p27 in siARTD1 and siARTD2 treated T24 cells 
revealed that both proteins affect the promoter structure through different mechanisms. These 
results therefore confirm non-redundant functions in cell cycle re-entry and progression of 
ARTD1 and ARTD2.  
Our results indicate that ARTD1 is required for the correct regulation of Cyclin E 
expression during cell cycle re-entry and G1 – S phase progression. The increased recruitment 
of ARTD1 to the Cyclin E promoter during G0 - G1 phase transition indicates that ARTD1 
might affect the initiation of Cyclin E transcription. Interestingly, this effect was independent 
of ARTD1 enzymatic activity, since no cell cycle deceleration could be observed in PARP 
inhibitor (e.g., Olaparib) treated cells. The Cyclin E promoter state was thus not regulated via 
the ADP-ribosylation of histone modifiers such as the demethylase KDM5B42, and the levels 
of H3K4me3 were not changed upon siARDT1 treatment. Beside a reduced acetylation of H4, 
the main observed changes in siARTD1 treated cells included an increase in H1.2 and a 
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reduction of the H2A.Z levels at the Cyclin E promoter. Increased H1 recruitment as well as 
decreased H2A.Z were both reported to coincide with a restrictive chromatin state and 
reduced gene expression 41, 43. While replacement of H1 by ARDT1 has been documented 
before for many promoters of actively transcribed genes43, changes of H2A.Z were not 
described before. It remains to be investigated whether the alterations of H2A.Z and H1 are 
regulated by separate mechanisms, or whether the H2A.Z changes are a consequence of the 
observed H1 changes. Moreover, it is not clear by which mechanism ARTD1-dependent 
regulation is confined to Cyclin E expression without affecting other E2F-1 target genes. It 
will be interesting to study if the recruitment of ARTD1 to promoters is fine-tuned and 
regulated by posttranslational modifications of ARTD1 (e.g., acetylation, mono-ADP-
ribosylation, phosphorylation, sumoylation or ubiquitylation) as previously suggested44.  
 In contrast to Cyclin E expression, our studies also revealed that the expression levels 
of two other E2F-1-induced miRNAs (microRNAs 15 and 16) are strongly enhanced after 
siARTD1 treatment, indicating that ARTD1 is able to regulate gene expression within the 
same cell in two different manners. This could be due to differential affinities of ARTD1 for 
different E2F-1 target genes would thus lead to an unequal chromatin distribution of ARTD1 
upon knock down and subsequently affect chromatin composition, the recruitment of 
transcription factor complexes, and gene expression. On a cellular level, these differential 
regulatory effects of reduced Cyclin E expression and enhanced microRNA15/16 levels would, 
however, both lead to reduced Cyclin E protein levels, since the miRNAs negatively regulate 
Cyclin E expression45. Interestingly, stably transduced shARTD1 T24 cells overcame the 
observed cell cycle delay after only 3 passages (not shown), suggesting that in these cells 
other cell cycle regulatory factors such as Cyclin D or Cyclin A could functionally 
compensate for the loss of Cyclin E, as it was speculated to be the case in Cyclin E knockout 
mice 46 or that the induced permissive chromatin changes are over-ruled by the plasticity of 
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the chromatin (i.e. compensatory mechanisms).  
 siARTD2 treated T24 cells exhibited an even stronger phenotype than cells with 
reduced ARTD1 levels and were arrested early during the cell cycle at the G0 - G1 transition 
and subsequently induced apoptosis. The G0 - G1 phase arrest was not observed in 
asynchronous siARTD2 treated cells, indicating that ARTD2 is particularly important for G0 
phase progression. Our data indicate that ARTD2 regulates p27 by enhancing the activatory 
mark H3K4me3 and reducing the inhibitory histone modification H3K27me3 at the 
promoters of p27, but not in the gene body or at the promoter of p21, suggesting that ARTD2 
is specifically recruited to the transcription start site of defined genes. ARTD2 thus likely 
regulates the recruitment of chromatin regulators such as histone methylases, as it has been 
recently shown for the expression of MYC 47 and SIRT1 48, 49.  
Interestingly, PARP inhibitors (e.g., Olaparip) did not inhibit progression of cells 
from G0 to G1, but rather decelerated cell cycle progression during late S phase, indicating 
that ADP-ribosylation is not required for the above-described functions during re-entry or 
early G1 progression in T24 cells. This observation is in contrast to earlier reports on serum-
stimulated, quiescent fibroblasts and lectin-stimulated, peripheral, mononucleated blood 
cells31. These opposing findings thus highlight the importance of studying cellular processes 
in undisturbed systems, because stimuli such as serum or lectin treatment likely induce 
cellular stress and consequently ADP-ribosylation. The functional contribution of ADP-
ribsoylation during late S phase was already reported in a recent publication providing 
evidence that ARDT1 interacts with pRNA and TIP5 during late S phase in an activity-
dependent manner and that this interaction is important during the formation of 
heterochromatin 34. Treatment with PARP inhibitors would lead to disrupted or unstable 
heterochromatin, which results, amongst other things, in sister chromatid exchange formation. 
The CIP/KIP family members p21 and p27 are highly homologous and therefore 
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believed to function similarly 50 and both proteins have been implicated in the regulation of 
cellular processes such as apoptosis and transcriptional activation 11, 51. p21 and p27 were 
reported to repress transcription indirectly by inhibiting cyclin-Cdk complexes and the 
consecutive phosphorylation of Rb-family proteins (p107, p110, and p130). In turn, 
hypophosphorylated Rb-related proteins sequester E2F family members and thereby repress 
the transcriptional targets of this transcription factor family52. The here described and 
observed increase of p27 was, however, unlikely mediated through E2F, since ARTD2 
knockdown in T24 cells did not change the phosphorylation status of pRB (data not shown).  
 ARTD2 down-regulation in T24 cells not only up-regulated p27, but also induced 
apoptosis, which was observed by ARTD1 cleavage and increased PAR formation. 
Interestingly, this event was not dependent on p53, indicating that the DNA damage response 
was not activated. This fits the observation that ARTD2 knockout mice do not show the 
propensity for the development of spontaneous tumors 14, but have a reduced thymic 
cellularity associated with increased apoptosis in thymocytes53. It therefore remains to be 
elucidated whether p27 mediates apoptosis or if the apoptotic program is initiated 
independent of p27 up regulation. Given the fact that p27 has been described as a tumor 
suppressor 54, the function of p27 and the mechanistic link to ADP-ribosylation and ARTD2 
might be further evaluated and reveal new potential therapeutic approach for specific cancer 
types. 
Together, we describe the regulation of Cyclin E and p27 in T24 cells by ARTD1 and 
ARTD2, respectively. Since the down-regulation of ARTD2 had a more dramatic effect on 
cell cycle re-entry and progression than siARTD1 treatment, these results are an example 
where ARTD2 plays a more prominent role than ARTD1, despites is significantly lower 
enzymatic activity. The results presented here thus confirm novel, non-redundant functions in 
cell cycle regulation for ARTD1 and ARTD2.  
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Materials and Methods 
Cell culture 
T24 cells were cultivated in McCoy’s 5A medium (Gibco, Invitrogen, CA, California, USA) 
at 37°C. All media were supplemented with 1% (v/v) Penicillin/Streptavidin and 10% (v/v) 
fetal calf serum (Gibco, Invitrogen, CA, California, USA). 
 
siRNA transfection 
Negative control allstars (siMock), human siPARP1 #6 and human siPARP2 #6 were ordered 
from Qiagen (Hilden, Germany). Cells were seeded 1 day before transfection (5x105 cells per 
6 cm plate) and transfection was carried out with 40 nmol siRNA per plate and RNAi MAX 
lipofectamine (Invitrogen, Carlsbad, CA, USA).  
 
Antibodies 
Following antibodies were used: From Santa Cruz Biotechnology, Inc (Dallas, TX, USA): 
PARP1/ARDT1 (H-250, rabbit); PCNA (PC10. mouse); p53 (FL-393,rabbit); p27 (C-19, 
rabbit),  p21 (C-19, rabbit), cyclin E (HE12, mouse), E2F-1 (C-20-rabbit), PARP-1 (C2-10, 
mouse). From Active motif (Carlsbad, CA, USA): PARP2 (rabbit). From Sigma Aldrich (St. 
Louis, MO, USA): tubulin (mouse). From Millipore (MS, USA): H3K4me3 (rabbit); 
phospho-Histone H2A.X (mouse); trimethyl-HistoneH3K27 (rabbit), H2A (rabbit); acetyl-
Histone H4 (rabbit). From Abcam pls (Cambridge, UK): Histone H2A.Z (rabbit), H1.2 
(rabbit); Histone H3 (rabbit). From Cell Signaling Technology, Inc. (MS, USA): P-Chk1 
(S345, rabbit). From NeoMarkers (Fremont, CA, USA): RPA / p34 (9H8, mouse). From 
Roche AG (Basel, Switzerland): BrdU. homemade: PAR 10H (mouse). Jackson 
ImmunoResearch Laboratories: CyTM3-conjugated AffiniPure Goat Anti-Rabbit (Suffolk, 
UK). 
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Cell cycle analysis by flow cytometry 
Cells were harvested with trypsin and washed once with PBS. Cells (at least 3.5x105) were 
fixed (70% ethanol, at least 30 min on ice or overnight at 4°C), washed once with 1ml PBS 
and centrifuged (865 g, 4°C, 8min). Cells were stained with a Propidium iodide solution 
(Sigma Aldrich, St. Louis, MO, USA), final concentration of 20 $g/ml in PBS with the 
addition of 100 $g/ml RNase A (37°C, 30 min in the dark). Flow cytometry analysis was 
performed with the CyANTM ADP 9 Analyzer (Beckman Coulter, Fullerton, CA, USA).  
 
RNA extraction and qPCR analysis 
Cells were harvested either by trypsin or directly lysed on the plate in lysis buffer. RNA 
extraction was performed with the NucleoSpin® RNA II kit (Macherey-Nagel, Düren, 
Germany). RNA was quantified with a NanoDrop (ThermoFisherScintific, Waltham, MS, 
USA) and reverse transcribed according to the supplier’s protocol (High Capacity cDNA 
Reverse Transcription Kit, Applied Biosystems, Foster City, CA, United States).  
Quantitative-real-time polymerase chain reactions (qPCR) were performed with SYBR® 
green SensiMix SYBR Hi-ROX Kit (Bioline Reagents Ltd, London, UK) and a Rotor-Gene 
Q 2plex HRM System (Qiagen, Hilden, Germany). 
 
Cell lysis, SDS-PAGE and Western blot analysis 
Whole cell lysis was performed either with trypsinized cells or directly on plates by using a 
Tris lysis buffer (50 mM Tris pH 8, 500 mM NaCl, 1% Triton X-100, 1 $g/ml pepstatin, 
1 $g/ml bestatin, 1 $g/ml leupeptin, 2 mM PMSF; 10 min, 4°C). Bradford assay (Bio-Rad 
laboratories, Hercules, CA, USA) was performed and, if not otherwise indicated, 30 $g of 
protein extract was loaded and separated on a 10% or 12% SDS-polyacrylamide gel (120V). 
The gel was blotted on a PDVF membrane and analyzed by using protein specific antibodies.  
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BrdU Incorporation assay 
Cells were seeded on cover slips (1x105 per well in a 24-well-plate) prior to the experiment 
as indicated. Cells were treated with 10 $M BrdU for 30 min, fixed with ice-cold methanol 
(10 min, 4°C), washed with PBS and denatured with 2 M HCl (60 min, 37°C). The reaction 
was neutralized by adding 0.1 M borate buffer (pH 8.5, 10 min). Cover slips were incubated 
with BrdU Antibody in PBS/BSA (60 min, room temperature) and after washing with PBS; 
the secondary antibody was applied ( 60 min, room temperature, in the dark). Cover slips 
were mounted and analyzed by immunofluorescence microscopy. For quantification, at least 
300 cells per condition were analyzed. 
 
Chromatin Immunoprecipitation  
ChIP analysis was performed as previously described (Santoro et al., 2002) using magnetic 
Dynabeads® (Life Technologies, Carlsbad, CA, USA). 
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Figure Legends 
Figure 1. Down regulation of ARDT1 in T24 cells leads to decelerated cell                   
cycle re-entry and cell cycle progression, while knocking down ARDT2               
maintains cells in G0. A) Western blot analysis of T24 and U2OS cell extracts was 
performed to compare the levels of Rb phosphorylation and E2F-1 levels. B) Western blot 
analysis was used to confirm the knockdown of ARTD1 and ARTD2 upon siRNA treatment 
of T24 cells. C) Flow cytometry analysis was performed of siMock, siARTD1 and siARDT2 
treated, synchronized T24 cells. The cells were analyzed over 24 h starting from confluence 
(G0) D) Quantification of the flow cytometry analysis shown in C. 
 
Figure 2.ARTD1 depletion leads to decreased Cyclin E expression A) Western              
blot analysis was performed to investigate p53 and RPA after cell cycle re-initiation of 
siMock (M) or siARTD1 (A1) treated T24 cells at different time points. B-C) qPCR (B) and 
Western blot (C) analysis of E2F-1 in siMock and siARTD1 treated T24 cells. D-E) qPCR 
(D) and Western blot (E) analysis of Cyclin E levels in siMock and siARTD1 treated cells. 
(F) qPCR analysis of Cyclin E expression in cells treated with the PARP inhibitor Olaparib. 
(n=3, t-test p* < 0.05)  
 
Figure 3. ARTD1 is recruited to the cyclin E promoter and keeps the                    
chromatin in an open conformation. Chromatin immunoprecipitation (ChIP) analysis of the 
cyclin E promoter in siMock or siARDT1 treated T24 cells. ARTD1 binding (A), H3 
occupancy (B), H3K4me3 during G1 phase (10h time point) (C), H4 acetylation during G1 
phase (10h time point)(D), H2A and H2A.Z occupancy (E) and H1.2 occupancy (F) were 
analyzed.  
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Figure 4. ARTD2 is a repressor for p27 transcription. A) qPCR and western blot        
analysis of p21 and p27 in siMock and siARTD2 treated T24 cells. B) and C) ChIP analysis 
of H3, H3K4me3 and H3K27me3 were analysed in siMock and siARTD2 treated confluent 
cells for B) the p27 promoter and C) the p21 promoter D) ChIP analysis to assess H4 
acetylation at the p21 and p27 promoter in siMock and siARTD2 treated cells.  
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Supplementary Figure Legends 
Supplementary Figure 1. Inhibition of the enzymatic activity leads to an S-              
phase delay. A) Experimental setup of cell cycle analysis in T24 cells. T24 cells were seeded 
and transfected on the next day at 70%-80% confluence. After 3 days of growth, cells 
reached confluence and entered the G0 phase. Upon splitting, cells re-initiated the cell cycle 
and samples for flow cytometry analysis, western blot analysis, qPCR analysis and ChIP 
analysis were taken at the indicated time points. B) mRNA expression of ARTD1 was 
measured by qPCR analysis during the cell cycle in siMock and siARTD1-treated cells. C) 
BrdU incorporation assay was performed and quantified by cell counting in siMock or 
siARTD1 treated cells, at least 300 cells were counted for each condition and time point. D) 
Flow cytometry analysis for shMock and shARTD1 transduced T24 cells after viral 
transduction. E) Overlay of flow cytometry analyses of untreated, Olaparib (20h, 10$M) and 
Veliparib (20h, 10$M) treated T24 samples (20h time point). 
Supplementary Figure 2. Cell cycle checkpoints and cdk-inhibitors are not           
affected upon siARTD1 treatment. A) Western blot analysis of Chk1- phosphorylation 
during the cell cycle re-initiation after siMock (M) or siARTD1 (A1) treatment was 
performed for the indicated time points. B-D) qPCR analyses of p21 (B), p27 (C) and p57 
(D). E) The corresponding Western blot analysis of p27 in siMock (M) and siARTD1 (A1) 
treated cells. F) qPCR analysis of Cdk2 in siMock and siARTD1 treated cells (left panel), 
Western blot analysis of G0 time point of Cdk2 protein levels (right panel). 
Supplementary Figure 3. A) qPCR analysis of cyclin A, B and D was performed in     
siMock and siARTD1 treated samples. (n=2). B) Western blot analysis was carried out of 
cyclin A and cyclin B in siMock and siARTD1 treated samples. C-F) qPCR analysis of c-
myc (C), miR15 (D) and miR16 (E) expression levels in siMock and siARTD1 treated cells 
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(n=3). F) Western blot analysis was performed of shARTD1 and shMock treated T24 cells in 
the G0 phase of the cell cycle to detect Cyclin E protein levels. 
Supplementary Figure 4. A) mRNA expression of ARTD2 during the cell cycle after 
siMock and siARTD2 treatment was analyzed by qPCR . B) Western blot analysis of siMock 
and siARTD2 treated samples was performed and analyzed for PAR formation, cleavage of 
ARDT1, and p53 and p27 levels. C) ChIP analysis was carried out for H3, H3K4me3, 
H3K27m3 and H4ac analyzing the occupancy at the p27 gene body (+2 kb from TSS) and at 
the p21 gene body (+1.5 kb from TSS) in siMock and siARTD2 treated confluent cells.  
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3.2  Unpublished Results 
3.2.1 Role of ARTD1 during immortalization of primary mouse embryonic   
fibroblasts 
 
A primary cell that is isolated from a tissue undergoes a definite number of divisions until it 
enters senescence, which is a state of growth arrest, even though cells may still be 
metabolically active (253). While normal human cells in culture will stop dividing after 
several passages and are not able to overcome senescence without additional treatment to 
immortalize them, some rodent cells are able to recover from senescence by recombination-
dependent mechanisms to maintain telomeres and by spontaneous mutations of cell cycle 
regulatory genes (254, 255). The most prominent genes, which are often mutated are the p16 
and p53 tumor suppressor genes (256).  
 
ARTD1 -/- MEF cells grow slower after outgrowth from senescence  
We were interested, whether ARTD1 plays a similar role during outgrowth from senescence 
as during cell cycle re-entry from the G0 phase of T24 cells (see 3.1.2). Primary wild type 
(WT) or ARTD1 -/- mouse embryonic fibroblasts (MEFs) were isolated from 14.5 days old 
embryos, passaged every third day, and their growth behavior was monitored until they 
became immortalized (knockout analysis Figure 1A). After passage six, cell growth started to 
slow down and a large fraction of the cells died. The culture medium was replaced every 
third day and residual cells started to form colonies. Detectable colony formation occurred 
earlier in WT than in ARTD1 -/- cells (Figure 1C). Directly after immortalization (around 
passage 15), ARTD1 -/- cells grew slower and were mainly arrested in G0/G1 phase as 
determined by FACS analysis (Figure 1B). After another 10 passages, cell cycle analysis and 
cell counting revealed that ARTD1 -/- cells grew as fast as WT cells (Figure 1C). Together, 
these experiments indicated that ARTD1 plays an important role during the transformation of 
MEFs, although the cells overcame this dependency after extended time in culture. 
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A 
 
B 
 
C 
 
Figure 1: ARTD1 -/- cells show a different cell cycle distribution shortly after cell immortalization 
but regain cell growth comparable to wild type cells after 25 passages. A) qPCR expression levels 
of ARTD1 in wild type and ARTD1 -/- MEF cells at different passages were performed to confirm 
ARTD1 knockout. (Average + SEM, n=2) B) Scheme and FACS analysis of wild type and ARTD1 -/- 
MEFs at different cell passages are displayed. C) Growth curve of wild type and ARTD1 -/- MEFs 
before immortalization and shortly after immortalization were analyzed (left panel). Growth curve was 
analyzed of cells shortly after immortalization as in left panel compared to cells after 10 passages after 
immortalization (right panel). (Average + SEM, n=2), P.5= before immortalization P.15= early after 
immortalization P.25= late after immortalization. 
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After outgrowth from senescence Cyclin E levels are down regulated in                     
ARTD1-/- cells  
Since we observed a cell cycle delay for ARTD1-/- MEFs that was comparable to the cell 
cycle effect observed in siARTD1 treated T24 cells after cell cycle re-entry (G0 to G1 phase), 
we analyzed whether the Cyclin E levels are also changed during the immortalization of 
primary MEFs.  
Western blot analysis revealed that Cyclin E protein levels increased early after 
transformation (passage 15) in WT MEFs. In ARTD1 -/- cells, such an increase of Cyclin E 
protein levels was not observed. qPCR analysis of Cyclin E levels in MEFs of different 
passages confirmed a reduced Cyclin E expression in ARTD1-/- MEFs after immortalization 
(compared to WT cells (Figure 2)). These results indicated, that ARTD1 might indeed be 
involved in the regulation of Cyclin E during the immortalization process.   
 
A        B 
           
 
Figure 2: Cyclin E levels are diminished in ARTD1 -/- cells shortly after transformation. A) qPCR 
analysis of MEFs at different passages was performed (average + SEM, n=2). B) Western blot analysis 
of MEFs at different passages was performed. p.5= before immortalization p.15= early after 
immortalization n p.25= late after immortalization. M=protein marker. 
 
E2F-1 and Cyclin A expression levels are decreased in ARTD1-/- MEFs in the                
early stages after immortalization 
Next, we investigated whether the lack of ARTD1 affects other cell cycle factors during 
immortalization. E2F-1 and Cyclin A transcript levels were reduced in ARTD1 -/- MEFs as 
compared to WT MEFs shortly after immortalization, whereas pRb expression was increased 
(Figure 3A). The p53 and p16 expression levels remained unchanged (Figure 3B). These 
results differed from our previous observation for T24 cells (chapter 3.1.2), where only 
Cyclin E expression was decreased upon ARTD1 knockdown. 
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A 
 
B 
 
Figure 3: Expression levels of cell cycle regulatory factors are differently affected during 
immortalization. A) qPCR analysis of pRb, E2F-1and Cyclin A was performed of  wild type and 
ARTD1 -/- MEFs at different passages. B) qPCR analysis of p53 and p16 was performed as in A). 
(Average + SEM, n=2) p.5= before immortalization p.15= early after immortalization p.25= late after 
immortalization.  
 
In conclusion, ARTD1 seemed to positively regulate cell immortalization. However, several 
passages after immortalization, ARTD1 -/- MEFs grow as fast as their wild type counterpart, 
suggesting a primarily beneficial role of ARTD1 during escape from senescence. Similar to 
our cell cycle studies with T24 cells, Cyclin E expression was dependent on the presence of 
ARTD1, but the general mechanism seems to be different, since also E2F-1 and Cyclin A 
levels were negatively affected by the lack of ARTD1, which was not observed for T24 cells. 
A western blot analysis of these genes should clarify whether the observed expression 
changes also affect the protein levels. 
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3.2.2 ARTD1 does not interact with Cyclin E or retinoblastoma protein in                
T24 cells 
 
ARTD1 was observed to influence Cyclin E expression in T24 cells upon cell cycle re-entry 
(chapter 3.1.2). To understand this regulation, initial experiments were performed to analyze 
a possible interaction of ARTD1 with Cyclin E, but also with Retinoblastoma protein pRb, as 
a key player of early cell cycle progression. Total pRb, Cyclin E or Cdk2 (as control for 
Cyclin E interaction) were immunoprecipitated from T24 cells harvested in G0 phase (in 
confluence) and, immunoprecipitated complexes were resolved by SDS-PAGE and analyzed 
by western blot analysis using antibodies against ARTD1, Cyclin E, total pRb and Cdk2 
(Figure 4).  
 
 
Figure 4: ARTD1 does not interact with Cyclin E or retinoblastoma protein. pRb, Cyclin E or 
Cdk2 were immunoprecipitated from T24 cells harvested in G0 phase (in confluence). Western blot 
analysis was performed and possible interactions were detected by using antibodies against pRb, 
ARTD1, Cyclin E and Cdk2. 
 
ARTD1 interacted neither with immunoprecipitated pRb nor with Cyclin E or Cdk2. A 
similar result was observed when ARTD1 was immunoprecipiated and analyzed for complex 
formation with pRb and Cyclin E (data not shown). The already described interaction of 
Cyclin E with Cdk2 and of pRb with Cyclin E served as positive controls for these 
experiments. Together, the analyses indicate that pRb and Cyclin E do not interact with 
ARTD1. If ARTD1 is still able to modify one of these targets and regulate them, has to be 
further experimentally evaluated by in vitro PARylation assays of pRb and Cyclin E. 
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3.2.3 Actinomycin D treatment affects mitochondrial gene expression, while           
H2O2 treatment has no effect 
 
Mitochondria are important organelles of the cell since they are the main supplier of ATP 
(257). A notable characteristic is that mitochondria contain their own DNA of approximately 
16.6 kbp, which encodes for 2 rRNAs, 22 mitochondrial tRNAs and 13 proteins in human 
cells (257). Most mitochondrial proteins are therefore encoded in the nucleus and have be 
transported to the mitochondria (258). The homeostasis of mitochondria is tightly regulated 
by mitochondrial chaperones, which assist proteins to fold correctly. Different factors such as 
mitochondrial biogenesis, production of reactive oxygen species (ROS), as well as other 
environmental stress conditions, affect the mitochondrial protein-folding environment (259). 
When the load of unfolded or incorrectly folded proteins in mitochondria exceeds a certain 
limit, the mitochondrial unfolded protein response (UPRmt) is activated to re-establish 
homeostasis (260). The UPRmt is a mitochondria-to-nucleus signaling pathway, which leads 
to the expression of mitochondrial protective genes (e.g., chaperones and proteases) (261). 
Given the link of ARTD activity and the consumption of NAD+, we were wondering whether 
H2O2 stimulated PAR formation influences mitochondrial homeostasis and trigger the UPRmt. 
Therefore, T24 cells were treated with H2O2 (1 mM, 60 min) and/or the PARP inhibitor 
Olaparib (1 $M, 3 h). Usually, PAR formation peaks after 10-15 minutes of H2O2 treatment 
and cannot be detected anymore after 60 minutes, although the generation of early PAR 
might influence downstream processes such as RNA transcription of e.g., mitochondrial gene 
expression. RNA was isolated from each condition and qPCR analysis was performed. To 
follow possible changes of mitochondrial gene expression, the NADH-dehydrogenase 
subunit 1 (ND1) and cytochrome C oxidase I (CO-1) were examined. These genes were used 
to investigate the direct effect of the different treatments on mitochondrial gene expression 
(mtDNA). Additionally, the expression of mitochondrial genes encoded in the nucleus 
(succinate dehydrogenase complex, subunit B (SDHB), and NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 2 (NDUFA2)) was analyzed. Furthermore, genes of the 
UPRmt pathway were investigated, namely mitochondrial heat shock protein 70 (mtHsp70) 
and caseinolytic peptidase (ClpP), which is a quality control protease. qPCR analysis of 
theses genes revealed that neither H2O2 treatment alone, nor additional Olaparib treatment 
had a significant effect on the expression of mitochondrially encoded genes, nuclear encoded 
mitochondrial genes and genes involved in the UPRmt (Figure 5). When cells are treated with 
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H2O2 in combination with Actinomcyin D (ActD), PAR formation is still detectable after 1 h 
of H2O2 treatment (data now shown) Since it was shown that additional ActD treatment 
enhanced PAR formation in the nucleus after H2O2 or MNNG treatment, we investigated 
whether ActD treatment affects the mitochondrial homeostasis in presence or absence of 
H2O2 or PARP inhibitor. T24 cells were treated with ActD (20 h, 50 ng/ml) and/or H2O2 
(1 mM, 60 min) and/or Olaparib (1 $M, 3 h). qPCR analyses for the same genes as described 
above were performed (Figure 5). Mitochondrial gene expression (mtDNA) increased upon 
ActD treatment, while co-treatment with additional H2O2 and/or Olaparib treatment did not 
have a significant effect. Interestingly, ActD had no uniform effect on the expression levels 
of nuclear encoded mitochondrial genes (nDNA). SDHB was down regulated after ActD 
treatment, whereas NDUFA2 was strongly increased (Figure 5). The same was observed for 
genes of the mitochondrial unfolded protein response pathway. mtHsp70 expression was 
decreased after ActD treatment, while ClpP expression did not significantly change. 
In conclusion, ActD increased gene expression of mitochondria encoded genes (mtDNA), 
while it had differential effects on the expression levels of genes encoded in the nucleus. 
H2O2 treatment and/or PAR inhibition by Olaparib treatment had no significant effect on the 
analyzed genes. Thus, increased PAR formation after ActD treatment in combination with 
H2O2 cannot be responsible for the disruption of mitochondrial homeostasis. 
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Figure 5: Actinomycin D treatment has an impact on the expression of mitochondrial genes, 
independent of H2O2 or Olaparib co-treatment. T24 cells were treated with Actinomycin D (20 h, 
0.05 $g/ml) and/or H2O2 (1 h, 1 mM) and/or Olaparib (3 h, 1 $M). RNA was isolated from 2 
independent experiments and expression levels were measured by qPCR analysis. A) Gene expression 
of mitochondrial encoded ND1 and CO-1. B) Gene expression of nuclear encoded mitochondrial 
proteins SDHB and NDUFA2. C) Gene expression of genes involved in the UPRmt: Hsp70 and ClpP. 
(average + SEM, n=2, t-test, p* < 0.05). 
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3.2.4 NQO1 and NQO2 are potential off-targets of PJ-34 
 
NQO1 (NAD(P)H: quinone oxidoreductase 1) and NQO2 (NRH: quinone oxidoreductase 2) 
are cytosolic flavoproteins catalyzing the oxygen independent two-electron reduction of 
quinone to hydroquinone by using NAD(P)H or dihydronicotinamide ribosyl (NRH) as 
electron donors (262, 263). This is a protective and detoxifying mechanism, since these 
enzymes prevent the formation of reactive oxygen species (ROS) by counteracting the one-
electron reduction of quinone (264, 265) (Figure 6).  
 
Figure 6: Quinone metabolism. A reaction scheme of a simple quinone is shown. 1e- reduction by 
e.g., P450 reductase leads to the radical semi-quinone, which in turn leads to ROS production. 2e- 
reduction by NQO1 results in the stable, less toxic hydroquinone formation (from Nioi et al. (265)). 
 
NQO1 is highly expressed in diverse cancer types (e.g., in breast cancer, colon cancer, 
pancreatic cancer and non-small cell lung cancer) probably as an adaptation to an increased 
metabolic activity (266). NQO1 is therefore often used as a marker of early carcinogenesis, 
but is also an interesting target for cancer therapy. The overexpression of NQO1 in cancer 
cells can be exploited by using special quinone derivatives. These derivatives are reduced to 
toxic hydroquinone, which are able to induce cell death through ROS formation. Different 
compounds are currently tested in pre-clinical trials (e.g., mitomycin C or &-lapachone) (267). 
Another approach used for cancer therapy is the direct inhibition of NQO1. Dicumarol, a 
natural compound, is known to inhibit NQO1 more specifically than other NADPH 
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oxidoreductase and was shown to have growth inhibitory effects in pancreatic cancer cells 
(268). In comparison to NQO1, NQO2 is less studied. It is 49 % homologous to NQO1 and 
uses another electron donor (NRH) (269). Consequently, NQO2 is resistant to the typical 
NQO1 inhibitors such as Dicumarol (269) and specific NQO2 inhibitors are currently being 
developed (270).  
Previous results of our laboratory and of other groups indicated that treatment with the PARP 
inhibitor PJ-34 leads to growth deficiencies and cell death (unpublished results and (160)). 
Madison et al. even observed that the growth inhibitory effects of PJ-34 was due to a mitotic 
arrest independent of ARTD1 (271), indicating that an off-target of PJ-34 is likely 
responsible for the observed growth arrest. 
A drug-profiling screen with PJ-34 in a yeast-based system was performed to identify PJ-34 
interacting proteins. Besides ARTD1, PJ-34 bound specifically to NQO2, but not to NQO1 
(unpublished data). To further investigate the functional relevance of this interaction, T24 
cells and NIH 3T3 cells were transiently transfected with siMock, siARTD1, siNQO1 (both 
as controls) and siNQO2. After plating equal amounts of cells (5x105 cells), cell growth was 
measured after 48 h (Figure 7B). siARTD1, siNQO1 as well as siNQO2 treatment led to a 
decrease in proliferation. The knockdown cells were additionally treated with PJ-34 (10 $M) 
for 48 h and cell growth was measured again (Figure 7C). PJ-34 treatment alone induced 
reduced cell growth of siMock treated T24 and NIH 3T3 cells. A similar effect was observed 
in siARTD1 treated samples, excluding ARTD inhibition as the reason for reduced cell 
growth after PJ-34 treatment. Treatment of siNQO1 cell with PARP inhibitors, in both cell 
lines did not further inhibit cell growth. A similar effect was also observed for siNQO2 
treated T24 cell, but was not observed in NIH 3T3 cells, indicating that PJ-34 induced growth 
defects were likely due to NQO1 and NQO2 inhibition, although the cell type or species 
might be important for the observed effect. 
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Figure 7: PJ-34 induces growth reduction, which is diminished by siNQO1 and NQO2 
knockdown. A) qPCR analysis was carried out to measure the knockdown efficiency in NIH 3T3 and 
T24 cells. B) and C) Cell counting was performed after 48 h of siRNA transfected T24 cells or NIH 
3T3 cells. Starting cell number was 5x105 cells for each condition. C) Cells were additionally treated 
with PJ-34 (10 $M). Cell numbers are shown relative to the untreated cells of each condition. siMock 
was set as 100 % as arbitrary unit. 
 
Since PJ-34 seemed to have an effect on NQO1 independent on the cell type and species, we 
decided to further analyze this effect in NQO1 overexpressing MBA-MD 231 breast cancer 
cells and H596 lung cancer cells (kindly provided by the Boothman laboratory). Bentle et al. 
previously reported that overexpression of NQO1 reduced ROS production, ARTD1 
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hyperactivation, cell death and DNA damage (272). Furthermore, it was shown that NQO1 
stabilizes p53 protein by protein-protein interaction independent of its enzymatic function 
(273, 274). NQO1 and vector-only overexpressing MBA-MD 231 and H596 cells were 
treated with PJ-34 (10 $M, 1 h) and/or H202 (1 mM, 10 min) and PAR formation was 
subsequently analyzed by western blot analysis (Figure 8B). NQO1 overexpressing cells 
showed indeed reduced PAR formation after H2O2 treatment (also observed by 
immunofluorescence microscopy, data not shown). Hence, it could be confirmed that PAR 
formation is reduced in NQO1 overexpressing 231 and H596 cells. PJ-34 treatment 
completely inhibited PAR formation. Additionally, colony formation assays were performed 
with these two cell lines. Cells were treated with different concentrations of PJ-34 (0-10 $M) 
and after 7 days (231 cells) and 12 days (H596 cells), colonies were stained and counted 
(Figure 8C and 8D). In general, NQO1 overexpressing cells generated more colonies 
compared to cells complemented with a control vector, but the number of colonies was 
reduced for all cell lines to a similar extend by PJ-34. At a PJ-34 concentration of 5 $M, the 
number of colonies was markedly reduced and a concentration of 7.5 $M almost completely 
inhibited colony formation. In conclusion, PJ-34 treatment induced a comparably growth 
inhibition in all tested cell lines independent of the overexpression of NQO1.  
To test a direct effect of PJ-34 on the enzymatic activity of NQO1, the commercially 
available WST-1 assay was used. In living cells, cellular dehydrogenases convert WST-1 to 
formazan, which leads to a color change that can be quantified spectrophotometrically. The 
WST-1 assay is usually used as a cell viability assay, but since the conversion of NADH to 
NAD+ involves oxidoreductases such as NQO1, it is rather a metabolic assay and thus can be 
used to indirectly measure the effect of PJ-34 treatment on NQO enzymes. Should PJ-34 
inhibit the NQOs, the conversion of WST-1 to formazan should be reduced. In the 231 breast 
cancer cell line, a reduced WST-1 conversion was indeed detected (Figure 8C). The reaction 
was controlled with Dicumarol, which is a direct inhibitor of NQO1. The sensitivity of this 
readout was rather low, since high concentrations of PJ-34 and Dicumarol had to be used. 
The effect in H596 overexpressing NQO1 cells was not very prominent, although Dicumarol 
inhibited the WST-1 conversion slightly stronger (Figure 8D). Together, our experiments 
provide evidence that PJ-34 indeed inhibits other NAD+ related enzymes in the cell. However, 
further investigations are required to strengthen the point, that PJ-34 can specifically inhibit 
NQO1 and/or NQO2.  
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A         B 
      
 
C 
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Figure 8: PJ-34 treatment strongly reduces cell growth in NQO1 overexpressing 231 cells and 
H596 cells. A) Western blot analysis of 231 and H596 cells stably transfected with vector-only (vector) 
or NQO1 over expressing vector (NQO1+) was performed. B) Western blot analysis of PAR formation 
was performed after H2O2 treatment (1 mM, 10min) and/or treated with PJ-34 (1 h, 10 $M) of 231cells 
and H596 cells. C) Colony forming assay of 231 cells NQO1 overexpressed or vector-only (n= 2, left 
panel), WST-1 assay of NQO1 overexpressing 231 cells. D) Colony forming assay and WST-1 assay 
for NQO1 overexpressed or vector-only H596 cells (as in C). PJ-34_2 is a duplicate measurement for 
PJ-34, uM= $M, DIC= Dicumarol, t-test *p<0.05. 
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3.2.5 Functional role of p65, ARTD1 and ARTD2 during LPS-induced       
inflammatory signaling in the colon cancer cell line MC-38 
 
Colorectal cancer is the 3rd most common malignancy and responsible for every 4th death due 
to cancer (275). Inflammation and hypoxia are common features of solid tumor development. 
Risk factors such as chronic intestinal inflammation and pathogens increase colon cancer 
formation dramatically, as seen in patients with bowel diseases (276). This cancer type 
exhibits increased expression of cytokines and often displays constitutive activity of NF-"B 
(276). NF-"B is a hetero-dimeric complex of p65 and p50, which is induced by inflammatory 
signals leading to its translocation to the nucleus where it acts as a transcription factor of 
inflammatory response genes. NF-"B activity supports tumorigenesis by inducing cell 
proliferation and angiogenesis, which were both shown to promote cell invasion and 
metastasis (277). Moreover, tumor cells with induced NF-"B are often resistant to 
chemotherapeutics (278). Increased levels of TNF# and IL6 in patient serum samples were 
described to correlate with an increased risk for colorectal adenoma (279). Colon cancer cells 
are known to highly metastasize into the lung, promoted by immune and inflammatory cells 
(280). Previous data of our laboratory revealed that NF-"B-dependent gene expression after 
TNF# or LPS treatment is heavily impaired in ARTD1-/- MLFs (137). It was therefore the 
goal of this sub-project to identify new target genes of p65 in MC38 cells (murine colon 
tumor cells, isolated from a chemically induced grade III adenocarcinoma of a C57BL/6 
female mouse) and to clarify the role of ARTD1 and ARTD2 during NF-"B-dependent gene 
expression after LPS treatment. Since hypoxia is an important aspect of tumors, we 
investigated the inflammatory response after LPS treatment under normoxic and hypoxic 
conditions in microtissues by RNA deep sequencing. Upon intracaecal injection, MC38 cells 
form primary tumors in the colon and secondary metastases in the liver. Borsig et al. 
established a MC38 cell line, stably transfected with GFP, to analyze and study the metastasis 
formation (281). For the induction of the cellular inflammatory response, cells were treated 
with bacterial lipopolysaccharide (LPS) from Escherichia coli 055:B5. Pathogens like E.coli 
are often involved in colorectal cancer formation (282, 283).  
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In comparison to 2D cell cultures, microtissues show an increased                   
inflammatory response after LPS stimulation 
The LPS-induced gene expression in MC38 cells was first analyzed under normal 2D cell 
culture conditions. Stimulation of MC38 cells in the presence of 10 % fetal calf serum (FCS) 
induced NF-"B target genes such as IP-10 only to a very low extent (approx. two fold, Figure 
9). Also other inducers of NF-"B such as IL-12 and TNF# did not cause a strong induction of 
IP-10 (data not shown). The expression could be enhanced up to 6 fold by starving cells over 
night  (medium with 0 % FCS) (Figure 9).  
 
 
Figure 9: FCS in medium quenches the inflammatory response. shMock MC38 cells were cultured 
overnight in medium with different FCS concentrations (as indicated). Upon LPS stimulation (1 $g/ml, 
1h) IP-10 gene expression was measured by qPCR (average + SEM, n=2). 
 
Recent studies provide evidence that the inflammatory response is enhanced in 3D 
microtissues compared to conventional 2D cell culture (284). Microtissues or spheroids are 
globular aggregates of several thousand cells (mostly tumor cells) that are generated in cell 
culture and that are used as in vitro tumors models. We thus generated MC38 microtissues 
with a diameter of approximately 300 $m by the hanging drop method using inverted 
microtest plates (Figure 10A). The LPS- induced inflammatory response was, even in 
presence of 10% FCS, greatly enhanced in 3D microtissues as indicated by increased IP-10, 
TNF# and IL6 expression (Figure 10B). Carbonic anhydrase IX (CAIX), a biomarker for 
induced hypoxia, was only slightly up regulated in 3D cell cultures as compared to 2D 
cultures, suggesting that the enhanced gene expression was not due to hypoxic areas within 
the microtissues. Together, these experiments revealed that the LPS-induced inflammatory 
response in MC38 was strongly enhanced in microtissues compared to 2D culture conditions. 
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A 
 
B 
  
Figure 10: The LPS-induced inflammatory response in MC-38 cells is enhanced in 3D compared 
to 2D culture conditions. A) Example picture of micro test plates (Greiner bio-one) used for hanging 
drop method to generate microtissues. In each well 2500 cells per 25 $l drop were seeded. Cells were 
cultivated in complete medium with 10 % FCS for 2 days. Example pictures of microtissues are shown. 
After 2 days of growth, microtissues had a diameter of approx. 300 $m. Detection of GFP expression 
for stable GFP- MC38 was carried out with the fluorescence microscope. B) Gene expression analysis 
of GFP-MC38 cells grown in 2D (normal cell culture) and 3D cell culture by hanging drop method in 
complete medium (10 % FCS). Cells were stimulated with LPS (1 h, 1 $g/ml). TNF#, IL6 and IP10 
expression levels were measured as markers of the inflammatory response. CAIX was used to control 
if hypoxia was induced in 2D versus 3D cell culture (average + SEM, n=2). 
 
Impaired inflammatory response after LPS stimulation in shp65 MC38 GFP                  
cells 
To investigate the contribution of p65, ARTD1 and ARTD2 to the LPS-induced 
inflammatory response in MC38 cells, p65/RelA, HIF1#, (established by Wenger group) 
ARTD1 and ARTD2 were knocked down. sh-targeting sequences for p65, ARTD1 and 
ARTD2 were cloned into a retroviral vector (pRDI292) and expressed under the regulation of 
the H1-promoter. After generation of retroviral particles and subsequent transduction of 
MC38 cells with retroviruses, cells were selected with puromycin (10 $g/ml). Knockdown 
efficiency was confirmed by qPCR analysis as well as by western blot analysis. Since there is 
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no reliable mouse ARTD2 antibody available, ARTD2 knockdown was only evaluated by 
qPCR. The knockdown efficiency was around 80 % for ARTD1 and around 65 % for p65 and 
ARTD2 (Figure 11A). The influence of shp65, shARTD1 and shARTD2 on defined NF-"B 
target genes was measured after LPS treatment (1 h or for 4 h with 1 $g/ml LPS ) by qPCR 
comparing two different conditions: 2D cell culture under starving conditions (0% FCS, over 
night incubation) and 3D cell culture in complete medium (10% FCS) (Figure 11B and 11C). 
Overall, the gene induction was again greatly enhanced under 3D culture conditions as 
compared to starved 2D conditions. The expression of TNF#, but not IL6 was impaired in 
shp65 cells. shARTD1 treatment led to decreased TNF# expression, as compared to shMock 
cells, although the effect was not statistically significant. shARTD2 treatment rather induced 
TNF# expression under both conditions, which may hint at different roles of ARTD1 and 
ARTD2 in NF-"B-dependent gene expression. IL6 expression was reduced in shp65 cells 
under 2D cell culture conditions, but this effect could not be observed under 3D cell culture 
conditions. Furthermore, as already shown in our laboratory, IL6 expression was strongly up 
regulated after LPS treatment in shARTD1 MC38 cells (Fig. 11C and unpublished results). 
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         A 
 
  
Figure 11: Influence of p65, ARTD1 and ARTD2 on TNF# and IL6 gene expression in GFP-
MC38 under 2D and 3D cell culture conditions. A) Western blot analysis of knockdown efficiency 
of shp65 and shARTD1 treated MC38 cells was performed (left panel). There is no ARTD2 antibody 
for mouse lysates available. qPCR analysis (right panels) of knockdown cells was carried out to 
measure knockdown efficiency of shp65, shARTD1 and shARTD2 B) and C) Comparison of 
inflammatory response in 2D cell culture under starving conditions (0% FCS over night, grey bars, 
right panel) and 3D cell culture (complete medium, 10% FCS, black bars, left panel) in different 
knockdown conditions after 1h and 4h LPS* stimulation (1 $g/ml) is shown. (average + SEM , n=3, t-
test p*<0.05). 
 
Together, TNF# was regulated by p65 and ARTD1 as well as ARTD2, although to different 
extents. Surprisingly, IL6 expression was not affected in shp65 MC38 cells under 3D cell 
culture conditions, indicating that other LPS-induced transcription factors than NF-"B are 
regulating IL6 in MC38. While ARTD1 has a rather stimulatory effect for TNF#, IL6 
expression was up regulated in shARTD1 cell, thus ARDT1 has repressory functions on IL6. 
In contrast, ARTD2 repressed the TNF# expression, while the IL6 expression seemed not to 
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be strong affected by this protein. To further elucidate these observations, more genes of the 
inflammatory response have to be analyzed. 
 
RNA deep sequencing analysis revealed strongly reduced p65-dependent                
expression under hypoxic conditions  
Since the 3D culture conditions led to a stronger LPS-dependent gene expression, this 
condition was used to investigate the p65-dependent genes of MC38 cells under normoxic 
and hypoxic conditions by using RNA deep sequencing.  
For the RNA deep sequencing analysis, three independent experiments with LPS stimulated 
(1 $g/ml for 1h) or unstimulated MC38 GFP cells under normoxic and hypoxic conditions 
were performed. To confirm the effective LPS stimulation and hypoxia, TNF#, IL6 and 
CAIX were quantified by qRT-PCR (Figure 12). IL6 and TNF# expression where induced by 
LPS under normoxic conditions, while TNF# expression was strongly reduced under hypoxia 
in comparison to normoxia. p65/RelA-dependence could again be confirmed for TNF! in 
shp65 cells. In contrast to normoxic conditions, IL6 expression was strongly decreased in 
shp65 cells under hypoxia, indicating that the NF-"B-dependent gene response depended on 
the oxygen supply. HIF1# knockdown did not affect TNF# or IL6 expression.  
These experiments corroborated the previous observation that TNF# expression is dependent 
on p65, but furthermore also on the oxygen supply, thus a subset of genes might be 
dependent on p65/RelA only under specific oxygen conditions.  
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Figure 12: Quality control of samples for RNA deep sequencing. The RNA deep sequencing was 
performed in collaboration with Wenger group (shMock 1 and shHIF1# established by Wenger group, 
shMock 2 and shp65 established by Hottiger group). LPS stimulation was performed (* 1 h, 1 $g/ml) 
under normoxia (21% O2) and hypoxia (0.2% O2) and qPCR analysis was carried out for following 
genes: A) TNF#- expression B) Il6-expression C) CAIX expression (average + SEM, n=3, p*< 0.05,) 
 
Following confirmation of LPS stimulation and hypoxia, RNA deep sequencing was 
performed and the data was analyzed with the help of the Functional Genomic Center Zürich 
(FGCZ). After alignment and normalization, 23’300 expressed transcripts were analyzed for 
the different tested conditions. RNA deep sequencing confirmed a similar induction of TNF# 
and IL6 expression as observed by qPCR analysis (Figure 13), although RNA deep 
sequencing was less sensitive (compare scales of the graphs of Figure 13 to Figure 12, 5x up 
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regulation versus 40x up regulation for TNF# expression), indicating that even small 
differences in expression levels observed by the RNA deep sequencing are likely relevant. 
 
 
Figure 11: RNA deep sequencing data for TNF! and IL6. Fold induction analyzed from RNA 
deep sequencing data for the two genes which were used as control before – compare to Figure 12.  
 
The analysis of the RNA deep sequencing run is currently in progress and only a first and 
initial analysis is presented here. The coverage of a specific transcript measured by RNA 
deep sequencing was displayed in signal intensities. These values differed from 0 up to 
60’000. Since significant changes were also detected for RNA species with low signal 
intensities, the data were analyzed without a signal threshold. We were especially interested 
in LPS-induced genes, which were p65/RelA dependent under different oxygen conditions. 
The thresholds for the fold change of genes after LPS stimulation were defined as 1.5 fold 
induction and 0.67 fold reduction (over untreated). The induction of gene expression after 
LPS stimulation was compared for both shMock cell lines and only genes up or down 
regulated compared to both shMock conditions were considered. Out of 23’300 genes, 359 
genes were induced after LPS treatment and 143 genes were reduced after LPS treatment 
(Figure 14A). Furthermore, out of the 359 induced genes, 213 genes (60 %) were positively 
regulated by p65 and only 2 (0.5 %) were negatively regulated (Figure 14B). We further 
analyzed also the HIF1# dependency for the p65 positively regulated genes. 68 genes (32 %) 
were HIF1# dependent of which only 4 genes (1.8%) were negatively regulated by HIF1#  
(Figure 14C). The same analysis was carried out for the samples under hypoxic conditions. 
From the 23’300 identified genes, 202 genes were induced by LPS and 183 genes were 
reduced (Figure 14D). From the 202 LPS-induced genes, only 76 (37.6 %) were positively 
regulated by p65 and only 4 (2 %) were negatively regulated by p65 (Figure 14E). From the 
76 LPS-induced, p65 positively dependent were genes, 41 genes (54 %) were HIF1# 
dependent (Figure 14F). Only 109 LPS-induced genes were common for both normoxic and 
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hypoxic conditions (Figure 14G). The comparison of LPS-induced, p65 positively regulated 
genes revealed only 18 genes in common under normoxia and hypoxia. Moreover, the LPS, 
p65 and HIF1# positively regulated genes were even independent between normoxia and 
hypoxia. Together, the number of induced p65/RelA-dependent inflammatory genes was 
reduced under hypoxia as compared to normoxic conditions. Moreover, comparison of the 
induced genes under these two conditions suggests that different genes are induced under 
normoxia and hypoxia and only a small number of genes are common in both conditions. 
Furthermore, these LPS-induced and p65-dependent genes were less induced under hypoxic 
conditions (e.g., Cxcl2: 40x induction under normoxia versus 17x induction under hypoxia, 
data not shown), suggesting that the induction of the inflammatory response is reduced under 
hypoxia. Interestingly, certain genes seemed to be regulated by p65 under defined oxygen 
conditions, whereas other genes are regulated by NF-"B independent of the oxygen 
conditions. Finally, p65 and HIF1# did not regulate common genes, irrespectively of the 
tested conditions (Figure 14C). Thus, the possible regulation by p65 and HIF1# is dependent 
on the oxygen conditions. 
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Figure 14: Deep sequencing analysis of LPS-induced genes under normoxic and hypoxic 
conditions. Threshold for fold induction was set >1.5 or <0.67 over untreated. A) Of 23300 genes, 
gene expression was induced by LPS stimulation for 359 genes and gene expression was reduced by 
LPS for 143 genes. B) Of 359 induced LPS genes, 142 genes were independent of p65, 215 genes were 
positively regulated by p65, 2 were negatively regulated by p65. C) Of 215 LPS-induced and p65 
positively regulated genes, expression of 63 genes were positively regulated by HIF1#, 4 genes are 
negatively regulated by HIF1# D) Of 23300 genes, gene expression was induced by LPS stimulation 
for 202 genes, gene expression was reduced by LPS for 183 genes E) Of 202 induced LPS genes, 122 
genes were independent of p65, 76 genes were positively regulated by p65, 4 were negatively regulated 
by p65. F) Of 76 LPS-induced and p65 positively regulated gene, expression of 36 genes was activated 
by HIF1#, 5 genes were negatively regulated by HIF1# G) Comparison of overlapping normoxic and 
hypoxic induced genes after LPS stimulation 
 
In collaboration with the Borsig and Jurisica laboratory, a functional interaction map was 
established by using the NAViGaTOR software indicating similar functional pathways for 
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the LPS-induced, p65-dependent genes under hypoxic and normoxic conditions (Figure 15). 
NAViGaTOR uses highly optimized layout algorithms to enable interactive visualization of 
large networks (285). The software program predicts possible functional interactions between 
proteins based on database searches of known (published) interaction partners. The map 
displays interaction of p65-dependent genes induced under normoxia (rectangle, left side) 
and under hypoxia (triangles, right side) after LPS stimulation. The diamonds in the middle 
display the genes, which were found to be regulated significantly under both conditions, 
whereby the width of the symbols displays the positive up regulation under normoxia and the 
height displays the fold induction under hypoxia. Interestingly, the genes with the most likely 
functional interactions were not necessarily those, which were up regulated the most. For 
example, Cxcl2 was up regulated the most in both conditions, but showed only a small 
interaction network. This analysis provides only a first insight into the functional relevance of 
obtained data. Further validation and interaction studies will follow. Interesting targets will 
moreover be verified by controlling their gene coverage using the genome viewer and by 
measuring their expression levels by qPCR analysis. In addition, interesting NF-"B target 
genes will be studied in the shARTD1 and shARTD2 background to evaluate to which extent 
these two proteins influence the gene expression profile of MC38 cells. 
 
  
Results 
  
 163 
 
 
 
Figure 15: Functional interaction map of p65 dependent target genes. Genes under normoxia  
(rectangle) are displayed on the left, for hypoxia (triangle symbol) on the right side. Diamond symbols 
display genes common for both conditions. The width of the rectangle symbols correlate with positive 
gene expression. The height of the triangle symbols correlate with fold induction of expression. Thus, 
genes regulated under normoxia and hypoxia (diamond symbols) change in width and height. Red 
lines display interaction of genes emanating from normoxic conditions. The bigger the letters, the 
more interaction partners exist. Grey lines display interaction between both conditions and blue line 
symbols interaction between hypoxic partners. Cxcl2 was the strongest induced gene after LPS 
stimulation in both conditions; therefore it is biggest displayed in size of its symbol. 
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3.2.6 Materials and Methods 
 
Cell culture 
The T24 urinary bladder cancer cell line was cultivated in McCoy’s 5A medium (Gibco, 
Invitrogen, CA, California, USA) at 37°C. NIH 3T3, HEK 293, H596 as well as U2OS cells 
were cultivated in Dulbecco's Modified Eagle's Medium (DMEM) (PAA, Pasching, Austria). 
231-MD-MBA cells were cultivated in Roswell Park Memorial Institute medium (RPMI) 
(Gibco, Invitrogen, CA, California). Mouse embryonic fibroblast (MEF) cells were obtained 
from wildtype (WT) and ARTD1 knockout mice and also cultivated in DMEM. The GFP-
transduced MC38 cell line was provided by Dr. Lubor Borsig (Institute of Physiology, 
University of Zurich, Switzerland) and was cultivated in DMEM supplemented with 1% (v/v) 
non-essential amino acids and 1% (v/v) sodium-pyruvate. Every 3rd passage, Geneticin 
(G418; 1 mg/ml) (Gibco, Invitrogen, CA, California) was added to select transduced cells. 
All media were supplemented with 1% (v/v) Penicillin/Streptavidin and 10% (v/v) fetal calf 
serum (Gibco, Invitrogen, CA, California, USA). 
 
Antibodies 
Following antibodies were used: From Santa Cruz Biotechnology, Inc (Dallas, TX, USA): 
PARP1/ARTD1 (H-250, rabbit); PCNA (PC10. mouse); p53 (FL-393,rabbit); Rb (IF8, 
mouse), p65 (C-20, rabbit), cyclin E (HE12, mouse), , mouse). From Active motif (Carlsbad, 
CA, USA): PARP2 (rabbit). From Sigma Aldrich (St. Louis, MO, USA): tubulin (mouse). 
From Epitomics Inc. (Burlingame, CA, USA): Rb (rabbit). Homemade: PAR 10H (mouse). 
 
Immunoprecipitation  
Cells were harvested with a scraper after adding 400 $l ice-cold lysis buffer (50 mM Tris-Hcl 
pH 7.5, 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM Na-pyrophosphate, 
0.5 mM Na-orthovanadate, 1 mM Benzamidine, 0.1 mM PMSF, 1% Nonidet P-40). After 
lysis (10 min on ice), cells were collected (12,000 rpm, 10 min) and proteins were quantified 
by the Bradford assay. Immunoprecipitation was carried out with 2 $g of antibody per 500 
$g of extract at 4°C for 3h. Sepharose G or A beads were added (20 $l per reaction, 
incubation for 30min at 4°C). Beads were washed with extraction buffer, 6x Laemmli buffer 
(4 $l) were added and the reaction was boiled for 5 min at 95°C. SDS-PAGE and western 
blot analysis were performed as described previously. 
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Colony survival assay 
Cells were seeded in 6-well-plates (500 cells per well), treated as indicated and grown for at 
least 7 days. The medium was discarded and cells were washed once with PBS and stained 
with Crystal violet solution (0.5% w/v crystal violet powder, 20% ethanol). Plates were 
washed twice with water and colonies were counted after drying. 
 
WST-1 assay (Roche, Basel, Switzerland) 
2x104 cells were seeded in a 96-well-plate per well. Treatment was carried out as indicated 
and 10 $l of the WST-1 substance was added to each well. WST-1 turnover was measured 
after 60min at a wavelength of 450nm with the microplate reader Infinite® Pro 200 (Tecan, 
Männedorf, Switzerland). 
 
Cloning of sh-constructs 
For stable knockdown in MC38 cells, sh-constructs for ARTD1, ARTD2 and p65 were 
cloned. Primers were designed for a 19 nucleotide target sequence flanked by specific 
sequences allowing to build a hairpin structure. Sequences for p65: forward primer: 5’ 
GATCCCCAGGGCAAACTGTAGAGTCATTCAAGAGAT 
GACTCTACAGTTTGCCCTTTTTTGGAAA, Reverse primer: 
5’AGCTTTTCCAAAAAAGGGCAAACTGTAGAGTCATCTCTTGAATGACTCTACAGT
TTGCCCTGGG, for ARTD2: Forward primer: 5’ GATCCCC CCATGAAAGTAATGAG 
TTTTTCAAGAGAAAACTCATTACTTTCATGG TTTTTGGAAA Reverse primer: 5’ 
AGCTTTTCCAAAAACCATGAAAGTAATGAGTTTTCTCTTGAAAAACTCATTACTT
TCATGG GGG  
The oligos were annealed, phosphorylated and ligated into the pSUPER vector. The construct 
and the H1-RNA promoter for expressing hairpin RNAs were cut out with BamH1 and SalI 
and ligated into the pRDI292 vector (received from Paul O. Hassa). The final vector was 
transformed in bacteria, purified and sequenced to control the correct insertion. 
 
Virus production 
HEK 293 cells were seeded (4x106 cells per 10 cm plate) 1 day before calcium phosphate 
transfection with 10 $g transfer plasmid with the desired sh-sequence, 6 $g of packaging 
plasmid, and 3.5 $g viral envelope plasmid. Medium was changed 6-8 h post transfection and 
Results 
  
 166 
after 40h, cells and supernatant were harvested, centrifuged and filtered (0.45 $g cellulose 
acetate filters). Supernatant containing the virus was frozen at -20°C in 1 ml aliquots. 
  
Viral transduction – Virus infection  
Cells were seeded 1 day prior to transduction on a 6-well- plate (5x105 cells per well). 
Polybrene was added to a final concentration of 4 $g/ml over night. 1 ml of supernatant 
containing virus was added per well. The medium was replaced 8 h post infection and to 
selective-medium after 1 day (Puromycin, 10 $g/ml for MC38 cells, 0.7 $g/ml for T24 cells) 
(Invivogen, San Diego, CA, USA). Cells were kept under constant selection.  
 
3D cell culture for hypoxic/normoxic LPS stimulation experiment 
Viral transduced GFP-MC38 cells were seeded on micro test plates (2500 cells/25 $l drop) 
(Greiner bio-one, Kremsmünster, Austria) for hanging drop 3-D cultivation. Cells were kept 
at 37°C for 2 days until a micro tissue was formed and were then transferred to constant 
hypoxic (0.2 % O2) or normoxic (21 % O2) conditions for 7 h. Following, cells were 
transferred to DMEM medium with or without LPS (1 $g/ml, Sigma Aldrich, St. Louis, MO, 
USA) in a bacterial plate to avoid attachment of micro tissues to the plate) and incubated at 
the corresponding O2 concentration for 1 h. Microtissues were collected, washed once with 
PBS and lysed in RNA lysis buffer RA1 (Nucleospin RNA II extraction kit, Macherey-Nagel, 
Düren, Germany) 
 
RNA deep sequencing  
RNA deep sequencing analysis was performed at the Functional Genomics Center Zurich 
(University of Zurich), supervised by Dr. Hubert Rehrauer and by Catharine Aquino. RNA 
was extracted and pooled from 3 independent, LPS-stimulated 3D-cultures that were grown 
under hypoxia or normoxia and that were treated with shMock, shp65 or shHIF1#. 
Ribosomal RNA in the pooled RNA was depleted (Encore® Complete RNA-Seq Library 
Systems, NuGEN, San Carlos, CA, USA) and RNA deep sequencing was performed with the 
Illumina HiSeq 2000 sequencer (San Diego, CA, USA).  
 
RNA deep sequencing analysis 
Isoform and gene expression levels were computed with RSEM (Version 1.2.0). 
(http://www.biomedcentral.com/1471-2105/12/323). RSEM was run in stranded-mode with 
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the additional option to estimate the distribution of the read start positions. The expression 
levels were normalized for sequencing depth using the geometric mean. The geometric mean 
was computed using only genes that had an abundance above zero in all samples. For 
heatmap visualizations at logarithmic scale, zero-valued abundance values were replaced 
with a small positive value. To attenuate expression ratios for low abundance genes, a fixed 
value of 5 was added to all expression values before computing the log-ratio. 
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4 DISCUSSION AND PERSPECTIVES 
The aim of this thesis was to investigate if ARTD1 and ARTD2 regulate different cellular 
processes or use different mechanisms to regulate common processes. To corroborate this 
hypothesis, we investigated the involvement of ARTD1 and ARTD2 during the diverse 
biological functions, the genotoxic stress response and the re-entry into cell cycle progression. 
 
4.1 ARTD2 activity is stimulated by RNA  
H2O2 and MNNG are well known inducers of genotoxic stress. Upon treatment of cells, PAR 
is formed in the nucleus. In this study we demonstrated that treatment of cells with H2O2 or 
MNNG induced PAR formation mainly in regions of the nucleoli of different cell lines (e.g., 
T24 and NIH 3T3). The inhibition of RNA polymerase I by Actinomycin D (ActD) in 
combination with the treatment of H2O2 or MNNG stimulated a massively increased and 
prolonged PAR formation. ARTD1 and ARTD2 were previously described to also localize to 
the nucleolus, although their localization only partially overlapped, which already hinted at 
different functions of both enzymes (153). Earlier studies also reported that the nucleolar 
localization of unstimulated ARTD1 and ARTD2 enzymes is disrupted upon ActD treatment 
(153, 286). Our experiments included not only the treatment of cells with ActD, but also a co-
treatment with genotoxic stress inducers. These conditions rather lead to an activation of the 
enzymes than their re-localization (112, 116). 
Treatment of cells with ActD alone did not induce PAR formation, although it was described 
to induce DNA double-strand breaks (287). The induction of strand breaks could be 
confirmed but only with a high concentration of ActD (1 $g/ml for 4 hours), which induced 
!H2AX foci, whereas only few foci were found at low concentration (50 ng/ml, 20h 
treatment, data not shown). Together, our findings indicate that strong stimulation of PAR 
formation by ActD in combination with H2O2 or MNNG was not due to the induction of 
DNA double-strand breaks, but rather due to its inhibitory effect on RNA polymerase I. 
Moreover, treatment with H2O2 or Olaparib with ActD did not cause significant changes on 
mitochondrial gene expression as already observed for ActD alone (chapter 3.2.3), indicating 
that the general lack of mitochondrial gene expression (e.g., ND1 and CO-1) and the possible 
reduction of ribosomes is most probably not involved in the induction of nuclear PAR 
formation. Moreover, the knockdown of ARTD1 by siRNA revealed that the initial PAR 
formation after H2O2 treatment was mainly dependent on this enzyme. However, knockdown 
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of ARTD2 revealed that ARTD2 is mainly responsible for the delayed and prolonged PAR 
formation after ActD exposure, indicating that the detected PAR is synthesized by the two 
different enzymes ARTD1 and ARTD2. 
Our experiments furthermore provide evidence that RNA (and also single stranded DNA, 
data not shown) is able to activate the enzymatic activity of ARTD2. Thus, the massive 
synthesis of short non-coding RNA transcripts by inhibiting RNA polymerase I (55) may thus 
be detected in vivo by ARTD2 and lead to its activation. Moreover, our data provides 
evidence that the SAP domain of ARTD2 is important for the activation by RNA. 
Furthermore, the WGR domain seems to be generally essential for ARTD2 activity, since 
upon deletion of the WGR domain the overall ARTD2 activity was reduced. Using an 
ARTD1 mutant lacking the DNA binding domain, earlier studies have shown that ARTD1 
binds RNA via the WGR domain, which induces PAR formation (68), thus the possibility of 
the ARTD2 WGR domain to bind RNA has to be further analyzed. Moreover, the WGR 
domain might work as a linker domain allowing ARTD2 to undergo certain conformational 
changes required for the ARTD2 activation by RNA. Unfortunately, there are currently no 
crystal structures of ARTD2 available to further elucidate this aspect. In addition to ARTD1 
and ARTD2, only ARTD3 contains a WGR domain, but neither a SAP domain nor zinc-
fingers (61). Interestingly, ARTD3 was also activated by RNA whereas ARTD10, which 
does not contain a WGR domain, was not stimulated by RNA (data not shown). This 
provides further evidence that the WGR domain may represent a general activation domain. 
In contrast to ARTD2, both ARTD1 and ARTD3 were stimulated to a lower extent by RNA, 
which might be explained by a different domain- and amino acid sequence composition of 
the CAT domains of these enzymes. The zinc-finger domains of ARTD1, which are distantly 
located from the catalytic domain, preferentially bind DNA (116) and induce a 
conformational change of the overall structure that may prevent further RNA binding (288). 
The observed activation of ARTD1 by RNA may thus only be relevant under special 
conditions in vivo and most likely not under genotoxic stress response.  
 Interestingly, the stimulatory effect of ActD in vivo was dependent on co-treatment 
with H2O2 or MNNG. It is possible that ARTD2 forms short polymers or oliogmers of poly-
ADP-riboses after ActD treatment, which are not detectable due to the PAR length-specificity 
of the antibody (77). The activity of endogenous PARG might be high enough to immediately 
shorten the newly formed PAR to a length, which is below the detection limit of the antibody. 
The additional genotoxic stress could induce a post-translational modification of ARTD2, 
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which hyper-activates ARTD2, subsequently allowing the formation of longer PAR chains. 
This can be addressed in vitro by elucidating a possible modification of ARTD2 by using 
different kinase-, methyltransferase- and acetyltransferase- modification assays or by 
knocking down these enzymes by siRNA and reanalyze the functional consequence on 
ARDT2 dependent activity after H2O2 or MNNG treatment. Alternatively, H2O2 or MNNG 
treatment might lead to the temporal inactivation of PARG (e.g., by a post-translational 
modification), which would also result in an enhanced PAR formation. Another possibility is 
that ADP-ribosylation is induced upon RNA damage. It was shown that H2O2 causes greater 
oxidation in cellular RNA than in DNA (289) and could thus also be a stimulator of ARTDs. 
Moreover, the RNA molecule is less compacted than the DNA, which makes it more 
susceptible to oxidative damage. Little is known about RNA repair mechanisms, but it was 
shown that alkylation damage of RNA is similarly repaired as in DNA in vivo (290). ARTDs 
could thus be involved in the recognition of damaged RNA molecules. This could be further 
analyzed by in vitro PAR activity assays using damaging agents on RNA or by RNA 
immunoprecipitation experiments allowing detecting which RNA molecule are indeed 
binding to ARDT2 in vivo. 
The activation of ARTD2 by RNA might additionally hint at new functions of ARTD2 in the 
cell. ARTD2 might for example recognize nascent RNA transcripts. In the context of the 
stress-response, this could be an important function. RNA polymerases stall when they 
approach a bulky DNA lesion (291). As a consequence, the transcription-coupled repair 
(TCR) pathway is activated (292). ARTD2 might recognize the nascent transcript of a stalled 
RNA polymerase and either recruit factors involved for the TCR pathway or inhibit RNA 
degrading enzymes, thus protecting the RNA. One could therefore investigate whether 
activated ARTD2 is able to interact with Mfd or other members of the TCR pathway or 
whether ARTD2 depletion induces defects of the TCR pathway. A general involvement of 
ARTD2 in RNA polymerase processivity could moreover be foreseen. It is known that 
transcription elongation factor 5 (Spt5) stimulated the processivity of RNA polymerase II and 
is later involved in factor recruitment for 3’ processing and chromatin modification factors 
(291). ARTD2 could play a similar function in transcription by recognizing the nascent RNA 
and recruiting mRNA modifying enzymes following its auto-modification. ARTD1 was 
already described to affect mRNA processing by PARylating the poly(A) polymerase (PAP) 
upon heat stress, which leads to the eviction of PAP and ARTD1 from the mRNA transcript 
(293). Further investigations are required to determine the minimal length of the RNA, which 
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can stimulate ARTD2 activity, and to assess whether the induction of PAR formation is 
dependent on a specific RNA sequence or structure. Since ARTD1 also seems to be activated 
by RNA, which was already reported by Guetg et al. during heterochromatin formation (131), 
we cannot exclude yet that the two enzymes are likely redundant with respect to this function. 
In our studies, PAR was found to mainly localize to nucleoli, but some foci were also 
detected in other regions of low DAPI staining, indicating that other nuclear bodies or 
chromatin structures could also contain PARylated targets. For example, other euchromatic 
sites, which are actively transcribed, but also nuclear speckles, which are also known as 
interchromatin granule clusters, enriched in pre-mRNA splicing factors and thus important 
for the processing of mRNA (294). In close proximity of the nuclear speckle are the recently 
identified paraspeckles, which are comprised of long, non-coding RNA and a few RNA 
binding proteins. At least 5 types of speckles are present in the nucleus, which are all 
rearranged upon transcriptional inhibition (294). So far, no clear function of paraspeckles 
could be identified. Since paraspeckles are built around long non-coding RNA, they are also 
sensitive to RNase treatment (294). RNase A treatment was shown before to change also the 
nucleolar localization of ARTD1 (131). Co-localization studies of PAR, ARTD2 and ARTD1 
with proteins of these nuclear speckles and paraspeckles, (e.g., paraspeckle protein 1) with or 
without RNase treatment would provide further evidence for spatial interaction. Knockdown 
experiments with siARTD1 and siARTD2 would potentially clarify if they play a role in 
paraspeckle or nuclear speckle assembly and maintenance.   
Finally, we could very recently observe that ARTD2 is not only stimulated by RNA, but also 
by single-stranded DNA molecules (data now shown). Single-stranded DNA is generated 
during stalled replication or upon torsional chromatin stress (77, 295). ARTD2 might thus be 
activated also under these conditions, independent of DNA damage. Further experiments 
along this line should provide more insights for a possible function of ARTD2 during these 
processes. 
 
4.2 ARTD1 and ARTD2 in cell cycle progression 
To investigate the function of ARTD1 and ARTD2 during cell cycle progression, we chose to 
work with the T24 urinary bladder carcinoma cell line as a model. These cells enter a 
quiescent state upon reaching confluence and cell cycle progression can be easily followed 
upon splitting. This allowed avoiding the treatment of cells with chemicals for their 
synchronization (e.g., Aphidicolin, Nocodazol, Thymidine), which were observed to induced 
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PAR formation (data not shown, Vetmed Dissertation of Sandra Bäckert, 2009). To address a 
possible function of ARTD1 or ARTD2, the enzymes were knocked down by siRNA 
treatment before splitting cells. The results presented here demonstrated that ARTD1 and 
ARTD2 are both important regulators of cell cycle re-entry or progression. ARTD1 was 
important for the expression of Cyclin E, likely by modulating its promoter site. In contrary, 
ARTD2 was identified to repress p27 gene expression, again indicating that ARTD1 and 
ARTD2 are regulating the same cellular process differentially. A detailed discussion of these 
aspects follows in the next two paragraphs. 
 
4.2.1 ARTD1 regulates Cyclin E promoter activity 
 
In this study we have found that ARTD1 positively influences Cyclin E expression during 
cell cycle re-entry and G1–S phase progression. We could show that chromatin marks at the 
Cyclin E promoter were changed when ARTD1 was knocked down, thus identifying ARTD1 
as a positive regulator of the Cyclin E transcription. The observed increased recruitment of 
ARTD1 to the Cyclin E promoter during G0 to G1 phase transition provides evidence that 
rather the initiation than the prolongation of Cyclin E transcription is affected. Since the 
treatment of cells with PARP inhibitors did not induce comparable changes of the Cyclin E 
expression levels, PAR formation seems not be important for the mechanism described here. 
This is different to published studies, where PARylation of KDM5B, a demethylase, 
prevented demethylation of H3K4me3 and thus kept promoters in an active state (142). Since 
the levels of H3K4me3 were not changed upon siARTD1 treatment in our studies, the 
changes at the Cyclin E promoter were probably induced by other mechanisms than altered 
histone modifications. In ARTD1 depleted cells, H1 levels, which mark closed chromatin, 
were increased and the marker for active transcription sites H2A.Z was decreased. It was 
shown before that ARTD1 and H1 occupancy have reciprocal binding at diverse promoter 
sites (141, 249). It is possible that ARTD1 itself replaces H1 at the Cyclin E transcription 
start site, perhaps by the interaction with other chromatin associated modifiers or by 
remodeling complexes as it has already been observed for the exchange of histone variants 
(296). Moreover, the presence of ARTD1 at transcription start sites could be regulated by 
posttranslational modifications of ARTD1 (e.g., phosphorylation or mono-ADP-ribosylation), 
which is not inhibited by commonly used PARP inhibitors (157). To test this hypothesis, the 
recruitment of ARTD1 to the Cyclin E promoter could be analyzed by inhibitor studies with 
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different kinase inhibitors, for example for ERK1/2 (120). Another explanation for the 
transcriptional changes of Cyclin E could be due to the transcriptional co-factor function of 
ARTD1. ARTD1 was reported to interact with p300, an acetyltransferase and co-activator of 
transcription (136). E2F-1 requires the interaction with acetyltransferase p300 in order to be 
transcriptionally active (203). Interestingly, the H4ac mark was slightly reduced upon 
knockdown of ARTD1. H4 acetylation levels may thus be decreased due to a reduced 
recruitment of p300 to the Cyclin E transcription start site. ARTD1 may therefore be involved 
in the recruitment of p300 to the Cyclin E promoter, similar to the described function of 
ARTD1 and p300 for NF-"B (136). Therefore, it would be important to investigate if E2F-1 
binding is changed at the promoter site of Cyclin E after ARTD1 depletion. These 
experiments failed so far due to the lack of an E2F-1 antibody allowing chromatin 
immunoprecipitation. Furthermore, luciferase activity assays could be carried out for ARTD1 
and p300 to confirm a possible cofactor function at the Cyclin E promoter. 
 Our studies revealed that the E2F-1-dependent microRNAs 15 and 16 expression 
levels are strongly enhanced after siARTD1 treatment. Since these miRNA negatively 
regulate Cyclin E expression, another layer of regulation involving a feedback loop after cell 
cycle interruption has to be considered (244). However, this is unlikely the chase, since no 
Cyclin E mRNA could be detected by qPCR. Knocking down the expression of microRNAs 
15 and 16 would further exclude that these RNAs contribute differently to the observed cell 
cycle progression phenotype. 
Interestingly, the ARTD1 depleted T24 cells are able to overcome the reduced Cyclin E 
expression in the course of three days, indicating that chromatin plasticity is able to overcome 
the lack of ARTD1. This observation was confirmed when ARTD1 was stably knocked down 
by shRNA (data not shown). Alternatively, other cell cycle regulatory factors such as Cylin D 
and A, which were up regulated at the transcriptional level in siARTD1 treated T24 cells, 
could functionally compensate the loss of Cyclin E. This is in agreement with the observation 
that Cyclin E knockout mice are still viable and healthy (297).  
 
4.2.2 ARTD2 positively regulates G0-G1 progression 
 
The function of ARTD2 during the cell cycle re-entry and progression, and in particular a 
possible redundant function with ARTD1, was not studied before and was thus an important 
aim of this work. siARTD2 treated T24 cells did not progress through the cell cycle, but were 
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early arrested at the G0/G1 transition and subsequently induced apoptosis. The cell cycle 
arrest was due to a strong induction of p27 levels. While the CIP/KIP family member p57 
was also up regulated on mRNA levels (data not shown), the DNA damage response protein 
p21 was not altered, indicating that the observed effect was not DNA damage dependent. 
ChIP analyses of the p27 promoter revealed a strong enrichment of H3K4me3, which may 
explain the up regulation of p27. ARTD2 was recently described to form a complex with 
HDACs and G9A methyltransferase and to negatively regulated MYC expression (152). 
ARTD2 might thus be responsible for the recruitment of chromatin regulators such as histone 
methylases. Therefore, further ChIP analyses have to be carried out in order to study the 
recruitment of such factors in presence or absence of ARTD2. Unfortunately, the current lack 
of ARTD2 antibodies for ChIP analysis does not allow confirming the recruitment of ARTD2 
to the p27 promoter. ARTD2 was already described to have repressory functions on SIRT1 
expression, which is a deacetylase that modifies histones (148). Whether SIRT1 expression is 
differently regulated in siARTD2 treated T24 cells has to be further elucidated. Interestingly, 
we did not observe the G0/G1 phase arrest in siARTD2 treated asynchronous cells, indicating 
that ARTD2 is especially important for the exit of cells from G0 phase. It would be 
interesting to study if ARTD2 overexpressing T24 cells are still able to enter the G0 phase or 
progress through the cell cycle uncontrolled. ARTD2 could thus be a positive regulatory of 
the early immediate genes 
 
4.2.3 The enzymatic activities of ARTD1 and ARTD2 do not contribute to                 
the function in early cell cycle progression 
 
Interestingly, PARP inhibitors (e.g., Olaparip) did not inhibit progression of cells through the 
early cell cycle phases, but rather inhibited cell cycle progression at late S phase, indicating 
that the enzymatic activities of ARTD1 and ARTD2 are not required for the above-described 
functions during re-entry or early G1 progression. A recent publication by Guetg et al. 
showed that ARTD1 interacts with pRNA and TIP5 during late S phase in an activity-
dependent manner and that this interaction was important during the formation of 
heterochromatin (131). PARP inhibitors would lead to a disrupted or unstable 
heterochromatin formation, which results in sister chromatid exchange formation. Together, 
our experiments provide further insight in the importance of ARTD1 and ARTD2 
independent of their enzymatic activities. 
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4.3 Role of ARTD1 during immortalization 
During the process of immortalization, cells overcome the growth arrest by recombination-
dependent mechanisms to retain telomeres and by spontaneous mutations (254-256). Our data 
provide evidence that primary ARTD1-/- MEFs reach the transformation state much slower 
than their wild type counterpart. The process is accompanied by reduced Cyclin E mRNA 
expression in ARTD1-/- cells, indicating that ARTD1 plays a direct or indirect regulatory role 
in Cyclin E expression. This observation was comparable to the regulatory effect during cell 
cycle re-entry and progression after knocking down ARTD1. However, other cell cycle 
regulatory factors such as pRb and E2F-1 were differentially regulated compared to the T24 
analysis. We thus conclude that the overall regulation induced upon transformation is likely 
different from the regulatory process induced in T24 cells. This might be due to the different 
nature of the tested cells. While MEFs are primary cells, the T24 cells are transformed tumor 
cells, which acquired already many mutations. Interestingly, the presence of ARTD1 is 
beneficial in both processes and confirms that ARTD1 plays an important role during cell 
growth initiation, although by different mechanisms. Further studies of wild type MEFs 
grown in presence of PARP inhibitors will reveal, if and how transformation is regulated by 
ADP-ribosylation.  
  
4.4 PJ-34 as off-target for NQO1 and NQO2 
PJ-34 is a potent PARP inhibitor with an IC of 20 nM, but is not specific for an individual 
ARTD family member (157, 158, 271). Recently it was shown that PJ-34 is even able to 
inhibit Pim kinases (159), thus questioning its selectivity. Our own data revealed that the 
growth inhibitory effect of PJ-34 is ARTD1-independent. A drug-profiling screen (data not 
shown) with PJ34 identified NQO2 as a potential binding protein for PJ-34. More specific 
analyses revealed that both, NQO1 and NQO2 might be new off-targets of the PARP 
inhibitor PJ-34 in T24 cells, NIH 3T3 cells and 231 cells. Thus it is likely that besides 
ARTD1, PJ-34 also targets NQO1 or NQO2. Interestingly, NQO1 is overexpressed in 
different cancer types (277). The identification of these new PJ34 off targets may thus be 
highly relevant and can potentially be exploited for cancer treatment. NQO1 inhibition leads 
to an increase of radical semi-quinones, which in turn cause an increase in ROS formation. 
ROS formation damages protein, lipids and DNA through oxidation, which eventually results 
in cell death. In addition, the inhibition of ARTD1 activity leads to an increased DNA 
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damage. Further experiments are required to strengthen this scenario e.g., by looking at the 
activation of DNA damage checkpoints or by performing viability assays. Moreover, it would 
be worthwhile to test the NQO1 activity in vitro by measuring NADH recycling in 
combination with PJ-34 treatment. In vitro and in vivo binding studies are required to clarify 
how PJ-34 binds the NQO enzymes in comparison to ARTD1.  
The functional correlation of NQO2 with PJ-34 could only be confirmed in human T24 cells, 
but not with mouse NIH 3T3 cells in vivo. NQO2 was shown to have mostly low endogenous 
activity and shows tissue-specific expression differences (298). Since NQO2 uses NHR than 
NADH, it remains questionable, whether PJ-34 is interacting with the catalytic domain of 
NQO2 or rather with another domain of the protein. As for NQO1, in vitro experiments 
including enzymatic activity assays should be performed to shed more light onto the exact 
mechanism. Furthermore, other PARP inhibitors should be tested to clarify, if NQO1 or 
NQO2 are indeed off-targets of PARP inhibitors. 
 
4.5 Functional role of p65, ARTD1 and ARTD2 during            
inflammatory signaling in the colon cancer cell line MC-38 
Inflammation and hypoxia are prominent characteristics observed in solid tumors. We 
therefore aimed to compare NF-"B (p65)-dependent gene expression under normoxic (21 % 
oxygen) and hypoxic (0.2 % oxygen) conditions in MC38 mouse colon cancer cells and to 
investigate the functional contribution of ARTD1 and ARTD2 for this gene expression.  
This project is still in progress and only the first results can be discussed here. RNA transcript 
levels were analyzed by RNA deep sequencing in collaboration with the Wenger group. LPS-
induced (1 h, 1 $g/ml) RNA transcript levels of MC38 cells expressing shMock, shp65 and 
also shHIF1# grown under normoxic and hypoxic conditions were analyzed. 3D cell cultured 
microtissues were more sensitive to LPS stimulation than cells cultured under normal 2D 
conditions. Most likely, the NF-"B response in microtissue is more efficient due to higher 
expression of LPS-sensitive receptors such as TLR4 on the surface of microtissues and 
possibly due to the higher interaction of the cells in that three dimensional network. 
RNA deep sequencing revealed that more genes are activated by LPS under normoxic 
conditions as compared to hypoxic conditions. Similar observations were reported by others 
before, but only for a small number of pro-inflammatory genes (299, 300). A possible 
explanation for this observation is that the HIF1# transcription factor, which is only stabilized 
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under hypoxic conditions, induces the expression of proteins involved the degradation of 
certain mRNAs. An indication pointing in this direction is the work of Werno et al., which 
demonstrates that TNF# mRNA is destabilized by the increased tristetraprolin (TTP) activity 
under hypoxia (299). In addition, the TLR4 receptor, which initiates the LPS-induced 
inflammatory response, might be down regulated upon hypoxia and thus diminishs the 
inflammatory response (300). However, this explanation is less likely, since we did not see 
expression changes for TLR4 (based on RNA deep sequencing data, not shown). This could 
be further investigated by western blot analysis for TLR4. 
Furthermore, the reduced expression of NF-"B target genes during hypoxia could be 
explained by an impaired translocation or chromatin recruitment of NF-"B to the nucleus. 
Microscopy and ChIP experiments of cells grown under normoxia and hypoxia could address 
these possibilities.  
Comparison of the LPS-dependent genes under hypoxia and normoxia revealed that only up 
to 50% of all induced genes were common for both conditions and that only 20% of the p65-
dependent genes were found under both, normoxia and hypoxia. Thus, hypoxia affected both 
the intensity of the NF-"B response as well as the type of induced NF-"B-target genes 
(Figure 12G). Difference in gene expression patterns may be due to the presence of the 
HIF1# transcription factor under hypoxic conditions. However, the LPS-induced, p65- and 
HIF1#-dependent genes were completely distinct with no overlapping candidates, suggesting 
that oxygen levels dramatically affects the inflammatory signaling and subsequent response. 
Metacore (Pathway) analysis of the deep sequencing data (comparing the LPS and p65-
dependent genes) could provide evidence whether there is a shift of signaling pathways that 
are responsive under the different oxygen supplies. To validate the importance of a distinct 
pathway under certain conditions, inhibitor and knockdown studies targeting one of the key 
proteins of a certain pathway and subsequent analysis of the expression profile by qRT-PCR 
could be carried out.    
 The interactome analysis performed by the Jurisica/Borsig laboratories with the 
NAViGaTOR software of the RNA deep sequencing data predicted most likely functional 
interaction based on known interactions and in silico databases. For the analysis of protein-
protein interaction networks, it was not important how strong a gene was induced upon 
stimulation, but in how many interactions the corresponding protein could participate. The 
interaction analysis confirmed that the LPS-dependent genes induced under normoxia in 
MC38 are indeed part of an inflammatory network. Furthermore, this software allows 
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performing an interactome analysis with miRNAs (mirDIP software, (301)), which are 
becoming more and more recognized as regulators of mRNA processing and pathway 
controls. There are strong evidences that miRNAs are also differently expressed depending 
on the oxygen levels and it is thus likely that miRNAs play a role in the differences detected 
in our analysis (302, 303). Such in silico studies have still to be done and will reveal if and 
which miRNAs most likely affect the expression of different pro-inflammatory genes and 
whether they regulate the inflammatory response under different oxygen conditions. 
A first analysis revealed potential new p65-dependent target genes. For example, Rnd1, 
Shroom4 and Ldhb were found to be up regulated by LPS under normoxic conditions and 
positively regulated by p65 and even by HIF1#. Under hypoxic conditions, Kremen2, 
Schlafen2 and Sap25 were specific p65- and HIF1#-induced genes (Table 1). To test their 
relevance for the inflammatory response, validation and knockdown experiments targeting 
the new genes should be performed and differences in cytokine expression should be detected 
by qPCR analysis. 
 
Table 1: Potential new identified LPS induced (fold induction over untreated) and p65 and HIF1! 
regulated genes under normoxic or hypoxic conditions. 
 
 
The newly identified LPS-induced NF-"B target genes in MC38 cells will also be analyzed in 
regard to a possible regulation by ARTD1 and ARTD2 under LPS stimulation. shARTD1 and 
ARTD2 treated MC38 cells will be exposed to different oxygen levels and stimulated with 
LPS. Gene expression analysis will be performed by qRT-PCR for a selected group of genes. 
ARTD1 is a positive regulator of the inflammatory response (304, 305) and regulates NF-"B-
dependent gene expression through the direct interaction with p65 (306). However, some NF-
"B target genes seem to be negatively regulated by ARTD1, as seen in our studies for IL6 in 
MC38 and by other group members in RAW and 3T3 cells (unpublished data). Since the 
same gene is positively regulated by ARTD1 in mouse lung fibroblast, the function of 
ARTD1 seems not only to be gene specific, but also cell type specific. These different 
regulatory functions of ARTD1 may be due to different roles in the recruitment of chromatin 
Gene Full name Function
Normoxia Hypoxia
Rnd1 Rho family GTPase 1 regulation of actin cytoskeleton upon growth factor 5.8 3.7
Shroom4 shroom family member 4 regulator of cyto-skeletal architecture 1.8 1.7
Ldhb lactate dehydrogenase B catalyzes the reaction from lactate to pyruvate 1.6 0.9
Slfn2 schlafen2 regulators of T cell development 3.1 4.7
Sap25 Sin3A-associated protein, 25kDa histone deacetylase complex subunit 1.2 1.9
Kremen2 kringle containing transmembrane protein 2 transmembrane receptor 1.0 1.8
Fold induction after LPS
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remodeling and modifying enzymes and have to be examined by ChIP analysis in different 
cell types. 
 So far, the role of ARTD2 in inflammatory gene expression has not been studied 
extensively. There is evidence that ARTD2 impacts T-cell development and improves 
chronic inflammation disease in an IL-10 deficient background (307, 308). It was also shown 
to reduce TNF# expression similar to the role of ARTD1 (308). However, our initial analysis 
revealed an increased expression of TNF# in shARTD2 cells upon LPS stimulation, which 
would rather point to a repressory function of ARTD2 during inflammation, whereas the 
TNF# expression was reduced in ARTD1 depleted cells. It might be that, as shown before, 
ARTD2 regulates NF-"B-dependent gene expression by recruiting HDACs to promoter sites, 
which would subsequently lead to a decrease in repressory histone modifications and 
silencing of target gene expression (152). ChIP experiments with ARTD2 and histone 
acetylation on the specific promoter sites at different time points after LPS treatment will 
reveal if ARTD2 regulates gene expression by modulating chromatin. Thus, distinct roles of 
ARTD2 and ARTD1 in the inflammatory response of TNF# seem likely. 
 
4.6 Distinct functions of ARTD1 and ARTD2 in various cellular     
processes 
Among the 18 ARTD family members, ARTD1 and ARTD2 share the highest homology 
(69% of the catalytic domain) (69). The data presented in this thesis document non-redundant 
functions for these two enzymes during cell cycle re-entry and cell cycle progression (chapter 
3.1.2) as well as during the genotoxic stress response (chapter 3.1.1). Furthermore, 
preliminary experiments analyzing the inflammatory response in MC38 cells indicate 
different regulatory effects of ARTD1 and ARTD2 (chapter 3.2.5), supporting our hypothesis 
that ARTD2 is an individual cellular player on its own and mostly acts independently of 
ARTD1. However, this finding does not exclude redundant function and the formation of 
heterodimeric complexes of both enzymes (112).  
ARTD1 is often displayed as the key enzyme of the ARTD family and involved in a variety 
of processes. Knockdown studies revealed that the siARTD2 effect on the cell cycle was 
stronger than for siARTD1 treated cells, since cells did not enter the cell cycle and were 
arrested in early G1 phase. It remains to be investigated how general the function of ARTD2 
in tumorigenesis is and whether the cell type contributes to the observed effects. We have 
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also discovered that ARTD2 is strongly stimulated by RNA, which provides new insights 
how ARTD2 is regulated and for which cellular processes this might be relevant. Thus, 
ARTD1 and ARTD2 are stimulated by different substrates and to a different extent. ARTD2 
enzymatic activity was more activated by a single-stranded structure (RNA or DNA), 
whereas ARTD1 recognizes mainly double-stranded DNA.  
By investigating different biological functions, we have provided new evidences that ARTD2 
is an important and distinct regulator of cellular processes that can act independently of 
ARTD1.  
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